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 Endothelial Progenitor Cells (EPCs) were first identified from human blood 
samples as a population of circulating mononuclear cells capable of displaying a mature 
endothelial cell phenotype in culture. Subsequent studies established that EPCs arise from 
the bone marrow (BM) and incorporate into the endothelium at sites of blood vessel 
growth, suggesting a potential role for these cells in neovascularization. Furthermore, a 
decline in EPC number correlates to multiple vascular pathologies, indicating that EPC 
counts could serve as a biomarker of cardiovascular disease. Unfortunately, due to the 
variability in techniques used for EPC isolation and identification, considerable 
heterogeneity exists within the population of cells commonly defined as EPCs. In order 
for the clinical potential of EPCs to be fully realized, thorough characterization of the 
BM-derived cell populations involved in neovascularization is required. 
  The objective of our study was to determine the functional significance of 
circulating EPCs in postnatal vascular growth and repair. Two separate strategies were 
employed to achieve this objective. In the first, we attempted to generate a mouse whose 
pool of bone marrow-derived endothelial precursors was drastically reduced or 
eliminated. Our overall approach was to deliver a “suicide” gene, under control of an 
endothelial cell-specific promoter, to bone marrow cells for use in bone marrow 
transplantation (BMT) experiments. Mice receiving BMTs would therefore lack the 
ability to deliver viable BM-derived EPCs to sites of neovascularization. Our central 
hypothesis for this study was that a reduction in EPC viability would hinder endogenous 
vascular repair mechanisms, thereby exacerbating cardiovascular disease. In the second 
 xxi
strategy, we attempted to identify novel progenitor cell populations based on the 
transcriptional regulation of pro-angiogenic genes. Our overall approach was to 
transduce BM with a retrovirus containing a fluorescent reporter gene under control of 
pro-angiogenic promoters for use in transplantation experiments. Our central hypothesis 
for this study was that unique populations of BM-derived cells could be identified by 
expression of the fluorescent reporter gene directed by the Vascular Endothelial Growth 
Factor (VEGF), endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial 
(VE) Cadherin promoters.   
 The BMT strategy utilized to address our first hypothesis was unsuccessful due to 
the use of a truncated form of the pro-apoptotic Bax as our suicide gene. A plasmid 
encoding GFP fused to a truncated Bax fragment (ΔN-Bax, consisting of amino acids 
112-192 of the full length protein) was used in transfection experiments to assess ΔN-Bax 
function. The GFP:ΔN-Bax fusion protein formed distinct extranuclear aggregates 
(presumably due to mitochondrial translocation) but did not induce apoptosis in 
transfected cells. The ΔN-Bax fragment also did not induce cell death when targeted to 
endothelial cells with retoviral-mediated gene delivery or in a transgenic mouse setting.  
 To address our second hypothesis, we generated retroviral vectors containing the 
fluorescent tdTomato reporter gene under control of the VEGF, eNOS and VE Cadherin 
promoters. Significant fluorescence was detected in cultured endothelial cells and ex 
vivo-expanded BM cells. Following transplantation of transduced BM cells into lethally 
irradiated recipient mice, we were able to identify circulating populations of tdTomato-
positive cells using flow cytometry. With these results we have identified novel 
subpopulations of circulating BM-derived cells which may play a significant role in post-
 xxii
 xxiii
natal neovascularization in mice. Therefore, results acquired from these studies could 
lead to improved cell therapy techniques for treatment of vascular disease.    
CHAPTER 1 
SPECIFIC AIMS  
Introduction 
 Since their initial discovery in 1997, controversy has surrounded Bone Marrow 
(BM)-derived Endothelial Progenitor Cells (EPCs) and their role in the repair and 
regeneration of the vasculature. Based on their apparent ability to incorporate into the 
endothelium at sites of blood vessel growth (1), EPCs were immediately identified as a 
cell source for the vascularization of tissue engineered constructs and for vaso-
regenerative therapy for treatment of conditions such as Acute Myocardial Infarction 
(AMI). Mounting evidence also suggests that EPC number and function are a strong 
indicator of overall cardiovascular health, and their reduction in number is a potential 
biomarker for atherosclerosis (2). 
 Despite the therapeutic and diagnostic potential of EPCs, several recent studies 
found that bone marrow (BM)-derived cells did not integrate into the endothelium in a 
number of different animal models of neovascularization (3; 4). These reports suggested 
that BM cells were recruited to sites of neovascularization and stimulated growth via a 
paracrine effect rather than differentiating into mature endothelial cells. The conflicting 
data regarding the incorporation of EPCs into the endothelium has lead to considerable 
controversy over the functional role of EPCs in vascular growth. As a result of this 
controversy, no consensus has been reached on the contributions of BM-derived cells 
during neovascularization. 
 Before EPCs can be employed in a clinical setting, their functional role in 
endogenous vessel growth and repair must be definitively elucidated. The objective of 
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our study was to determine the functional significance of circulating EPCs in postnatal 
vascular growth and repair.  
 Two separate strategies were employed to achieve this objective. In the first, we 
attempted to generate a mouse whose pool of bone marrow-derived endothelial 
precursors was drastically reduced or eliminated. Our overall approach was to deliver a 
“suicide” gene, under control of an endothelial cell-specific promoter, to murine BM cells 
for use in BM Transplantation (BMT) experiments. Mice receiving BMTs would 
therefore lack the ability to deliver viable BM-derived EPCs to sites of 
neovascularization. Our central hypothesis for this study was that a reduction in EPC 
viability would hinder endogenous vascular repair mechanisms, thereby exacerbating 
cardiovascular disease. Specific Aims I and II outline our attempts at generating a mouse 
model of EPC depletion. 
 In the second strategy, we attempted to identify novel progenitor cell populations 
based on the transcriptional activity of pro-angiogenic genes. Our overall approach was 
to transduce murine bone marrow with a retrovirus containing a fluorescent reporter gene 
under the control of multiple promoters previously implicated in neovascularization. 
Transduced cells are then transplanted into lethally irradiated recipient animals, where 
detection of fluorescence allows identification of BM-derived progenitor populations in 
both the circulation and tissues. Our central hypothesis for this study was that unique 
populations of BM-derived cells could be identified and isolated by transcriptional 
activation of a fluorescent reporter gene from the Vascular Endothelial Growth Factor 
(VEGF), endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial (VE) 
Cadherin promoters.   
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 To test these hypotheses, the following specific aims were proposed: 
 
AIM I 
Specific Aim 1: Develop a retroviral construct to induce endothelial specific cell 
death in vitro.  
Our working hypothesis was that a retroviral construct, containing a suicide gene 
under direction of an endothelial cell-specific promoter, would induce death only in 
endothelial cells. To this end, we designed a Retrovirus for Endothelial cell Death (RED) 
in which a truncated form of the pro-apoptotic gene Bax was directed by the murine VE 
Cadherin promoter. To assess construct efficacy, RED was transduced into endothelial 
cells and fibroblasts in vitro. Construct function was evaluated with microscopy, flow 
cytometry, western blot, and quantitative Reverse Transcription-Polymerase Chain 
Reaction (qRT-PCR).  
 
AIM II 
Specific Aim 2: Generate a transgenic mouse model to induce endothelial specific 
cell death in vivo.  
Our working hypothesis was that a transgenic mouse, containing the RED 
construct, would allow us to temporally regulate endothelial cell apoptosis in a tamoxifen 
inducible system. To achieve this aim, we generated a Cre-Inducible Endothelial cell 
Death (CrIED) mouse containing the RED construct described in Aim I. Histology, 
chemiluminescence imaging, western blot, and qRT-PCR were used to evaluate the 




Specific Aim 3: Fluorescently label subpopulations of bone marrow cells using 
retroviral-mediated gene transfer.  
 Our working hypothesis was that pro-angiogenic bone marrow cells could be 
identified using retroviral-mediated gene transfer of promoter/reporter constructs. We 
developed retroviral constructs containing the VE Cadherin, eNOS, and VEGF promoters 
driving expression of the tdTomato gene. To evaluate construct efficacy, retroviral 
mediated gene transfer was used to genetically label endothelial cells in vitro.  Bone 
marrow cells were then transduced and used in a transplantation model to identify and 
characterize the cell subpopulations in vivo with flow cytometry. 
 
Innovation and Significance 
 The strategy proposed in Specific Aims I and II would have offered valuable 
insight into EPC biology by resolving the functional contributions of bone marrow-
derived endothelial cells in vascular growth and repair. Unfortunately, we were unable to 
successfully implement these approaches, and as a result the potential impact of this 
project was not fully realized.  
  The work in Specific Aim III is innovative because it describes a straightforward 
but effective method for labeling unique populations of bone marrow-derived cells in 
mice. Current methods for labeling of bone marrow cells involve the development of 
transgenic mice, but this process is prohibitively expensive and time consuming. Our 
approach allows the genetic tagging of many different bone marrow cell types at a 
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fraction of the cost of generating transgenic mouse strains, and in a considerably shorter 
time frame. Furthermore, our approach can be applied to any strain, transgenic, or 
knockout mouse permitting studies of multiple pathologies without the need for 
complicated breeding strategies.  
 This work is significant because it allows tracing of previously undefined bone 
marrow-derived cell types in a setting of neovascularization. Circulating peripheral blood 
(PB) cells are typically identified almost exclusively by surface marker expression. Here, 
however, we demonstrate the ability to identify circulating cells based on gene expression 
that implies function (i.e. VEGF secretion, nitric oxide production). Furthermore, this 
approach permits the imaging of live cells based on the expression of intracellular protein 
expression. Intracellular protein labeling typically requires membrane permeabilization, 
preventing use of the cells following antibody staining. Promoter-specific expression of 
tdTomato permits identification and isolation of live eNOS or VEGF-expressing cells 
without the need for permeabilization, enabling use of the cells for transplantation studies 
following isolation.  
 In conclusion, we were unable to generate a mouse model with a depleted pool of 
endothelial progenitor cells. However, we were able to identify several previously 
uncharacterized populations of bone marrow cells that could potentially be involved in 
neovascularization, and in doing so developed a new methodology for the identification 





BACKGROUND AND LITERATURE REVIEW  
Endothelial Progenitor Cells 
 In their report that first identified a circulating endothelial progenitor cell (EPC), 
Asahara et al. (1) described a peripheral blood cell that presumably arose from the bone 
marrow, yet was also capable of displaying characteristics of mature endothelium. This 
monumental study immediately challenged the prevailing paradigm of post-natal 
neovascularization (5). Previously, it was assumed that blood vessel growth was the 
result of two distinct processes: angiogenesis and arteriogenesis. Angiogenesis consists of 
the generation of new blood vessels from the existing endothelial cells through sprouting 
or intussusception, is directed by growth factors such as VEGF and basic Fibroblast 
Growth Factor (bFGF) (Figure 2.1), and is frequently observed in response to hypoxia. 
The presence of a Hypoxia Response Element (HRE) within the VEGF promoter results 
in Hypoxia Inducible Factor 1-α (HIF-1α) regulated gene expression, so that VEGF-
induced angiogenesis is often a consequence of tissue ischemia (6). Arteriogenesis 
involves the expansion of preexisting collateral vessels due to an increase in blood flow, 
and is presumably initiated by changes in shear stress experienced by the endothelium (7) 
(Figure 2.1).  
The work by Asahara et al.(1) suggested a third mechanism of blood vessel 
growth, in which circulating BM-derived cells lead to the formation of de novo blood 
vessels. This process has been referred to as post-natal vasculogenesis, and it bears 
similarity to the formation of blood vessels from primitive hemangioblasts during 
embryonic vasculogenesis (Figure 2.1).  The notion of vasculogenesis in the adult, as   
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Figure 2.1: The different mechanisms of blood vessel growth. A) Arteriogenesis 
involves the expansion of preexisting collateral vessels due to changes in physical forces 
experienced by endothelial cells as a result in increase in flow. B) Angiogenesis is the 
sprouting of blood vessels from the existing endothelial cells in response to growth 
factors generated in hypoxic tissue. C) Vasculogenesis involves the de novo formation of 
blood vessels from circulating endothelial progenitor cells (EPCs), in a process similar to 
that seen in embryonic development.  
 
 
suggested by Asahara et al.(1), encouraged a plethora of subsequent studies examining 
the origin and functional involvement of EPCs in various settings of neovascularization. 
Unfortunately, the lack of a consensus definition for an EPC has led to a variety of 
methodologies for isolation and characterization of the cells. This in turn has led to 
conflicting reports regarding quantification of EPC number as well as the functional 
attributes of these cells. Despite various claims linking the putative EPC to certain 
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subpopulations of circulating peripheral blood mononuclear cells (PB-MNCs) based on 
the expression of surface markers, at present no single definitive marker for identification 
of an EPC exists. Consequently, EPCs described as described throughout the literature 
may be separate, distinct cell types, necessitating cautionary interpretation when 
comparing findings (9).  
  
Initial Discovery and Role in Blood Vessel Growth 
 In their pioneering work identifying the EPC, Asahara et al. (1) enriched human 
peripheral blood samples for either CD34+ or Flk-1 (VEGFR-2) mononuclear cells, 
which were then plated in an endothelial growth medium (1). The markers CD34 and 
VEGFR-2 were used for enrichment due to their expression in both hematopoietic stem 
cells and endothelial cells; the simultaneous expression of both markers could potentially 
indicate biphenotypic fate. Within 3 days, a subset of the PB-MNCs enriched for CD34 
or VEGFR-2 became adherent and obtained an endothelial-like spindle shape. After 7 
days in culture, characterization of the surface markers on the cultured cells revealed a 
mature endothelial phenotype. Injection of the CD34 or Flk-1 enriched cells into the 
ischemic limb of a nude mouse resulted in incorporation into the endothelial layer of 
blood vessels at sites of neovascularization, thus suggesting that ex vivo expanded cells 
were circulating endothelial precursors. It should be noted that the purity of CD34 and 
Flk-1 cells was 20% or less for each antigen, making it impossible to distinguish if the 
CD34 or Flk-1 cells directly gave rise to the endothelial-like colonies seen in culture
 Prior to the discovery of EPCs, Circulating Endothelial Cells (CECs) were 
observed in a number of pathologic settings (10). However, CECs, although isolated from 
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blood in a manner similar to EPCs, presumably originate from mature blood vessels.  
Frequently identified by the endothelial marker CD146 (11), CECs are thought to be cells 
“sloughed off” of the native endothelium. In contrast to the origins of CECs, Asahara et 
al. (12) used a series of elegant bone marrow transplantation experiments to establish that 
some cells that contribute to neovessel formation originate in the bone marrow. To 
distinguish donor cells from recipient cells, donor BM from Flk1-LacZ or Tie2-LacZ 
transgenic mice was transplanted into lethally irradiated nude mice recipients. Donor-
derived cells were then detected in a setting of tumor angiogenesis, wound healing, and 
hind limb ischemia (12), establishing the bone marrow-origins of Flk1 or Tie2 expressing 
cells in mice.  
 The origination of EPCs in the bone marrow was also explored independently by 
Shi, et al.(13) in a BMT model in dogs. Endothelial-like cells were generated ex vivo 
from CD34+ cells isolated from PB samples. Genotyping of the cells revealed that they 
were of donor origin. Following bone marrow transplantation, cells that adhered to the 
intimal surface of implanted Dacron grafts were CD34 + and determined to be of bone 
marrow origin (13), leading the authors to conclude that the donor-derived cells seen in 
culture were the same as those populating the grafts. It should be noted that the cultured 
“EPCs” isolated by Shi, et al. (13) were derived from a nonadherent fraction of peripheral 
blood cells following 3 rounds of adherence depletion.  This method of isolation is differs 
from that described by Asahara, et al. (1), in which EPCs were obtained from an adherent 
population of PB cells.  
 In an attempt to isolate EPCs in mice, Takahashi, et al. (14) cultured mouse 
Sca1+ cells in conditions similar to those described by Asahara, et al. (1) for isolation of 
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human EPCs. As was seen in human PB-MNC samples, mouse Sca1+ cells also formed 
an endothelial-like adherent cell population in culture. The relationship between the 
endothelial-like cells seen in culture and the bone marrow cells involved in 
neovascularization was then pursued more thoroughly. Treatment of mice with GM-CSF 
led to an overall increase in neovascularization in both the ischemic hind limb and in a 
corneal micropocket assay. This functional increase in neovascularization correlated to an 
increased number of circulating mouse EPCs which were identified as Sca1+ cells in the 
PB (14). However, from these data it is unclear if the Sca1+ cells or their progeny were 
directly involved in the formation of new blood vessels.  
Other markers besides Sca1+ have also been used to identify EPCs in mice. An 
increase in the number of circulating CD34+, Flk-1+ and VE Cadherin+ cells was 
observed following treatment with VEGF (15), establishing a correlation between the 
number of circulating cells and the increase in blood vessel formation following VEGF-
induced angiogenesis. However, none of these studies were able to confirm that cells 
identified as circulating EPCs were the same as those isolated in culture or those BM-
derived cells found in nascent blood vessels. Although a strong correlation was observed 
in each case, causality was never established.  
 A number of clinical trials using PB-MNC populations in the hopes of utilizing 
EPCs for cell therapy have begun to explore the therapeutic potential of different BM-
derived cell populations for treatment of peripheral limb ischemia (16) and AMI (17). 
Endothelial progenitor cell number, as defined by either the number of EPC colony 
forming cells or the number of circulating PB-MNCs expressing various combinations of 
surface markers, has also been used as a biomarker of overall cardiovascular health. 
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Vasa, et al. (18) found that EPC number, as assessed by both number of adherent 
endothelial-like colonies derived from PB-MNCs after 5 days and number of circulating 
CD34+/KDR+ cells, inversely correlated to the number of risk factors for coronary artery 
disease (19). Colony number and CD34+/KDR+ cells also increased within one week of 
initiating statin therapy (18). These data demonstrate that EPC number may be an 
additional metric to assess efficacy of various treatments for cardiovascular disease 
(CVD).  
Using a 48 hour pre-plate method to remove adherent cells, Hill, et al. (2) further 
established a link between CVD and EPC number by demonstrating an inverse 
correlation between EPC number and Framingham risk score.  Hill, et al. (2) went on to 
establish an inverse correlation with EPC number and vascular function, as determined by 
flow-mediated brachial reactivity, in a cohort of healthy patients (2).  
 
Culturing of EPCs 
 The studies outlined above are significant for a number of reasons. First, they 
provide evidence for a previously undefined mechanism of endogenous blood vessel 
growth (post-natal vasculogenesis) in addition to the established mechanisms of 
angiogenesis and arteriogenesis. Second, the existence of a circulating cell that naturally 
augments the process of angiogenesis offers a convenient source for cell therapy 
strategies. Finally, EPCs are a novel biomarker of vascular health, both as an indicator of 
disease and a metric of therapeutic efficacy for treatment of CVD. However, careful 
examination of the methodologies underlying each of these studies reveals considerable 
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variation in cell isolation techniques.  In each case, although the cells examined are 
referred to as EPCs, in reality they may be remarkably different cell types.  
The original EPC, as described by Asahara, et al.(1) was isolated from a CD34-
enriched PB-MNC population that adhered to fibronectin, and exhibited an endothelial-
like phenotype in 7 days. The EPC described by Vasa, et al. (18) was also derived from 
an adherent population of PB-MNCs, but was characterized after just 4 days in culture. In 
order to remove any macrophages and contaminating mature endothelial cells, Hill, et al. 
(2) added a single 48 hour pre-plate step for removal of adherent cells, followed by a 
replate and 7 day culture of the non-adherent cells. Shi, et al. (13) enriched PB-MNCs for 
CD34+ cells and then performed 3 pre-plate steps to remove adherent cells before 
replating the non-adherent cells. Each of these studies, despite utilizing different culture 
techniques, generated cells resembling an endothelial cell ex vivo. Unfortunately, 
subsequent studies built upon these early disparate and varied approaches, so that at 
present there is no consensus as to how one should definitively isolate and quantify 
EPCs.  
 Recently, several reports have explored the subtle differences between cells 
derived from the different EPC culture techniques. In an effort to determine the origin of 
EPCs in humans, Lin, et al (20) obtained PB samples from gender-mismatched bone 
marrow transplant recipients so that donor marrow-derived cells could be distinguished 
from recipient cells by in situ hybridization of the Y-chromosome. Through ex vivo 
expansion of PB-MNCs from the BMT recipients, Lin, et al. (20) identified two distinct 
populations of circulating endothelial cells in peripheral blood. The first was an early 
adherent cell type of recipient origin (i.e. not from the bone marrow) that exhibited an 
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endothelial phenotype. However, these early endothelial cells showed a limited 
proliferative capacity and were soon outgrown by a second highly proliferative 
endothelial cell of donor origin. The authors suggested that the early-circulating ECs 
were from mature vessel walls, while the late-circulating ECs arose and differentiated 
from the bone marrow.  
 The two cell types are frequently referred to as early EPCs (7 day culture) and 
“late” or Outgrowth Endothelial Cells (OECs, 21 day culture). Molecular characterization 
of “early” EPCs from adherent PB-MNCs has revealed that they are of monocytic origin, 
as evidenced by CD14 expression (21). In contrast, the OEC population does not express 
CD14, and was shown to originate from a CD14 negative population of cells (21). The 
OECs are functionally more representative of endothelial cells, as only the OECs form 
tubular structures in matrigel and integrate into a monolayer of Human Umbilical Vein 
Endothelial Cells (HUVECs). The OECs also exhibit a phenotype more typical of a true 
endothelial cell compared to the early EPC, although injection of either cell type results 
in enhanced neovascularization in the ischemic hind limb of nude mice (22). 
Interestingly, transplantation of a mixed population of both early EPCs and OECs results 
in and even greater improvement in recovery from hind limb ischemia than transplant of 
either cell type alone (23). Although early EPCs are unable to acquire a mature 
endothelial phenotype, the angiogenic potential of these cells is evident by their 
production of the pro-angiogenic cytokines VEGF and IL-8 (22). Early EPCs were also 
shown to enhance tube formation in a transwell fibroblast-co-culture experiment, 
establishing a pro-angiogenic phenotype capable of augmenting vessel formation (24).  
 13
In addition to the phenotypic differences between early EPCs and OECs, 
phenotypic heterogeneity has been observed even within the early EPC population alone. 
Examination of the clonogenic potential of late EPCs by single cell replating of the 
primary EPC colonies identified a small subset of cells within the early EPC population 
capable of proliferating and expanding upon further passage. Plated umbilical cord blood 
(CB), and additional source of EPCs, showed a 15-fold higher number of high-passage 
proliferative cells compared to PB samples, suggesting CB may serve as a highly 
enriched cell source for regenerative therapies (25).  
Although EPCs presumably arise from the bone marrow, the variation seen in 
phenotype among the different groups of EPCs may indicate different sites of origin. 
Ingram, et al. (26) observed a highly proliferative subpopulation of cells within HUVEC 
and Human Aortic Endothelial Cell (HAEC) cultures, suggesting that the vessel wall 
itself may be a niche where proliferative EPCs reside. Zengin, et al. (27) examined 
excised aortic segments and observed a highly proliferative and migratory endothelial-
like cell in ex vivo culture assays that originated at the medial-adventitial border of the 
blood vessel. The expression of CD34 on these cells, and the location within the blood 
vessel wall, preclude them from being classified as mature endothelial cells. Others have 
postulated that EPCs exist as a pool of cells within the native endothelium either derived 
from the endothelium itself, or as bone marrow cells translocated to a secondary niche 
within the mature endothelium (28).  
Yoder, et al. (29) observed that the endothelial cell colony forming units (CFU-
EC) first described by Hill, et al. (2) expressed both the leukocyte antigen CD45 and the 
monocytic identifier CD14, indicating that the CFU-ECs were of hematopoietic origin. 
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This was in contrast to the analysis of OECs, which were largely CD14 negative (29). 
Limited dilution and replating of single cells from the CFU-ECs also demonstrated that 
the cells were unable to form secondary CFU-ECs. However, some of the replated CFU-
ECs were capable of forming HSC-like colonies (29). These data suggest that CFU-ECs, 
although capable of expressing some endothelial markers, are more closely related to a 
hematopoietic progenitor than an endothelial cell.  
 In summary, several different methods for ex vivo culturing of PB-MNCs have 
been used to identify colonies which are commonly referred to as EPCs. However, there 
are marked differences in phenotype between the populations of cells obtained using 
these different techniques. Cells generated from each of the culture methods show some 
capacity to enhance angiogenesis, but it is unclear which, if any, of the cultured EPCs are 
capable of forming true endothelial cells. Furthermore, it is unclear if any cells derived 
from the different EPC cultures are involved in endogenous neovascularization, as 
causality between the ex vivo and in vivo data has yet be established. 
 
Circulating EPCs 
 EPCs were first identified based on their ability to display an endothelial cell-like 
phenotype in culture. The ex vivo approach for identification is problematic because it 
necessitates a retrospective analysis of the entire PB-MNC population of cells. For their 
effective use in cell therapy, it is necessary to prospectively identify EPCs. Unfortunately, 
no unique surface marker or group of markers exists that permits the unequivocal 
identification and purification of an EPC population.  
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Asahara, et al. (1) hypothesized that CD34 and Flk-1 (VEGF Receptor-2 or 
VEGFR2) could be used to identify an adult hemangioblast (i.e. cell capable of giving 
rise to both hematopoietic and endothelial cells) with angiogenic capacity. The authors 
reasoned that both of these markers were present on embryonic hemangioblasts, and that 
the same expression profile may be recapitulated in the adult bone marrow. Single cell 
clonogenic culture assays have supported this hypothesis, demonstrating that a limited 
number of CD34+/VEGFR2+ cells in chord blood are capable of forming both 
endothelial and hematopoietic stem cells (30). Gehling, et al. (31) expanded upon this 
idea by identifying a subset of CD34+ cells that were also positive for CD133 (AC133) 
(31). CD133 enriched cells formed both an adherent (EC-like) and non-adherent (HSC-
like) cell population in culture, and led to increased tumor size when co-injected into 
Severe Combined ImmunoDeficiency (SCID) mice with A549 cells. Cells containing a 
combination of all three markers (CD133+/CD34+/VEGFR2+) have been described as a 
non-adherent precursor capable of obtaining an endothelial phenotype in culture (32), and 
may be derived from a CD34 negative(but CD133+/VEGFR2+) population (33).  
 The combination of some or all of the markers CD133, CD34, and VEGFR2 has 
been widely used for the prospective identification of circulating EPCs. The number of 
circulating  CD133+/CD34+/VEGFR2+ cells were shown to increase in response to 
exercise (34; 35; 36) or G-CSF treatment (37), and were elevated in patients with non-
small cell lung cancer (38) and immediately following AMI (39). Patients who smoked 
(40), or suffered from hypercholestoremia (41) or obesity (42) had reduced numbers of 
circulating EPCs, as defined by coexpression of CD133, CD34 and VEGFR-2. However, 
while the number of circulating CD34+/CD133+/VEGFR2+ cells may serve as an 
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indicator of vascular health and may be relevant to blood vessel function, it is unclear if 
these cells truly give rise to endothelial cells in a setting of neovascularization. Case, et 
al. (43) demonstrated that the CD34+/CD133+/VEGFR2+ cells did not form endothelial 
colonies in culture and, unlike mature endothelial cells, did not form tubular structures in 
a matrigel tube forming assay. Instead, CD34+/CD133+/VEGFR2+ cells readily formed 
HSC colonies, suggesting that they are actually a hematopoietic precursor. Interestingly, 
a CD34+/CD45- population ably formed endothelial-like colonies, but not HSC colonies 
in culture (43).  
 
Evidence Against a Bone Marrow-Derived Endothelial Cell 
 The bone marrow origins of EPCs were established in mice through a series of 
bone marrow transplantation experiments in which genetically labeled bone marrow was 
transplanted into wild type recipients. In the resulting BM chimeras, cells of donor origin 
were found to incorporate directly into the endothelium. However, a number of reports 
have since surfaced that contradict some of the initial findings regarding the bone marrow 
origins of endothelial cells. Rajantie, et al. (44) observed that, following transplantation 
of transgenic-GFP expressing BM in a sub-lethally irradiated WT recipient, GFP+ cells 
were detectable in a setting of VEGF-induced angiogenesis and B16 melanoma. 
However, no GFP+ endothelial cells were detected. The majority of the GFP+ donor cells 
expressed the leukocyte and monocyte markers CD45 and CD11b, respectively, with a 
subset of GFP+ cells expressing NG2-proteoglycan (44). Expression of NG2-
proteoglycan.indicates a pericyte-like, but not endothelial-like, phenotype. This report 
also demonstrated the importance of using scanning laser confocal microscopy for 
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colocalization studies. Many of the BM-derived cells identified in ischemic tissue were 
so close to the blood vessel intima that they could only be identified as pericytes 
following z-stack analysis through the tissue section. The discrepancy between this report 
and the results of earlier studies could be attributed to the use of confocal imaging, which 
prevented the false identification of bone marrow-derived endothelial cells.  
Ziegelhoeffer et al. (3) used another BMT approach in which GFP-labeled donor 
cells were transplanted into lethally irradiated wild type recipients. In both hind limb 
ischemia and BSF-1 tumor models, GFP+ cells were detected around growing vessels, 
but none of the GFP+ cells could be definitively identified as endothelial cells (3). The 
GFP+ cells did stain positively for FGF-2, VEGF, and MCP-1, suggesting a paracrine 
role in augmenting neovascularization (3).  
Case, et al. (43) utilized the GFP-BMT approach in a novel model of hypoxia-
induced angiogenesis by housing animals in a hypoxic environment. Following exposure 
to hypoxia, an increase in blood vessel number was observed in the spinotrapezius 
muscle, and GFP+ cells were detected around nascent blood vessels (43). However, as 
observed by Ziegelhoeffer et al, (3), no GFP+ cells incorporated into the endothelium 
(43). Despite the absence of true BM-derived endothelial cells, a paracrine support role 
for these cells was suggested given that they expressed VEGF and MMP-9 (43). Case, et 
al. (43) utilized an additional BMT strategy in which donor marrow from mice containing 
the GFP gene transcriptionally regulated by the Tie-2 promoter was used to determine the 
contributions of BM-derived cells to blood vessels. In this case no GFP+ cells (and 
therefore no bone marrow-derived endothelial cells) were found in a setting of hypoxia-
induced neovascularization (4).  
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Purhonen, et al. (45) performed BMT experiments utilizing GFP-labeled donor 
cells transplanted into lethally irradiated WT recipients, and found no BM-derived ECs in 
VEGF-induced angiogenesis, a B16 melanoma, or an in vivo matrigel plug. Transplants 
with donor marrow from VEGFR2-LacZ or Tie1-LacZ reporter mice (in which the 
VEGFR2 or Tie1 promoters drive expression of LacZ) indicated the presence of rare 
populations of cells expressing VEGFR-2 or Tie-1 in the bone marrow. However, these 
cells did not incorporate into the endothelium (45). In order to examine the role of EPCs 
in a non-myeloablative setting, a parabiosis model in which a GFP reporter and an 
APCmin mouse shared a circulatory system was also utilized. Again, no GFP+ ECs were 
detected within APCmin adenomas (45). 
 
Pro-angiogenic Monocytes 
 Increasing evidence suggests that monocytes may have the ability to acquire an 
endothelial-like phenotype under specific culture conditions. Several studies have 
examined the role of monocytes in the formation of early EPCs in culture. Schmeisser, et 
al. (46) plated the monocytic CD14+/CD34- fraction of PB-MNCs in endothelial culture 
conditions and observed an adherent cell population with an endothelial-like morphology 
develop within 4 days. Expression of the endothelial markers von Willibrand Factor 
(vWF), eNOS, and VE Cadherin was retained up to 4 weeks in culture (46). Since the 
adherent cells grew from cells enriched for CD14, the authors concluded that the colonies 
arose from monocytes. Over the 4 weeks in culture, however, CD14 expression became 
diminished with a concomitant increase in CD68 expression, perhaps indicating that the 
cells had undergone a phenotypic switch to macrophages (46). Others have observed a 
 19
similar increase in endothelial-specific markers with a concurrent decrease in monocytic 
markers from CD14-enriched cells (47).  
In order to assess the origins of the adherent population of cells from EPC culture 
assays, Rehman, et al. (48) performed surface marker analysis on PB-MNCs cultured for 
4 days. Nearly all of the cells expressed the leukocyte antigen CD45, and >90% of the 
cells expressed the monocyte marker CD14 and myeloid marker CD11b. Conversely, 
endothelial and hematopoietic stem cell (HSC) markers (VE Cadherin, E-selectin, CD31, 
CD133 and ckit) were all expressed in less than 5% of total adherent cells. The authors 
concluded that the endothelial cells observed later in culture were derived from a 
monocytic population since the majority of the starting population was positive for CD14 
and CD11b (48).  These results raise the possibility that EPCs or, more specifically, early 
EPCs, are either monocytes or a subset of monocytes capable of undergoing an 
endothelial-like transformation.  
The role of monocytes in the formation of CFU-ECs (EC culture of PB-MNCs 
following adherence depletion) has also been examined. Rohde, et al. (49) observed that 
cultured CD14+ (monocytes) or CD14- (non-monocytes) cells alone did not lead to CFU 
formation. However, adding CD14+ cells to a CD14- population restored the colony 
forming ability of the cells (49). These results indicate that monocytes may serve as a 
source of paracrine signaling in CFU-EC colonies. 
Implantation of monocyte-derived EPCs was used to demonstrate a functional 
role for monocytes in neovascularization. Urbich, et al. (50) injected 4 day cultured EPCs 
from either CD14+ or CD14- cell populations into the ischemic hind limb of Nude mice, 
and saw equivalent improvement in blood flow for both groups. When freshly isolated 
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CD14+ cells were implanted, however, no improvement in blood flow was observed (50). 
Bailey, et al. (51) determined that a myeloid population within the bone marrow was 
capable of giving rise to endothelial cells in the hepatic portal vein. An isolated myeloid 
subpopulation defined as Lin-/sca1-/ckit+/CD34+/FcγRlow and FcγRhigh cells from 
genetically tagged mice were used in BMT experiments, and found to incorporate in the 
endothelium of the hepatic portal vein. A similar result was also seen in a parabiosis 
model, confirming the incorporation of BM cells into the endothelium in a non-
radioablative setting (51). Grunewald, et al. (52) examined the role of myeloid cells in a 
setting of VEGF-induced angiogenesis using a liver or myocardial-specific tet-activated 
VEGF over-expresser in a bone marrow transplant model. Donor GFP+ cells, obtained 
from the bone marrow of myeloid-specific CX3CR1-GFP mice, were recruited to both 
liver and myocardium following induction of VEGF expression (52). Despite the 
presence of GFP+ BM-derived cells in a setting of angiogenesis, there was no observable 
incorporation of BM-derived cells into the endothelium (52).  These data suggest that 
myeloid cells play a significant role in angiogenesis, but don’t necessarily differentiate 
into endothelial cells. 
A growing number of reports have implicated a circulating monocyte/myeloid cell 
population in tumor angiogenesis. Tie-2 expressing monocytes (TEMs) were first 
observed by De Palma, et al. (53) following transduction of bone marrow with a 
lentivirus expressing GFP under control of Tie-2 transcriptional regulatory elements (53). 
In a BMT model where the donor cells were labeled with the Tie-2-GFP lentivirus, TEMs 
were found abundantly localized adjacent to nascent tumor vessels. However, the 
majority of TEMs expressed CD45, indicating that they were of hematopoietic origin and 
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not true EPCs. Using a similar lentiviral strategy, De Palma, et al. (53) used the Tie-2 
promoter to drive expression of the HSV-TK suicide gene in bone marrow cells. 
Following administration of ganciclovir, a reduction in circulating TEMs and concurrent 
decrease in tumor volume was noted (53). These experiments established a functional 
role for TEMs in tumor angiogenesis. An additional subset of Tie2+ cells, characterized 
as Tie2+/CD13+/Sca1+/CD45-/CD31- , was also observed in tumors. Based on surface 
marker expression, this cell type was characterized as a mesenchymal stem cell-derived 
pericyte not of endothelial or hematopoietic origin (54).  
Another monocyte-like cell type potentially relevant to angiogenesis was isolated 
from ovarian carcinomas, and found to express both the monocytic marker CD14 and the 
endothelial marker VE Cadherin. These cells, identified as Vascular Leukocytes (VLs), 
demonstrated the ability to form vessel-like structures in matrigel (55) and have 
subsequently been found in a variety of tumors (56). Like TEMs, VLs were determined to 
be of hematopoietic origin. Furthermore, VLs were highly responsive to VEGF, and 
underwent an endothelial-like differentiation following exposure to VEGF in tumors 
(57). Pulaski, et al. (56) were able to selectively deplete VLs using saporin toxin 
conjugated to an anti-CD52 antibody. In an ovarian tumor model, mice that received 
treatment of the CD52-saporin toxin showed a reduction in VL number, concurrent with a 
reduction in tumor volume and an increase in lifespan compared to controls (56).  
The function of VLs in tumor angiogenesis appears to be mediated, at least in 
part, by TNFα. Li, (58) showed that TNFα induced an endothelial-like phenotype in VLs 
in vitro (58). The implantation of tumor cells expressing low levels of TNFα led to robust 
tumor growth and angiogenesis. However, cells expressing either high levels of TNFα or 
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no TNFα showed abrogated tumor formation with impaired angiogenesis (58). This result 
was in contrast to that found by De Palma, et al. (59), who showed that targeted TNFα 
over expression in TEMs led to a reduction in tumor formation (59). The discrepancy in 
between these studies could be due to either the relative levels of TNFα expressed, or the 
fact that two different cell types were examined. The latter seems less likely, however, 
because a comparative analysis of TEMs and VLs showed that nearly all VLs were 
TEMs, while half of TEMS were VLs (56). 
Ahn and Brown (60) observed that bone marrow-derived cells localized in tumors 
following BMT with GFP-labeled donor cells did not differentiate into endothelial cells, 
but were instead a subset of CD11b+ myeloid cells. The authors noted that Matrix 
Metalloproteinase-9 (MMP-9) colocalized to the CD11b+ cells within the tumors, 
suggesting that the bone marrow-derived CD11b+ cells expressed MMP-9 (60). A role 
for MMP-9 in angiogenesis was further established by studies with MMP-9 knockout 
animals, which showed impaired tumor formation. Transplantation of WT marrow into 
MMP-9 KO animals restored tumorigenic ability (60). The functional role of CD11b cells 
was also explored in a tumor model using a transgenic mouse that expressed the 
diphtheria toxin receptor (DTR) under control of the CD11b promoter. Treatment of 
these mice with diphtheria toxin led to ablation of CD11b cells, and resulted in 
significant inhibition of tumor formation (60). 
In addition to TEMs, VLs and CD11b+ cells, a number of other 
monocyte/myeloid derived cells have been implicated in tumor angiogenesis (61). 
Unfortunately, since the markers used to identify each of these subpopulations are 
expressed on multiple cell types, it is extremely difficult to distinguish between the 
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different groups of monocytes/myeloid-derived cells. It is likely that there is considerable 
overlap between the different monocytes/myeloid-derived cell types involved in tumor 
formation. A direct comparison of several tumor related bone marrow derived-myeloid 
cells showed striking similarity between some cell types (62), suggesting the potential for 
a shared lineage.  
Not only is there a potential phenotypic overlap of these cell types, but functional 
redundancy is also likely. Pahler, et al. (63) noticed a decrease in macrophage number in 
cervical tumors from CCR2-null mice, but only minor differences in tumor size and 
progression were observed compared to WT controls. The authors concluded that this 
result was due to a compensatory effect from an increase in neutrophil infiltration (63). In 
addition to the difficulties encountered in characterizing the subsets of myeloid-derived 
cells involved in tumor formation, determining the relative functional role and 
contribution of each cell type adds an additional layer of complexity to the field.  
 
Clinical EPC Studies 
 The therapeutic potential of EPCs was explored at the onset of their discovery 
when Asahara et al. (1) implanted ex vivo expanded EPCs in the ischemic hind limb of 
mice. From a theoretical perspective, a highly proliferative pro-angiogenic cell within the 
peripheral blood is an ideal source for cell therapy treatment of acute myocardial 
infarction (AMI), angina, or peripheral limb ischemia (PLI). However, the successful use 
of EPCs in a clinical setting has been complicated by a number of factors.   
 The lack of a concise definition for EPCs has plagued clinicians attempting to 
utilize PB or BM-derived cells for therapeutic neovascularization.  The rarity of cells 
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defined as circulating EPCs has also been problematic, leading researchers to employ 
more straightforward approaches: using non- selected, whole PB (64; 65) or BM-MNCs 
(11, 45, 46, 48, 49, 50, 51, 52). Others have attempted to enrich PB cells for populations 
of pro-angiogenic cells by selecting for CD34 (74; 75) or CD133 positive cells (76; 77; 
78) isolated from either BM or PB.  An advantage to using a sorted or unsorted cell 
population directly from the BM or PB is that no ex vivo culture or expansion is required. 
This is of particular importance for treatment of AMI when faster isolation and 
preparation of the cells potentially allows for intervention prior to the onset of 
irreversible tissue damage. An additional benefit of using whole or sorted cells is that 
Good Manufacturing Practice (GMP) facilities are not required for preparation. For 
clinics and hospitals that lack GMP facilities, this provides a treatment option without a 
significant increase in cost to the institution. Despite these caveats, ex vivo expanded cells 
have been used therapeutically, albeit in a 3-day EPC culture system (78; 79; (81).  
 Although some clinical trials have shown modest improvement in cardiac 
function following cell therapy for treatment of AMI (66; 71; 76; 77), others have shown 
no improvement over patients receiving standard therapies (17; 69; 70). One study found 
an improvement in left ventricular ejection fraction (LVEF) at 6 months (67), but no 
differences were observed at an 18 month follow-up (68). These initial studies 
demonstrated feasibility for using PB or BM cells for treatment of AMI, but 
improvements in cardiac function following cell therapy have been minimal thus far.  
There are a number of limitations with progenitor cell therapy that could be 
curtailing the potential of EPC treatment. Once such constraint is that the number of cells 
which can be isolated from a single donor is finite, limiting the total number of cells that 
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can be transplanted back into the patient. To achieve comparable delivery of cells in a 
human to that seen in successful animal studies, an unrealistically large number of cells 
are needed. The importance of cell number in humans was addressed by Meluzin, et al. 
(73), who observed a dose dependent improvement in LVEF following intracoronary 
infusion of BM-MNCs for treatment of AMI. In this study, patients who received a 
higher cell dose (108 cells) showed improvement over standard treatment groups while 
those that received a lower cell dose (107 cells) saw no improvement (73).  
Although the use of EPCs as an autologous cell source for treatment of CVD is an 
appealing therapy, the approach is not without its drawbacks. A number of CVD risk 
factors have been shown to correlate with reduced EPC number and/or function, 
including total cholesterol (2; 41), LDL cholesterol (2; 19), Type I and II  diabetes (82; 
83; 84), and smoking (40). Patients suffering from AMI are likely to have several of these 
risk factors. As a result, the EPC pool in patient populations with AMI (and therefore 
requiring cell therapy) is likely impaired. It stands to reason that the depleted EPC pool 
would have lower regenerative capacity relative to EPCs isolated from healthy 
individuals. In fact, several studies have found the number of circulating EPCs to be 
lower in patients with vascular disease such as coronary artery disease (CAD) (85), 
erectile dysfunction (86), and stroke (87). Surprisingly, an increase in EPCs was observed 
in patients who had suffered an AMI (39; 88). It is possible that traumatic vascular event 
such as AMI may illicit an acute reparative response in the form of an increased number 
of circulating EPCs. However, the long-term effects of AMI likely lead to a reduced 
number and impaired function of circulating progenitors. Indeed, although EPC number 
was initially increased at the onset of heart failure, a reduction in EPC number was 
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observed in the late stages of heart failure compared to controls (89). Although EPCs 
may be a convenient autologous cell source easily isolated from PB, the impairment in 
function resulting from vascular disease presents a challenge that must be overcome for 
successful use of EPCs for therapeutic augmentation of angiogenesis.   
 
Apoptosis and Bax 
 Apoptosis, or programmed cell death, can be initiated by a number of internal or 
external stimuli, leading to activation of either the extrinsic or intrinsic apoptotic 
cascades (Figure 2.2). The extrinsic pathway is triggered by the binding of ligands (FasL, 
TRAIL) to the extracellular domain of their respective membrane-bound death receptors 
(Fas, TRAIL-R1,2). The cytoplasmic domain of the death receptors (DR) are maintained 
in a death inducing signaling complex (DISC) with FADD, Pro-Caspase-8, Pro-Caspase-
10, and FLIPL/S. Binding of ligand to the DR results in proteolytic activation of Caspase-
8 and Caspase-10 which activate additional effector caspases to continue the apoptotic 
program (90). Additionally, activated caspase-8 can cleave the cytosolic proapoptotic Bid 
protein. The cleaved product, tBid, is then translocated to the mitochondria where it 
further propagates the apoptosis pathway (91). 
 The intrinsic pathway is activated by environmental stresses such as hypoxia, UV-
damage, and growth factor starvation, but does not require extracellular ligand binding 
for initiation of apoptosis.  The initial phase of the intrinsic pathway is regulated by the 
Bcl-2 family of proteins (Figure 2.3). In the absence of an apoptotic stimulus, the pro-
survival members of the Bcl-2 family (Bcl-2, Bcl-XL, Mcl-1, Bcl-w and A1) dimerize  
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Figure 2.2: The intrinsic and extrinsic apoptosis pathways. The Extrinsic pathway is 
activated by binding ligand to the death receptors (DR), such as Fas or TNF-R. Caspases 
8 and 10 are proteolitically activated at the cytoplasmic tail of the DRs, which then 
activate Caspase 3 and the rest of the apoptosis cascade. The intrinsic pathway, on the 
other hand, is initiated in response to environmental stresses. The BH3-only proteins 
(blue) either directly activate the pro-apoptotic Bcl-2 family members (Bax and Bak, in 
pink) or sequester the pro-survival proteins (purple) so that Bax and Bak aggregate and 
form pore complexes in the mitochondria outer membrane (MOM). Cytochrome c is then 
released from the MOM, which binds Apaf-1 and Pro-Caspase 9 to form the apoptosome. 
Caspase 9 is then activated by proteolytic cleavage. Smac/Diablo released from the 
mitochondria can also activate Caspase 9, which continues to propagate the Caspase 
cascade, resulting in apoptotic cell death.  
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with the multi-domain pro-apoptotic Bcl-2 family members (Bax, Bak and Bok), 
sequestering the pro-apoptotic members to prevent induction of cell death. The third Bcl- 
2 family member, the BH3-only proteins (Nox, Puma, Bim, Bid, Bad, Bik), are involved 
in activation of the pro-apoptotic members.  The mechanism by which this activation 
occurs is currently under debate. Once activated, the pro-apoptotic family members 
oligomerize and form pore complexes within the mitochondrial outer membrane (MOM), 
permitting membrane depolarization and causing the release of cytochrome c and 
Smac/Diablo from the intermembrane space. The proteins released from the MOM then 
bind apoptosis protease-activating factor 1 (Apaf-1) and Pro-Caspase-9 in a complex 
called the apoptosome. When bound in the apoptosome, Pro-Caspase-9 is cleaved into the 
active form Caspase-9, which in turn activates Caspase-3 and the rest of the Caspase 
cascade.  
 The Bcl-2 proteins are categorized into family members based on Bcl-2 homology 
(BH) domains 1-4. The pro-survival members contain all four of the BH domains and a 
transmembrane (TM) domain, while the pro-apoptotic members contain the TM domain 
and BH1-3. The BH3-only members contain only the BH3 domain and the TM domain. 
The interplay between the three groups of family members, and particularly the role of 
the BH3-only proteins, has recently been a source of controversy.  
Two models are currently hypothesized to explain the interactions of the Bcl-2 
family of proteins: the direct and indirect activation models. In the direct activation 
model (93), the BH3-only proteins are divided into two groups: the activators and the 
sensitizers. The activators directly bind the pro-apoptotic family members, leading to 

















Figure 2.3: The Bcl-2 Family Members. The B-cell Lymphoma-2 (Bcl-2) family 
contains three members (pro-survival, pro-apoptotic, and BH3-only proteins), all of 
which share Bcl-2 Homology (BH) domains. The pro-survival members contain all four 
of the BH domains, as well as a transmembrane domain, and exert their effect by binding 
and sequestering the pro-apoptotic family members. The pro-apoptotic family members 
lack the BH4 domain, but contain BH domains 1-3, as well as a transmembrane domain. 
When activated, the pro-apoptotic family members form pores in the mitochondrial outer 
membrane (MOM), causing the release of Cytochrome c. Finally, the BH3-only family 
members contain only the BH3 domain. At present, the mechanism of BH3-only initiated 
apoptosis is unclear. In the “direct activation” hypothesis, the BH3-only proteins bind the 
pro-apoptotic family members, which results in pore formation and Cytochrome c 
release. In the “indirect activation” hypothesis, the pro-apoptotic members aggregate and 
form pore complexes in the MOM due to sequestration of the pro-survival members by 
the BH3-only proteins.  
 
 
the other hand, bind the pro-survival proteins, which prevents apoptosis inhibition by 
sequestering the pro-survival proteins and preventing them from binding Bax/Bak. 
Several groups have reported an interaction between the BH3-only proteins Bid (or the 
cleaved form tBid), Puma, and Bim, with the pro-apoptotic Bcl-2 family member Bax 
(93; 94; 95), supporting the direct activation hypothesis. Gavathiotis, et al. (96) identified 
a unique interaction site for Bim (BH-3 only) on Bax (pro-apoptotic) and found that point 
mutations in this site prevented Bim-induced apoptosis (96). The authors concluded that 
the binding of Bim to the novel interaction site on Bax resulted in Bax activation (i.e. 
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direct activation). The BH3-only protein Bad, on the other hand, can only further 
propagate apoptosis by sequestering the pool of pro-survival Bcl-xL (93; 95), suggesting 
that Bad acts as a sensitizer. 
 In the indirect activation model, BH3-only proteins do not interact with the pro-
survival proteins directly. MOM depolarization is achieved simply by sequestering the 
pro-survival proteins so that pro-apoptotic proteins can homo-oligomerize and form pore 
complexes. Willis, et al. (98) proposed this model after showing that Bid, Bim and Puma 
could induce apoptosis without interacting directly with the pro-apoptotic proteins Bax or 
Bak (98).  
The pro-apoptotic protein Bax is a key mediator in the formation of pores within 
the MOM. Structurally, Bax contains 8 amphipathic α-helices surrounding a single 
hydrophobic α-helix groove, and bears a striking similarity to the bacterial diphtheria 
toxin (99; 100). Like diphtheria toxin, it has been presumed that activated Bax is capable 
of forming a pore complex that, when inserted in the MOM, facilitates the release of 
cytochrome C. Specifically, the α5/α6 region of Bax is responsible for formation of these 
pores (101). As a result of its ability to induce apoptotic cell death, Bax has been a 
popular therapeutic target for gene therapy in treatment of cancer (102; 103; 104; 105; 
106; 107). 
 
Genetic Ablation Strategies 
 A number of strategies utilizing a “suicide gene” have been employed to 
selectively eliminate certain cell types. Over expression of both the diphtheria toxin (DT) 
and diphtheria toxin receptor (DTR) are techniques that have been extensively 
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characterized in cell depletion studies. The DT consists of two subunits: subunits A and 
B. In most eukaryotic cells, internalization of DT via endocytosis is mediated by the DTB 
subunit. Once internalized, the A subunit then catalyzes the ADP-ribosylation of 
elongation factor-2, leading to inhibition of protein translation and, ultimately, cell death 
(108). Over expression of the DTA gene under control of a tissue-specific promoter has 
been widely used in a transgenic mouse setting to prevent the development of specific 
cell types (109; 110; 111; 112).  A transgenic mouse has also been generated using a 
tetracycline-responsive promoter to drive DTA expression, permitting temporal control of 
cell ablation (113). Both spatial and temporal control of cell ablation was achieved with a 
Cre-inducible DTA mouse (111; 112; 113; 114; 115). In this system, the DTA transgenic 
can be crossed with any Cre or inducible Cre mouse currently available to generate mice 
lacking the cell types in which Cre is expressed. 
 The DTR transgenic system was developed to capitalize on the resistance of 
murine cells to DT toxicity. The full length DT is internalized by the binding of the DTB 
subunit with the heparin-binding EGF-like growth factor receptor (HB-EGF, or the 
DTR). However, the DTB subunit only weakly binds the murine HB-EGF, so that mouse 
cells are highly resistant to DT toxicity (119). Over-expression of the human DTR gene 
in transgenic mice allows inducible cell ablation following administration of DT. The 
DTR system has been used for tight spatio-temporal control of cell ablation in a number 
of transgenic animals (117; 120; 121).  
 Another popular gene therapy strategy for the elimination of specific cell types 
has been the use of the herpes simplex virus-thymidine kinase (HSV-TK) system. The 
HSV-TK protein converts ganciclovir to toxic nucleotide analogues, disrupting DNA 
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synthesis and eventually causing cell death (122). In a transgenic mouse setting, 
administration of ganciclovir to a transgenic animal will only ablate cells expressing the 
HSV-TK gene. When gene expression is driven with tissue-specific regulatory elements 
in a transgenic setting, the HSV-TK system can be used for spatio-temporal deletion of 
specific cell types (123; 124). 
 
Background Summary 
 Despite the explosion of research over the past decade in the area of EPCs, the 
fundamental mechanism by which bone marrow-derived cells contribute to 
neovascularization remains unknown. Although initial studies demonstrated that EPCs 
participate in nascent blood vessel formation by direct incorporation into the endothelium 
(1; 12; 125; 126)14; 15; 127), a number of reports refute this hypothesis (3; 4; 43; 44; 
45). Instead, it has been proposed that bone marrow-cells home to incipient vessels and 
reside in a perivascular location within the vessel wall, augmenting angiogenesis through 
paracrine pathways. This hypothesis has been supported by the characterization of 
colonies generated from circulating EPCs, many of which appear to be derived from 
monocytes. Several bone marrow-derived monocyte-like cells have recently been shown 
to play a functional role in tumor angiogenesis, albeit without incorporation into the 
endothelium. The varying progenitor cell definitions, disparate reports over the 
contributions of bone marrow cells toward neovascularization, and controversy over 
whether bone marrow cells differentiate into endothelium obviates the need for a strict 
definition and rigid characterization of circulating pro-angiogenic cells. To this end, we 
have developed a novel method for fluorescent labeling of bone marrow subpopulations, 
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TWO MOUSE MODELS FOR ENDOTHELIAL PROGENITOR 
CELL DEPLETION 
Introduction 
 The initial characterization of an Endothelial Progenitor Cell (EPC) in 1997(1) 
challenged the prevailing paradigm of post-natal blood vessel growth.  Previously it had 
been assumed that new vessels formed through expansion and remodeling of pre-existing 
vascular networks (5; 6). However, the work by Asahara et al. (1) for the first time 
suggested that a circulating cell in the peripheral blood could also contribute to 
neovascularization.  Subsequent studies confirmed that EPCs originate in the bone 
marrow (12; 13; 20; 12; 30; 127; 128; 129), supporting the existence of a circulating adult 
hemangioblast.   
 The absence of a surface marker to uniquely identify EPCs in vivo has led to 
considerable confusion within the field, and no consensus has been reached as to the role 
that circulating peripheral blood-derived cells play in various settings of post-natal 
neovascularization. Endothelial Progenitor Cells from blood samples are typically 
identified and characterized by one of two methods: surface antigen presentation or 
expansion and differentiation ex vivo.  In the former strategy, positive selection for a 
combination of the surface markers CD34, Vascular Endothelial Growth Factor 
Receptor-2 (VEGFR-2), CD133, and CD31, or the exclusion of markers such as CD45 
and CD14, have been used to isolate or enrich for EPCs from PB-MNCs.  The 
combination of antigens CD34, VEGFR-2, and CD133 were originally used for EPC 
identification due to their presence on either hematopoietic stem cells (HSCs; CD34, 
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CD133) or endothelial cells (VEGFR-2 and CD31). Although PB-MNCs expressing 
these markers may contain a progenitor population, it is also possible that sorting 
strategies based on these markers isolates an enriched HSC population that aberrantly 
express some endothelial markers.   
 The second method of EPC identification involves the generation of endothelial-
like colonies from peripheral blood samples. EPCs obtained from PB samples expanded 
ex vivo contain multiple cell types from different origins (21; 22; 25; 29) although it is 
unclear which (if any) of these cells are directly involved in blood vessel growth. The use 
of several different culture methods for ex vivo expansion/differentiation of PB-MNCs 
has also generated conflicting data (28), and made comparative analysis between studies 
extremely difficult.  The lack of consistency in defining and characterizing EPCs has also 
led to a number of reports that refute the ability of bone marrow cells to incorporate into 
blood vessels in vivo (3; 44; 45).   
 The objective of this study was to definitively resolve the functional contribution 
of bone marrow-derived EPCs in post-natal neovascularization. The first step in reaching 
this objective was to rigidly define the target cell population. For the purpose of this 
study, we define “EPCs” as all bone marrow-derived cells that differentiate into mature 
endothelial cells in vivo. Mature endothelial cells are further defined as cells that express 
VE Cadherin. It follows that, for this study, EPCs are all bone marrow-derived cells that 
express VE Cadherin. 
  Our overall approach was to generate a mouse model in which the ability to 
produce viable EPCs was drastically reduced or eliminated.  The general strategy, 
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Figure 3.1: General Strategy for EPC Depletion. The general strategy for EPC 
depletion involves the genetic manipulation of bone marrow so that the cells contain a 
suicide gene regulated by VE Cadherin transcription. The manipulated bone marrow is 
then transplanted into a WT, lethally irradiated host. All bone marrow cells then contain 
the VE Cadherin regulated suicide gene. The majority of bone marrow cells do not 
express VE Cadherin, so they are unaffected by the genetic manipulation. However, all 
bone marrow-derived cells that begin to express VE Cadherin (and only those that begin 
to express VE Cadherin) undergo apoptosis regardless of lineage. WT=Wild Type, 
BM=Bone Marrow, HSC=Hematopoietic Stem Cell, LPC=Lymphoid Progenitor Cell, 
MPC=Myeloid Progenitor Cell. 
 
 
differentiate toward an endothelial lineage, they undergo apoptosis. To this end, we first 
devised a retroviral (RV) bone marrow-transduction strategy in which an expression 
construct could be delivered to the bone marrow. The construct was designed so that as 
bone marrow cells express VE Cadherin (an endothelial cell marker), they will undergo 
apoptosis.  However, our vector, the Retrovirus for Endothelial cell Death (RED), was 
unable to effectively initiate apoptosis in target cells, rendering this strategy unusable for 
BMT experiments. Therefore, we employed a second strategy in which the RED 
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construct was included in a transgenic mouse line (referred to as the Cre-Induced 
Endothelial cell Death [CrIED] mouse) that we planned to use in bone marrow 
transplantation experiments.  Due to unanticipated complications in our strategy, the 





Male ROSA26-βgeo mice(130), CAG-cre/Esr1 mice(131), and wild type 
C57BL/6 mice were purchased from the Jackson Laboratory.  Tie2Cre-ERT2 (132) mice 
were generously donated by Dr.  Hanjoong Jo (Emory University, Wallace H.  
Department of Biomedical Engineering).  All animals were fed a standard chow diet ad 
libitum and had free access to water.  All protocols were approved by the Institutional 
Animal Care and Use Committee and carried out in accordance with the federal 
guidelines on the principles for the care and use of animals in research. 
 
Generation of Retroviral Plasmids 
 All plasmids were propagated in Top10 E.Coli (Invitrogen).  Transformed E.Coli 
were grown on LB-Agar plates containing 50 μg/mL of ampicillin.  For large scale 
plasmid preparation, inoculated cultures were grown overnight in 2 L Erlenmeyer flasks 
containing 200 mL of LB-broth supplemented with 50 μg/mL of ampicillin.  Plasmid 
DNA was isolated using Qiagen HiSpeed Plasmid Maxi-prep. 
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 Construct pFloxLuc: 5’ and 3’ loxP sites were added sequentially to the pGL3-
basic vector (Promega) encoding modified firefly luciferase.  Forward and reverse single 
strand oligonucleotides (Table A1) were synthesized (IDT DNA Technologies) and 
annealed so that the double stranded sequence contained a HindIII overhang with 
complete HindIII recognition site at the 5’end, a loxP sequence, and a HindIII overhang 
lacking the complete recognition site at the 3’ end.  The annealed, double-stranded oligo 
was then ligated into the HindIII site located in the MCS of the pGL3-basic vector.  A 
second pair of forward and reverse single strand oligonucleotides (See Appendix B) were 
synthesized and annealed so that the double stranded sequence contained SalI overhang 
lacking the complete recognition site at the 5’end, a loxP sequence, and a SalI overhang 
with complete SalI recognition site at the 3’ end.  The annealed, double-stranded oligo 
was then ligated into the SalI site at the 3’ end of the luciferase gene.  The resulting 
construct, termed pFloxLuc, contained a modified firefly luciferase gene and 
polyadenylation signal flanked by LoxP sequences. 
Construct pRED/REF: The pRED and pREF retroviral plasmids were constructed 
from the pTJ124 vector backbone (Donated by Dr. TJ Murphy, Emory University).  A 
polylinker sequence containing ApaI, DraIII, HindIII, and SalI restriction sites was 
ligated into pTJ124 following removal of the Zeo-eGFP sequence by digestion with StuI 
and NotI.  The resulting plasmid, termed pSRO2, was essentially an empty MMLV-based 
SIN vector with a multiple cloning site between the retroviral LTR’s.  Either the ΔN-Bax 
sequence from pBax-N1 (for pRED) or the EGFP coding sequence from pEGFP-N1 (for 
pREF) was cloned into the ApaI and DraIII sites of pSR02.  The floxed luciferase 
sequence from pFlox-luc was then cloned into the HindIII and SalI sites of pSR02.  
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Finally, the 2.5 kb fragment of the murine VE Cadherin promoter (from pVECad, 
donated by Dr.  Roy Sutcliffe, Emory University, Department of Medicine) was ligated 
into the remaining SalI site.  The sequence of the resulting plasmids, termed pRED and 
pREF, was verified by restriction digests and direct sequencing.   
Construct pREF3: The EGFP coding sequence from pEGFP-N1 was cloned into 
the ApaI and DraIII sites of pSR02.  The 2.5 kb fragment of the murine VE Cadherin 
promoter was then ligated into the SalI site of pSR02.  The resulting sequence construct, 
pREF3, was identical to pREF2 except it lacked the floxed luciferase reporter.   
 
 
Generation of Transgenic IED mice 
 The VE-Cadherin promoter-floxed luciferase- ΔN-Bax fragment from pRED and 
VE-Cadherin promoter – EGFP fragment from pREF3 were isolated by digestion with 
SalI and DraIII and gel purified.  Pronuclear micro-injections were performed by the 
Emory Transgenic Mouse and Gene Targeting Core in C57BL/6 embryos, which were 
transferred to pseudo pregnant females for the generation of founders.  PCR from tail 
biopsies of offspring identified two founders.   
 
Retroviral Production 
The 293-derived Phoenix Amphotropic (Phx-Ampho) and Ecotropic (Phx-Eco) 
packaging cell lines (ATCC) were grown to 80% confluence in 100ml plates with growth 
media consisting of DMEM (Gibco) supplemented with 10% Fetal Bovine Serum, L-
glutamine, and Pen/Strep (Invitrogen).  Before transfection, 10 ml of fresh media was 
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added to each plate.  Transfections were performed following the JetPRIMETM 
manufacturers recommended protocol (Polyplus).  Briefly, 10 μg of plasmid DNA was 
added to 500 μL of JetPRIMETM buffer and briefly vortexed and centrifuged.  Twenty μL 
of JetPRIMETM were then added to the DNA mixture, which was again briefly vortexed 
and centrifuged.  The DNA/JetPRIMETM mixture was incubated for 10 minutes at room 
temperature, then the solution was added to the cells in a drop-wise manner and 
transported to a 37 Co/5% CO2 incubator.  After 6-8 hours, transfection media was 
aspirated and replaced with 25ml of fresh media.  Twenty-four hours after the start of 
transfection, the media was again aspirated, 9 ml of fresh media was added, and the cells 
were transferred to a 32 Co/5% CO2 incubator.  Fourty-eight hours after transfection, the 
conditioned media was collected in a 10 mL syringe and passed through a 45µm low 
protein binding filter and either frozen and stored at -80˚Cor used immediately for 
transduction.  Conditioned media was collected afterward at 12 hour intervals for up to 7 
days following transfection. 
 
Bone Marrow Isolation and Transduction 
 A detailed protocol for bone marrow transduction is included in the Appendix. 
The transduction protocol was modified from Ide, et al (133). Briefly, mice were 
euthanized by CO2 inhalation and the long bones were flushed with cold PBS.  Bone 
marrow cells were labeled with anti-Sca1-PE antibodies (Miltenyi), then separated with 
anti-PE micro-beads (Miltenyi) using an AutoMACS sorter (Miltenyi).  Sorted cells were 
cultured in Stempro-34 media (Invitrogen) supplemented with mSCF (100 ng/ml, Sigma), 
Flt-3 (100 ng/ml, R and D), Il-3 (20 ng/ml, Sigma), and Il-11 (100 ng/ml, Sigma) for 24 
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hours.  Retroviral supernatant was centrifuged overnight at 4˚C and 9000g, then the 
resulting pellet was resuspended at 1/20 the original volume in complete Stempro-34 with 
cytokines.  Retrovirus was bound to retronectin coated plates by centrifugation for 1 hr at 
4˚C and 2500 rpm.  Bone marrow cells were plated on RV/retronectin plates, and 
cultured for 24 hrs at 32 Co. 
 
Cell Lines and Culture 
The NIH/3T3 cells (ATCC) were grown at 37 Co, 5% CO2 in DMEM 
supplemented with 10% calf serum, L-glutamine, and Pen/Strep, respectively.  The 3T3 
cells were grown in 10 cm tissue culture-treated dishes to 80% confluence, then passaged 
at a ratio of 1:5.  SVEC4-10, HMEC-1, and MS1 cells (all obtained from ATCC) were 
grown at 37 Co, 5% CO2 in DMEM supplemented with 10% fetal bovine serum, L-
glutamine, and Pen/Strep in 10 cm tissue culture-treated dishes coated with gelatin until 
80% confluent, then passage at a ratio of 1:5.   
For transduction, cells were plated in 6-well dishes at 40% confluence.  Two mL 
of retrovirus and media was added per well, and supplemented with 8 μg/mL polybrene 
(Sigma).  Plates were spun in a spinning bucket rotary centrifuge pre-warmed to 32˚Cfor 
1 hr, then returned to the inital culture conditions.   
 
Retroviral Titration 
 A qPCR-based titration kit (Clontech) was used to determine viral copy number in 
each viral supernatant.  Viral RNA from 150 μL of retroviral supernatant was isolated 
and DNase purified.  Reverse transcription and qPCR was performed in a 96-well light 
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cycler (Applied Biosystems).  Threshold cycle values were calculated for serial dilutions 
of RNA from each virus, and copy number was calculated from an exponential standard 
curve generated from serial dilutions of premade MMLV-RNA standards.   
 
qRT-PCR 
 Genomic DNA or mRNA was purified using a commercial kit (Qiagen).  RNA 
was reverse transcribed into cDNA using the SuperScript™ III First Strand Synthesis 
System (Invitrogen), which was subsequently purified using a commercially available kit 
(Qiagen).  Primers were designed using PrimerQuest software (IDT DNA technologies) 
for mouse VE Cadherin, EGFP, and mouse 18s.  SYBR Green intercalating dye (Applied 
Biosystems) was used to perform real time PCR with the ABI Prism 7700 Sequence 
Detection System (Applied Biosystems).  Standards for each gene were amplified from 
cDNA and purified.  Standard concentrations were determined using spectrophotometric 
measurement at 260 nm, and standards were serially diluted to an appropriate range of 
concentrations.  Transcript concentration in template cDNA solutions was quantified 
from the linear standard curve, normalized to 18s copy number, and expressed as copies 
per 106 18s. 
 
TUNEL Stain 
 Mice were euthanized by CO2 inhalation, and pressure fixed in 10% formalin. 
Liver, heart, lung, spleen, kidney and aorta were dissected, embedded in OCT medium, 
and snap frozen at -80 oC. Tissues were sectioned in 7 μm slices, then stained using an 
ApopTag Red apoptosis detection kit (Millipore) according to the manufacturers’ 
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instructions. The ApopTag is based on the TUNEL assay, and labels the 3’-OH termini 




 Cell and tissue lysates were isolated using the Promega luciferase assay system.  
For tissue isolation, samples were homogenized for 30 seconds in a rotary tissue 
homogenizer, centrifuged for 1 minute at 10,000g, and then the supernatants were 
removed for analysis.  Total protein content was determined using a modified BCA assay 
(Biorad), and luminescence was quantified using a Zylux luminometer.   
 
Chemiluminescence Imaging 
Mice were anesthetized by i.p. injection of a mixture of xylazine (10 mg/kg) and 
ketamine (80 mg/kg) and, prior to imaging, all hair was removed from the legs and lower 
abdomen using depilatory cream (Nair, manufacturer).  Sterile filtered luciferin substrate 
dissolved in PBS was administered via i.p.  injection (150 mg/kg).  Mice were placed on 
a heated stage in an IVIS Lumina system (Caliper Life Sciences) and chemiluminescent 
images were recorded 3 minutes following luciferase injections.  After imaging was 
completed, mice were allowed to recover from anesthesia on a heating pad before being 






A Retroviral Bone Marrow Transduction Approach for Eliminating EPCs 
 Our initial approach was to implement a retroviral bone marrow-transduction and 
transplantation procedure that would allow us to selectively ablate EPCs.  As stated 
previously, we defined EPCs as all bone marrow-derived cells that express VE Cadherin. 
The proposed Bone Marrow Transduction and Transplantation (BMTT) strategy is 
outlined in Figure 3.2. In the BMTT approach, bone marrow cells are transduced ex vivo 
with a retrovirus containing a suicide gene driven by the VE Cadherin promoter.  The 
genetically modified cells are then transplanted into a lethally irradiated WT host, so that 
only the bone marrow contains the desired transgene.  Following hematopoietic 
reconstitution, the entire marrow compartment (including all cells derived from bone 
marrow) of the recipient animal carries the retroviral construct.  Since VE Cadherin is 
only expressed in mature endothelial cells, the majority of the cells from the BM are 
unaffected by the suicide gene. In any BM cells that differentiate toward an endothelial 
lineage (i.e., BM-derived endothelial cells), the transgene is activated, causing cell death.  
As a result, the transplant recipient, containing RV-transduced marrow, is unable to 
produce viable BM-derived endothelial cells.   
Implementation of the BMTT strategy required careful design of the Retrovirus 
for Endothelial cell Death (RED) construct.  To circumvent a potential reduction in titer 
due to expression of a toxic gene product in the retroviral packaging cell line, we 
incorporated the cre/LoxP system in our construct design.  The RED vector was derived 
from TJ124 (Figure 3.2): a self-inactivating Moloney murine leukemia virus (SIN-
MMLV) with a mutation in the 3’ long terminal repeat (LTR) TATA-box that inactivates 
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the endogenous retroviral promoter. To generate RED, the murine VE Cadherin promoter 
driving expression of a floxed luciferase reporter gene (including a poly-adenylation 
[poly-A] signal) upstream of a sequence corresponding to amino acids 112-192 of the 
human Bax gene (ΔN-Bax) and a second poly-A signal was inserted in place of the 
cytomegalovirus promoter/enhanced green fluorescent protein (CMV-EGFP) sequence 
between the retroviral LTRs of TJ124 (Figure 3.2).  The RED expression construct was 
incorporated into the retroviral backbone in reverse orientation (i.e. in the 3’ to 5’ 
direction) as additional security to prevent expression of the toxic ΔN-Bax protein in the 
packaging cell line and to avoid truncation of the viral RNA due to the presence of an 
internal poly-A signal between the retroviral LTRs.   
 A Retrovirus for Endothelial cell Fluorescence (REF, Figure 3.2) was generated 
identically to RED, except that EGFP was inserted in place of the ΔN-Bax gene.  Both 
the RED and REF constructs were designed so that when a homogeneous cell population 
was transduced (i.e. bone marrow), only the cells that differentiate into endothelial cells 
undergo apoptosis (with RED) or become fluorescently labeled (with REF), respectively.  
A simplified Retrovirus for Endothelial cell Fluorescence version 3 (REF3, Figure 3.2) 
was also generated which contains the VE Cadherin promoter directly driving expression 
of EGFP.   
 
Feasibility of a Bone Marrow Transduction Strategy 
Due to the large number of RV constructs and packaging systems available, as 
well as the innumerable reports for the optimization of RV-mediated bone marrow 



































Figure 3.2: Strategy for Retrovirus-Induced Bone Marrow-derived Endothelial Cell 
Ablation. The Bone Marrow Transduction and Transplantation (BMTT) strategy requires 
the isolation of bone marrow cells from a mouse ubiquitously expressing Cre 
recombinase. Bone marrow cells are transduced with the RED vector; a construct that 
induces cell death in an endothelial-specific manner.  Cells containing the RED construct 
are transplanted into a lethally irradiated WT host.  After engraftment, bone marrow cells 
from the resulting chimera will undergo apoptosis if they differentiate into endothelial 
cells. B) All constructs were derived from a self-inactivating (SIN) MMLV vector. TJ124 
contains a CMV promoter driving expression of the EGFP/Zeocin resistance gene. The 
REC vector consists of a CMV promoter driving expression of Cre recombinase, with an 
Internal Ribosome Entry Site (IRES) regulating expression of Puromycin resistance. 
REF3 contains an internal VE Cadherin promoter driving expression of EGFP, followed 
by a poly-A sequence.  The Insert is in reverse orientation to the retroviral LTRs to allow 
transcription through the poly-A sequence during virus production.  The REF construct 
contains the VE Cadherin promoter driving expression of a floxed luciferase reporter, 
upstream of EGFP.  This construct generates endothelial specific expression of luciferase 
until activated by Cre, at which point the floxed reporter is excised and EGFP is 
expressed.  The RED construct contains the VE Cadherin promoter driving expression of 
a floxed luciferase reporter, upstream of ΔN-Bax, thus generating endothelial specific 
expression of luciferase until activated by Cre, at which point the floxed reporter is 
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Figure 3.3: Comparison of BOSC23 and Phoenix Ampho Packaging Cell Lines 
Flow cytometry was performed on unsorted bone marrow transduced with TJ124 
(containing an internal CMV promoter driving GFP expression) retroviral supernatant 
obtained from BOSC23 or Phoenix Ampho packaging cell lines.  The number of GFP 
positive cells was higher when transduced with virus generated from the Phoenix Ampho 


















Figure 3.4: Effect of LSC on transduction efficiency.  3T3 cells were transduced with 
non-concentrated (A) or 10X concentrated with LSC (B) TJ124 retrovirus, then imaged 
for fluorescence and examined with flow cytometry. Concentration by LSC increased the 
amount of GFP positive cells more than 3-fold.   
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transduction of bone marrow prior to testing our custom-designed constructs.  Following 
a simplified protocol established by Gough and Raines (134), we transduced murine bone 
marrow cells with RV supernatant containing TJ124 (an MMLV-based SIN vector with  
CMV driven EGFP) generated from either BOSC 23 (135) or Phoenix Ampho (136) 
packaging cell lines.  GFP expression in TJ124-transduced cells was near baseline 
following infection with supernatant from the BOSC 23 cell line, and only observed in 
~3% of TJ124-transduced cells infected with supernatant collected from the Phoenix 
Ampho cell line (Figure 3.3).  Due to the observed inefficiency of gene delivery to bone 
marrow cells, we explored additional techniques to improve transduction rates.   
Significant improvements in titer have been obtained by concentration of RV 
supernatant with overnight, low speed centrifugation (LSC) (133).  In our hands, 
transduction of 3T3 cells improved 3-fold following 10x concentration of TJ124 
(generated with the Phoenix Ampho packaging line) using LSC (Figure 3.4).   
  Improvements in bone marrow transduction have also been reported following 
enrichment for cells expressing Stem Cell Antigen 1 (Sca1).  Magnetic bead sorting 
resulted in an increase in Sca1 purity to ~85%, compared to ~5% in whole bone marrow 
(Figure 3.5).  Sorting for Sca1 prior to the addition of 20x concentrated TJ124 RV 
supernatant enabled transduction efficiencies of 20% in bone marrow cells when GFP 
expression was analyzed by flow cytometry 48 hours after transduction (Figure 3.5). 
Transduction efficiencies could be further enhanced through the use of retronectin-
mediated transduction with a concentrated MSCV vector expressing GFP. Lethally 
irradiated mice receiving transplants of cells transduced with concentrated RV through 




































Figure 3.5: Optimized Bone Marrow Transduction Protocol.  (A) Flow cytometry for 
Sca1+ in whole bone marrow before (top) and after (bottom) enrichment with magnetic 
bead sorting. (B) Flow cytometry for GFP expression in Sca1+ cells 48 hours after 
transduction with 20X LSC concentrated TJ124. (C) Flow cytometry on peripheral blood 
sample of a BMT mouse receiving cells transduced with an MSCV vector expressing 
GFP and Retronectin-enhanced transduction protocols following Sca1 selection. The 
schematic in (D) shows the final BM transduction protocol.  Donor cells are sorted for 
Sca1+ and cultured with concentrated RV in Stempro-34 media with a cytokine cocktail 
on Retronectin coated plates.  (C courtesy of Dr. Natalia Landazuri; Orange is MSCV-
GFP transduced, blue is untreated).   
 
 
 (Figure 3.5, see Methods for a detailed protocol).  Our final bone marrow transduction 
protocol consisted of a Sca1 sort, culture in mitogenic media, followed by a retronectin-
facilitated transduction using virus concentrated with LSC (Figure 3.5).  The ability to 
consistently achieve transduction efficiencies of at least 85% demonstrated the feasibility 
of using an MMLV-based vector for gene delivery to bone marrow cells in mice.   
 
An in vitro System for Assessment of Retroviral Function 
To establish a system for evaluating the efficacy of the RV constructs in vitro, we 
examined the susceptibility of various cell lines to retroviral-mediated gene transfer.  An 
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immortalized mouse lymphoid endothelial line [SVEC4-10 (137)], a human dermal 
microvascular endothelial cell line [HMEC-1 (138)], and a mouse embryonic fibroblast 
cell line [NIH/3T3 (139)] were transduced with concentrated TJ124.  Robust fluorescence 
was seen in all cell types, with >90% of SVEC4-10 and 3T3 cells expressing GFP.  The  
HMEC-1 line showed more modest transduction efficiency, with ~35% of the cells 
expressing GFP (Figure 3.6).   
Activity of the mouse VE Cadherin promoter was then examined by transducing 
different cell types with 10x concentrated REF3 (in which the VE Cadherin promoter 
drives GFP expression directly).  As shown in Figure 3.6, the percentage of GFP+ cells in 
both SVEC4-10 and HMEC-1 cells was markedly lower following REF3 transduction 
(3.3% and 1.4%, respectively) than TJ124 transduction (84.9% and 35.3%, respectively).  
Interestingly, transduction of 3T3 cells with REF3 yielded the highest number of GFP+  
cells out of the 3 cell lines.  The low fluorescence intensity of cells transduced with REF3 
indicates that the VE Cadherin promoter provides weak transcriptional activity. The weak 
fluorescence and low transduction efficiencies in the SVEC4-10 and HMEC-1 lines was 
suprising, since we anticipated robust activity of the VE Cadherin promoter in endothelial 
cells. 
 
Attempted In vitro Validation of RED/REF 
 Although the VE Cadherin promoter showed limited activity when delivered to 
endothelial cells with a retrovirus, it was still necessary to assess the functionality of  
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RED and REF in vitro.  HMEC-1 cells were first transduced with a retrovirus containing 
a bicistronic expression cassette to overexpress Cre recombinase and confer puromycin 
resistance (REC).  Following antibiotic selection, the cells (HMEC-1/Cre) were 
transduced with REF and assessed for GFP expression with flow cytometry.  Even after 3 

























Figure 3.6:  Evaluation of Cell Lines For Use In Assessment of Construct Function.   
SVEC4-10, HMEC-1, and 3T3 cells were transduced with either 10x concentrated TJ124 or 
REF3.  GFP was detected either microscopically (A) or with flow cytometry (B).  All cell lines 
showed robust GFP expression following transduction with TJ124.  GFP was detected in all cell 
lines following transduction with REF3, but expression was reduced compared to that seen 




However, HMEC-1/Cre cells transduced with TJ124 in parallel expressed GFP in nearly 
75% of the cells.   
 The absence of GFP in REF transduced HMEC-1/Cre cells indicated that the REF 
construct was not efficiently transducing the target cells, or that Cre-mediated 
recombination was inhibited.  To address this issue, luciferase activity was examined 
following RED/REF transduction. Measurement of luciferase activity allowed us direct 
assessment of the retroviral VE Cadherin promoter activity within the RED and REF 
constructs. Two cell lines, SVEC4-10 and 3T3 cells, were transduced with REF and 
RED, and then cell lysates were assayed for chemiluminescence using a luciferase assay.  
Both RED and REF transduced SVEC4-10 cells exhibited luciferase activity above 
baseline (Figure 3.7).  3T3 cells transduced with RED and REF showed higher luciferase 
activity than SVEC4-10 cells (Figure 3.7), but the values were still extremely low.  The 
results from the luciferase assay indicate the presence of luciferase in lysate from RED 
and REF transduced SVEC4-10 and 3T3 cells, albeit at very low levels.  These data 
verify that the luciferase gene was functional in both constructs.  However, we  
 could not determine whether the low level of luciferase activity was due to low 
transduction rates of RED and REF, inactivation of the vectors following transduction, or 
low transcriptional activity of the VE Cadherin promoter.   
 
Retroviral Integration 
 The use of a tissue-specific promoter confounded our ability to determine the 
overall transduction efficiency with RED, REF and REF3 vectors.  Since GFP 
fluorescence was used as an endpoint, it was impossible to determine if the absence of  
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Figure 3.7: REF and RED Function in vitro.  SVEC4-10 were transduced with REC 
and selected for puromycin resistance.  Flow cytometry was performed on the SVEC4-
10/Cre cells following transduction with REF (A) or TJ124 (B).  TJ124 transduction 
generated an increase in the percentage of cells expressing GFP, while transduction with 
REF3 led to no appreciable GFP fluorescence.  C) Lysates from SVEC4-10 and 3T3 cells 
transduced with either RED or REF showed low luciferase activity, but 
chemiluminescence was elevated over baseline.   
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signal was due to ineffective transduction or inactivity of the VE Cadherin promoter 
following transduction cells.  Fifty-one percent of 3T3 and 24% of MS1 cells (an 
immortalized mouse endothelial cell line) transduced with TJ124 expressed GFP.  
However less than 2% of either cell type expressed GFP when transduced with REF3 
(Figure 3.8).  We anticipated a low percentage of GFP+ events in 3T3 cells containing 
the REF3 construct, since the VE Cadherin promoter should not be active in fibroblasts.  
However, if both viruses were produced at equivalent titers, we expected the frequency of 
GFP-positive MS1 cells after transduction with REF3 to have been equivalent to that 
seen following transduction with TJ124.  In light of this evidence, we hypothesized that 
our tissue specific vectors were not generated at comparable titers.   
A retroviral titering kit that determines the number of viral RNA copies in an 
aliquot of viral supernatant via qRT-PCR by amplification of the RV packaging 
sequence, was then used to estimate titer for the different vectors. This approach allowed 
us to circumvent the complications associated with titering tissue-specific vectors.  
As shown in Table 3.1, PhxE packaging cells produced virions at an equivalent rate for 
TJ124, REF, and REF3; a surprising result given the low number of GFP+ cells 
following REF and REF3 transduction.  To explore the possibility that REF and REF3 
were incorporating into target cells with less efficiency than TJ124, qRT-PCR for GFP 
was performed on genomic DNA from transduced 3T3 and MS1 cells.  Remarkably, 
relative GFP copy number in genomic DNA from TJ124 transduced cells was ~10 times 
higher then in genomic DNA from REF or REF3 transduced cells (Figure 3.8).  This 


















































Figure 3.8: Genomic Integration of Vector DNA following REF and REF3 
Transduction. A) Flow cytometry on MS1 and 3T3 cells following transduction with 
TJ124 showed.  B) Quantitative Real Time-PCR for EGFP indicated a 10 to 20-fold 
higher frequency of genomic integration following transduction with TJ124 compared to 
REF or REF3.   
 
 
ability of the vectors to incorporate into the host cells genomic DNA was greatly 
diminished.   
A Transgenic Bone Marrow Transplantation Approach to Eliminating EPCs  
 The difficulties encountered using the BMTT approach led us to pursue an 
alternative transgenic mouse strategy for EPC depletion studies.  Two female founders  
Table 3.1: Estimated viral load of vectors.  The number of viral RNA copies per mL of 





were established that carried the RED and REF3 transgenes (founders 15 and 19), which 
were then crossed with male CAGGCreTM mice.  Protein lysates isolated from tail  
clippings were taken from both founders and their F1 progeny, and a luciferase assay was 
performed to assess transgene function.  Some of the offspring from the #19 founder 
contained the transgene, as confirmed by PCR analysis, but tail lysates showed no 
luciferase activity. However, all offspring from the #15 founder that contained the 
transgene (as confirmed by PCR analysis) also showed robust luciferase activity (data not 
shown).  These results indicate that there were multiple integration sites in the #19 
founder, at least one of which contained an inactive copy of the transgene.  Therefore, all 
subsequent studies were performed on mice from the #15 founder. 
 The proposed transgenic mouse approach to eliminate bone marrow-derived 
endothelial cells is outlined in Figure 3.9.  In this strategy, bone marrow from the CrIED 
mouse is transplanted into a lethally irradiated recipient.  The resulting BM-chimera 
contains the CrIED transgene only in the bone marrow.  When given tamoxifen (TM), the 
luciferase gene from the RED construct is then excised.  Due to the inherent specificity of 
the VE Cadherin promoter, the toxic ΔN-Bax is only expressed as the bone marrow cells 






























Figure 3.9: General CrIED transgenic strategy.  (A) In the CrIED BMT strategy, bone 
marrow from mice containing the Cre Inducible Endothelial cell Death (CrIED) 
transgenes is transplanted into a lethally irradiated WT recipient.  Following engraftment, 
the chimeras are treated with Tamoxifen to activate cre-mediated recombination.  Any 
bone marrow-derived cells that begin differentiation into endothelial cells will undergo 





Functional Assessment of CrIED Transgene ex vivo 
 In order to examine the function of our transgenic construct, an ex vivo approach 
was utilized that permitted avoidance of the complexity frequently encountered in an 
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intact animal.  Aortic endothelial cells from the CrIED transgenic mouse were isolated 
and immortalized with the SV-40 Large T antigen and expanded in culture (cells were 
generated by Chi When Ni, Emory University).  Flow cytometry was performed to detect 
GFP expression in immortalized mouse aortic endothelial cells (iMAECs) derived from 
CrIED or C57BL/6J.  There was no detectable GFP fluorescence in CrIED/iMAECs, and 
no discernable shift in the fluorescence intensity compared to C57B/6J/iMAECs (Figure 
3.10).  The absence of any GFP signal in CrIED/iMAECs indicates that the VE Cadherin-
EGFP expression construct is not functional in the CrIED mouse.   
 We next examined luciferase activity in cell lysates from CrIED/iMAECs.  
Although VE Cadherin expression by qRT-PCR in iMAECs was low (data not shown), 
we were able to detect a slight but significant increase in luminescence in lysates from 
CrIED/iMAECs compared to lysates from C57BL/6/iMAECs (Figure 3.10).  The 
magnitude of the signal was not as high as we had anticipated, but the data indicated that 
luciferase was indeed expressed by the RED transgene in cultured CrIED/iMAECs.   
 The ΔN-Bax gene was activated in culture by the addition of 4-hydroxytamoxifen 
(4-OHT) to the culture media of CrIED/iMAECs.  Cell viability was assessed from 0 to  
 48 hours following addition of 4-OHT.  No cytotoxicity was observed in either 
CrIED/iMAECs or C57B/6J/iMAECs (Figure 3.11).  The failure to detect dead cells in 




Figure 3.10: Characterization of iMAECs from CrIED mice.  Aortic endothelial cells 
were isolated from C57B/6J and CrIED mice, and immortalized with the SV-40 Large T 
antigen to generate iMAECs.  CrIED iMAEC showed no detectible GFP positive cells 
(A) or shift in GFP fluorescence (B) when analyzed with flow cytometry.  (C) 
Chemiluminescence of lysates isolated from iMAECs assessed to determine luciferase 
activity in iMAECs.  Luciferase activity in lysates from CrIED-derived iMAECs was 




Figure 3.11: Sensitivity of CrIED-Derived iMAECs to 4-Hydroxytamoxifen.  
iMAECs from CrIED and C57B/6J were cultured in normal media supplemented with 4-
hydroxytamoxifen to induce Cre recombination, then stained with a Live/Dead kit from 
0-48 hours.  No changed in cell viability was observed between groups.  Green = Live, 
Red = Dead.   
 
 
 Luciferase activity In Vivo 
 The transcriptional activity of the VE Cadherin promoter was much lower than 
anticipated in all cell culture experiments. We hypothesized that the low promoter 
activity was a result of the in vitro environment, and that in vivo gene regulation by the  
VE Cadherin promoter would be stronger. Therefore, we sought to examine the activity 
of the VE Cadherin promoter in vivo. Transgenic CrIED mice were injected with D-
luciferin substrate in PBS and imaged simultaneously using an IVIS chemiluminescence 




Figure 3.12: Chemiluminescence of CrIED mice.  WT and CrIED mice were injected 
with D-luciferin substrate and imaged with an IVIS chemiluminescence imaging system.  
Chemiluminescence was easily detected in the CrIED transgenic animals, but none was 
observed in the WT.  
 
 
 signal was detected at all of the exposed skin in the CrIED animals (Figure 3.12).  This 
data verified that the luciferase gene was indeed expressed, but the luminescence imaging  
 system did not have the spatial resolution to determine if luciferase was expressed in a 
tissue-specific manner. 
Results from earlier in vitro experiments, specifically the comparison of GFP 
expression between REF3 transduced 3T3 and MS1 cells (Figure 3.8), suggested that VE 
Cadherin expression was not restricted to endothelial cells.  To address the issue of 
promoter specificity in vivo, we attempted to stain tissues sections from CrIED mice 
using an antibody for luciferase. Unfortunately, no anti-luciferase antibody was found 
that performed well in histological applications.  As an alternative approach to address  
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Figure 3.13: Luciferase Activity In CrIED Tissue Lysates.  Both protein lysates and 
mRNA were isolated from tissue samples of liver, kidney, lung, heart, aorta and spleen in 
CrIED mice. A) Luciferase activity in protein lysates isolated showed abundant levels of 
luciferase in the lung and Aorta.  B) qPCR on mRNA isolated from the same tissues was 
performed to assess VE Cadherin expression . A similar trend was noted between A and 
B, with the exception that VE Cadherin and luciferase levels within heart tissue.   
 
 
promoter specificity, luciferase activity was examined in protein lysates from multiple 
dissected tissues. Using this method, differential expression of luciferase was observed 
throughout liver, kidney, lung, aorta, heart and spleen. Luciferase activity was highest in 
the lung and aorta (both endothelial-rich tissues), moderately expressed in the heart and  
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spleen, and barely detectable in the liver and kidney (Figure 3.13).  VE Cadherin gene 
expression was then measured in the same tissues by qRT-PCR (Figure 3.13).  Lung and 
aorta showed high VE Cadherin expression similar to that observed in the luciferase 
assay. Minor discrepancies were noted between luciferase activity and qRT-PCR data in 
the heart and kidney, which showed high VE Cadherin expression but relatively low 
luciferase activity.  In general, however, these data suggest that the VE Cadherin 
promoter in the CrIED transgene confers endothelial specific expression of the luciferase 
reporter.   
 
Induction of Cre Activity and Absence of Apoptotic Cell Death 
 For EPC depletion, it was only necessary to use bone marrow from the CrIED 
mouse. However, to ensure that the transgene was functioning properly, TM was 
administered to the intact CrIED mouse.  Not surprisingly, the TM treated CrIED mice 
quickly showed signs of distress and soon had to be euthanized.  TUNEL stain on lung 
sections revealed considerable apoptosis, while no apoptosis could be detected in the 
liver (Figure 3.14). These data indicate that apoptosis was localized to the same tissues in 
which high luciferase activity was detected.  Unfortunately, several of the WT animals 
treated with TM also showed signs of distress. Those animals were also euthanized, and  
 TUNEL stain on WT lung tissue showed a similar staining pattern to that seen in the 
CrIED lung (Figure 3.14).   
 Since the initial dose of tamoxifen (10 mg/day) was lethal in all mice, a dose 
response curve was generated by treating mice with daily injections of 0 to 10 mg of 
tamoxifen for up to 5 days.  Significant mortality was observed above  the 3 mg/day dose 
 64
(Figure 3.14).  Lungs from animals receiving each dose were isolated and luciferase 
activity was measured from the extracted protein.  A dose-dependent decrease in 
luminescence was observed following TM delivery, with all treatment groups showing a 
loss of luciferase activity relative to the TM-treated IED only mice (i.e. mice lacking the 
inducible Cre so that luciferase activity was maintained following TM treatment).  These 
results indicate a functional Cre/LoxP system in the CrIED transgene (i.e. a loss in 
luciferase activity due to excision of the gene) but the apoptosis seen by TUNEL stain 
was due to the toxicity of excessive tamoxifen levels and not ΔN-Bax expression.   
 To further verify that the Cre/LoxP system was functional, CAG-cre/Esr1 mice 
were crossed with ROSA26-βgeo mice and treated with 3 mg TM/day in parallel with 
CrIED mice.  Upon TM-mediated activation of Cre, CAG-cre/Esr1x ROSA26-βgeo mice 
express the βgeo gene and stain positively for β-gal activity.  As shown in Figure 3.15, 
multiple tissues stained positively for β-gal activity following TM administration, 
indicating successful recombination.  However, none of the CrIED mice showed signs of 
physical distress, and TUNEL stain of the multiple tissues failed to detect significant 
apoptosis (data not shown).  Taken together, these data demonstrate that the CrIED 
transgene functions only as a VE Cadherin luciferase reporter, but the inducible 
expression of ΔN-Bax does NOT cause cell death.   
 
Discussion 
 The data presented here are the results of two attempts to generate a mouse model 
of EPC depletion.  Unfortunately, neither approach attained the desired objective.  
Broadly speaking, the failure of both strategies was the “top-down” implementation of  
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Figure 3.14: Apoptosis In CrIED Tissue Following Tamoxifen Treatment.  CrIED mice 
treated with 10 mg/mouse/day of tamoxifen showed signs of distress and were sacrificed within 
4 days.  A) TUNEL staining on lung showed evidence of apoptosis restricted to the lung, while 
no apoptosis was detected in the liver. WT animals treated with TM doses >3 mg also showed 
signs of distress, so were sacrificed tissues were isolated. B) TUNEL staining on lung from WT 
mice showed a similar pattern of apoptotic staining was seen in the lung of CrIED animals (B).  
C) A Kaplan-Meier survival curve in WT mice showed TM-induced toxicity in doses greater 
than 3 mg/mouse indicating that deaths seen were not due to the CrIED construct.  D) A dose 
response to tamoxifen treatment was performed, and luciferase activity was examined in lysates 
from lungs of TM-treated CrIED mice isolated immediately following sacrifice. A dose-
dependent decrease in luciferase activity indicates gene excision due to cre-mediated 
recombination.   
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Figure 3.15: Tamoxife-induced Cre Activity In CAGCreTM Mice.  CAGCreTM mice were 
crossed with R26R mice.  Following 3 days of treatment with 1 mg/mouse TM, tissues were 
stained for β-gal activity.  Evidence of recombination was seen in multiple tissues of the 
transgenic but not in WT controls.  Kidney from a LacZ reporter mouse was used as a positive 
control.   
 
 
each system.  Rather than individually testing each component of the retroviral constructs 
(i.e. the promoter, luciferase reporter, cre/loxP system and ΔN-Bax activity), we first 
generated the complete RED vector. When the vector did not work, it was then necessary 
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to backtrack to isolate the problem. A factor further confounding our results was the 
apparent disconnect observed between VE Cadherin expression in vitro and in vivo. We  
assumed that the VE Cadherin promoter, while nearly inactive in cultured endothelial 
cells, would confer endothelial specific gene expression in the intact animal. However, 
our inability to use the VE Cadherin promoter to robustly activate our construct in vitro 
prevented us from validating functionality of all aspects of the vector prior to its 
utilization in a transgenic setting.  
 The use of retroviral constructs for expression of exogenous genes in the bone 
marrow is a challenging task that has been limited by the inability to efficiently transduce 
a majority of the bone marrow compartment. Despite the ability of other groups to 
achieve maximum transduction efficiencies of <50%, experience with our protocol 
indicates that nearly the entire bone marrow population can be transduced (Figure 3.5).  
Several caveats to our strategy exist, however.  First, we must be able to generate 
extremely high titers of retrovirus.  Second, our promoter cannot be silenced; a problem 
frequently observed following bone marrow transduction.  We assumed that the limiting 
factor in our procedure was the aforementioned titer problem.  However, the RED and 
REF constructs appeared to generate a sufficient number of infectious particles.  The 
problem, rather, was a reduction in the frequency of viral-to-host genomic integration. 
Although virus particles were generated, they were not infectious. The inefficient 
integration of our construct was entirely unanticipated, and we can only speculate as to 
why this occurred.  
 During virus production, the retroviral plasmid is transfected into a packaging cell 
line where viral genes are previously introduced in trans.  The viral RNA is the 
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transcribed from the 5’LTR to the 3’LTR of the transfected plasmid, where a poly 
adenylation (poly-A) sequence in the 3’ U3 region halts transcription.  Once integrated 
into the host genome, the same poly-A signal in the U3 region of the 3’LTR regulates 
mRNA capping of the viral transcript in the host cell (140; 141).  In the RED, REF and 
REF3 constructs, however, the use of an internal poly-A signal required us to insert the 
expression construct in reverse orientation relative to the direction of the retroviral LTRs.  
Therefore, full viral RNA would theoretically be transcribed from the 5’LTR to 3’LTR 
without premature transcriptional terminate. We predicted that this orientation would 
generate high titer retrovirus, as the inclusion of an internal poly-A signal has been 
reported to improve virus performance(142; 143).  Sequence analysis of our constructs, 
however, showed that the SV40 poly-A sequence downstream of EGFP, ΔN-Bax, and 
luciferase in RED, REF and REF3 also contained the AAUAAA poly-A motif in reverse 
orientation.  This cryptic poly-A signal could lead to premature transcriptional 
termination of the viral RNA in packaging cells, resulting in deletion of the 3’LTR and 
the inability of infectious particles to integrate in the genome of the host cell.  The 5’LTR 
and viral packaging sequence would remain unaffected, so that the shortened transcript 
would still be packaged and delivered to the target cells.  This hypothesis could easily be 
tested by generating a series of deletion mutants removing portions of the cryptic poly-A 
sequence, or replacing the existing bi-directional poly A sequence with a unidirectional 
poly-A.   
During the course of this thesis work, a study was published in which a strategy 
similar to our own was employed to eliminate bone marrow cells.  DePalma, et al. (53) 
generated a lentiviral vector that expressed the HSV-TK gene driven by Tie-2 
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transcriptional regulatory elements. The construct was used to transduce bone marrow 
cells, which were then transplanted into recipient mice. Administration of ganciclovir  
was used to transiently reduce the number of circulating Tie-2 positive cells, which in 
turn reduced the extent of tumor formation in a mouse model (53).  The same constructs 
were then used to generate a transgenic mouse, which resulted in the identity of Tie2 
expressing monocytes (TEMs) (54). Elimination of circulating TEMS severely abrogated 
tumor formation, demonstrating the functional significance of this cell type. Another 
study used a similar HSV-TK-based lentiviral vector that targeted ALL bone marrow-
derived cells (not just those of an endothelial phenotype) in several models of 
neovascularization, and found that the continued presence of bone marrow cells in the 
regenerative milieu was a requisite for blood vessel growth (144). Although there are 
some weaknesses in the approaches described in these reports, these two groups 
successfully implemented strategies remarkably similar to our BMTT approach.  
 While still in the process of validating RED function in vitro, we generated the 
transgenic CrIED mouse.  Surprisingly, activity of the VE Cadherin promoter (as 
assessed by luciferase activity) was easily detectible in the intact animal. Luciferase 
activity was highly variable in lysates obtained from different tissues, suggesting 
regulation in an endothelial-specific manner.  Sequence analysis of a PCR amplicon 
generated from CrIED genomic DNA confirmed that sequence of the CrIED transgene in 
vivo matched the predicted sequence of our expression construct (data not shown).  
Unfortunately, the entire RED construct did not function as we anticipated, since TM 
treatment did not induce apoptosis in the endothelium. The potential impact of the CrIED 
mouse has also been mitigated somewhat, as De Palma, et al. expanded on the 
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development of a Tie2-HSV-TK lentivirus by using the lentiviral construct in a 
transgenic setting (54). These studies established a functional role for Tie-2 expressing 
PB-MNCs in tumor angiogenesis. 
In retrospect, the RED construct we generated included several design flaws that 
may have led to our inability to induce endothelial apoptosis in the CrIED mouse.  Due to 
the orientation of the loxP sites, cryptic start codons were present upstream of the 
luciferase gene (and hence upstream of the ΔN-Bax gene following recombination).  
Translation from one of the cryptic ATG sequences would retain the peptide sequence of 
the luciferase gene but not ΔN-Bax following Cre-mediated recombination.  If translation 
was initiated from the cryptic ATG, luciferase expression would be maintained, but no 
ΔN-Bax protein would be generated.  To circumvent this problem, we should have 
inserted the loxP sites in reverse orientation.   
The pronuclear microinjection technique that we utilized to generate the CrIED 
mouse was also not the ideal strategy for generating transgenic mice containing loxP 
sites.  Pronuclear microinjections typically lead to a single integration site, with multiple 
copies inserted in tandem (145).  The presence of multiple pairs of loxP sites would 
generate many different possible recombination events, only a few of which would result 
in ΔN-Bax expression.  The net effect is a considerable reduction in recombination 
efficiency in the presence of Cre. 
 The most likely cause of construct failure is not the minutia of the construct 
design described above, but rather the failure of ΔN-Bax to successfully induce 
apoptosis.  This hypothesis is the basis of Chapter 4, and as such will not be discussed 
further here.    
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CHAPTER 4 
DELETION OF THE BH3 DOMAIN INHIBITS THE APOPTOSIS-
INDUCING ABILITY OF BAX  
Introduction 
 In Chapter 3, we devised a strategy in which overexpression of a pro-apoptotic 
gene (ΔN-Bax) was expected to induce cell death in endothelial cells of a transgenic 
mouse. However, following ΔN-Bax expression, no apoptosis was observed in the 
endothelium of these animals. This surprising result led us to question the mechanism of 
ΔN-Bax activity. In this chapter, we sought to explore the role of ΔN-Bax in apoptosis 
more fully.  
 The process of programmed cell death, or apoptosis, is a complex, highly 
regulated pathway mediated by a plethora of signaling molecules. The extrinsic apoptotic 
pathway is initiated by the extracellular binding of ligands such as FasL and TRAIL to 
the death receptors, which leads to further activation of the caspase cascade. The intrinsic 
pathway, on the other hand, is initiated by cellular stresses such as hypoxia, DNA 
damage, and growth factor starvation. Activation of the intrinsic pathway leads to the 
release of cytochrome c from the mitochondria outer membrane (MOM). Cytochrome c 
then binds with Apaf-1 to form the apoptosome complex. The apoptosome complex then 
initiates the caspase cascade, eventually leading to cell death.  
 One of the key mediators of the intrinsic pathway is the pro-apoptotic protein, 
Bax. A member of the Bcl-2 family of proteins, Bax is activated by specific apoptotic 
stimuli which causes its translocation from the cytosol to the MOM. Once targeted to the 
MOM, Bax forms aggregates that lead to MOM depolarization (146; 147). Bax contains 
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8 amphipathic α-helices surrounding a single hydrophobic α-helix groove, and bears a 
striking structural similarity to the bacterial diphtheria toxin (99; 100). Diphtheria toxin 
gains entry into eukaryotic cells by insertion of the B subunit into the cell membrane, 
which is followed by aggregation and pore formation. Presumably Bax facilitates the 
release of cytochrome C by a similar mechanism; i.e. by insertion within the MOM and 
formation of a pore complex. The α5/α6 region of Bax, in particular, has been implicated 
in the formation of MOM pores(101). As a result of its ability to induce apoptosis, Bax 
has been a popular choice as a potential therapeutic target for cancer gene therapy (102; 
103; 104; 105; 106; 107). 
 In the absence of an apoptotic stimulus Bax is sequestered by survival proteins, 
such as Bcl-2, so that the apoptotic activity of Bax is blocked (148; 149) 147). As a result, 
overexpression of recombinant Bax for gene therapy can be inhibited by endogenous 
anti-apoptotic regulators. To ensure total cell death in tumorigenic cells, Usui et al. (151) 
generated a construct containing a truncated form of the human Bax gene lacking the N-
terminus of the full-length peptide sequence (152). The truncated protein, ΔN-Bax, lacks 
the BH3 domain required for dimerization with Bcl-2 (150). Therefore, the cytotoxic 
effect of ΔN-Bax continues unabated by the cells endogenous anti-apoptotic mechanism.  
The ΔN-Bax fragment (consisting of the sequence pertaining to amino acids 112-196 of 
the full length Bax) was used in an adenoviral vector for treatment of a mouse model of 
non-small cell lung carcinoma (151). Injection of tumors with the ΔN-Bax adenovirus 
halted progression of tumor formation, and in some cases led to complete tumor 
remission. However, the mechanism of ΔN-Bax-induced cell death was never fully 
established. 
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 To determine the specific role of ΔN-Bax in apoptosis, we developed expression 
plasmids for ΔN-Bax and an EGFP:ΔN-Bax fusion protein. These constructs were 
transfected in multiple cell lines in vitro to assess the efficacy of ΔN-Bax as a potential 
target for induction of apoptosis. 
 
Methods 
Plasmid Construction and Propagation 
 All plasmids were propagated in Top10 E.Coli (Invitrogen). Transformed E.Coli 
were grown on LB-Agar plates containing 100 μg/mL of Kanamycin. For large scale 
plasmid preparation, inoculated cultures were grown in 2L Erlenmeyer flasks containing 
200 mL of LB-broth supplemented with of 100 μg/mL Kanamycin. Cultures were 
propagated overnight in a rotary shaker at 250 rpm and 37 oC. Plasmid DNA was isolated 
using Qiagen HiSpeed Plasmid Maxi-prep. 
 pEGFP:ΔN-Bax:  Polymerase Chain Reaction (PCR) primers were designed to 
amplify the 3’ region of the human Bax-α gene corresponding to amino acids 112-192 
(see appendix for primer sequences). For cloning purposes, a BsrGI restriction site was 
incorporated into the forward primer immediately upstream of the alanine codon. A NotI 
restriction site was incorporated into the reverse primer immediately downstream of the 
final cysteine codon of Bax-α. PCR was performed using Platinum Taq Hi-fidelity 
Polymerase (Invitrogen) under the manufacturers specified conditions with the following 
thermocycler settings: 5 cycles X [95 oC, 30s denaturing, 50 oC, 1 minute annealing, 68 
oC, 1 minute extension] followed by 27 cycles X [95 oC, 30s denaturing, 58 oC, 1 minute 
annealing, 68 oC, 1 minute extension]. The amplified  PCR product was then ligated into 
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the corresponding restriction sites of the pEGFP-N1 plasmid (Clontech). The resulting 
plasmid contained the first alanine codon of the ΔN-Bax sequence immediately 
downstream of the final 3’ Lysine codon of the EGFP gene. A stop codon was not 
included at the 3’ end of the ΔN-Bax sequence, resulting in a C-terminal tail containing 
the 7 amino acid sequence CGRDSRS following the terminal glycine residue 
corresponding to amino acid 192 in the full length Bax-α gene. 
 pBax-N1: PCR primers were designed to amplify the 3’ region of the human Bax-
α gene containing the sequence corresponding to amino acids 112-192. The forward 
primer was designed to include a Kozak sequence (containing a methionine [ATG] 
codon) upstream of the first Alanine codon of the ΔN-Bax sequence and immediately 
downstream of an AgeI restriction site. The reverse primer was modified to so that the 
resultant product contained a stop codon (TGA) between the final Glycine codon at the 3’ 
end of ΔN-Bax, and the NotI restriction site. PCR was performed using Platinum Taq Hi-
fidelity Polymerase (Invitrogen) under the manufacturer’s conditions with the following 
thermocycler settings: 5 cycles X [95 oC, 30s denaturing, 50 oC, 1 minute annealing, 68 
oC, 1 minute extension] followed by 27 cycles X [95 oC, 30s denaturing, 58 oC, 1 minute 
annealing, 68 oC, 1 minute extension]. The amplified PCR product was then ligated into 
the corresponding AgeI and NotI restriction sites of the pEGFP-N1 plasmid.  
 
Cell lines and culture 
HEK-293 cells and NIH/3T3 cells (ATCC) were grown at 37 Co, 5% CO2 in 
DMEM supplemented with 10% fetal bovine serum, L-glutamine, and Pen/Strep or 
DMEM supplemented with 10% calf serum, L-glutamine, and Pen/Strep, respectively. 
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Both 293 and 3T3 cells were grown in 10 cm tissue culture-treated dishes until 80% 
confluent, and passaged at a ratio of 1:5. Human Umbilical Vein Endothelial Cells 
(HUVECs) were purchased from Lonza. Cells were grown at 37 Co, 5% CO2 in EGM-2 
endothelial growth medium. HUVECs were grown in 10 cm tissue culture-treated dishes 
until a monolayer formed, then passaged at a ratio of 1:5. HCT-15 cells (generously 
donated by REMEDI, National University of Ireland, Galway) were grown at 37 Co, 5% 
CO2 in DMEM supplemented with 10% fetal bovine serum, L-glutamine, and Pen/Strep.  
 
Transfection 
 HEK-293 cells were transfected using Lipofectamine 2000 (Invitrogen) according 
to the supplier’s recommendations. Briefly, cells were grown to 50% confluence in 6-
well tissue culture treated dishes. Twenty-four hours prior to transfection, full media was 
replaced with antibiotic-free media. DNA complexes were formed in 500 μL of DMEM 
(without serum or antibiotics) with 8 micrograms of DNA and 10 μL of Lipofectamine 
2000. After removing the old media from the cells, the DNA complexes were added drop 
wise then slowly swirled for even distribution. After 6 hours of incubation, the complexes 
were removed and replaced with full media. For all time points, 0 hrs corresponds to 
point at which the DNA complexes were replaced with fresh media.  
 HUVECs, 3T3, and HCT-15 cells were transfected using the AMAXA 
electroporation system with the HUVEC Nucleofector Kit, Nucleofector Kit R, and 
Nucleofector Kit V, respectively. Transfections were performed according to the 
manufacturer’s recommendations. Briefly, cells were grown until ready for passage, then 
dissociated from the culture dish using gentle trypsinization. Trypsin was neutralized 
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using full media, and the total cell number was calculated with a hemocytometer. 
Following gentle centrifugation, the supernatant was aspirated and the pellet resuspended 
in 100 μL of Nucleofector solution. Unless otherwise stated, for each transfection 4 μg of 
plasmid DNA was added to the cell mixture, and then transferred to a Nucleofector 
cuvette for electroporation. Immediately following electroporation, cells were 
resuspended in the appropriate volume of full media and plated in a 6-well dish.  
 
Imaging 
 GFP expression in transfected cells was imaged using an Olympus inverted 
fluorescent microscope or a Zeiss confocal laser scanning microscope.  
 
Western Blot 
 A rabbit polyclonal anti-Bax antibody generated from a synthetic peptide 
corresponding to amino acids 150-165 of human Bax, and a rabbit polyclonal anti-GFP 
antibody were obtained from Abcam (catalogue numbers ab16837 and ab290, 
respectively). Protein was extracted from transfected cells using RIPA lysis buffer with 
protease inhibitors, and total protein was quantified using a modified Bradford assay 
(Biorad).  Twenty micrograms of protein per sample was separated in a 10% 
polyacrylamide gel, and then transferred overnight to a nitrocellulose membrane. 
Membranes were blocked for 1 hr at room temperature in 1% TBS-tween and 5% skim 
milk, and then incubated with the primary antibody overnight at 4 oC in 1% TBS-tween 
and 1% skim milk. Secondary antibody incubation was performed in 1% TBS-tween and 
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1% skim milk with goat anti-rabbit horseradish peroxidase conjugates, then imaged using 
an ECL imaging kit (Amersham).  
 
qRT-PCR  
 RNA was purified using a commercial kit (Qiagen) and reverse transcribed into 
cDNA using the SuperScript™ III First Strand Synthesis System (Invitrogen), which was 
subsequently purified using a commercially available kit (Qiagen). Primers were 
designed using PrimerQuest software (IDT DNA technologies) for the 3’ end of human 
Bax, EGFP, and mouse 18s. SYBR Green intercalating dye (Applied Biosystems) was 
used to perform real time PCR with the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems). Standards for each gene were amplified from cDNA and purified. 
Standard concentrations were determined using spectrophotometric measurement at 260 
nm, and standards were serially diluted to an appropriate range of concentrations. 
Transcript concentration in template cDNA solutions was quantified from the linear 
standard curve, normalized to 18s copy number, and expressed as copies per 106 18s. 
 
Nuclear Fragmentation 
 Cells were isolated via tryspsinization, washed with cold PBS,  and then fixed for 
10 minutes in 1% paraformaldehyde/PBS at 4 oC. Following fixation, cells were again 
washed in cold PBS then pelleted via centrifugation. After resuspension in 100 
microliters of PBS, the cell solution was cytospun transferred to glass slides. Slides were 




 Transfected adherent cells were isolated via trypsinization, washed with full 
media to neutralize the trypsin, and then resuspended in cold PBS prior to analysis. 
Expression of EGFP was quantitatively assessed using a BD FACSort flow cytometer. 
5,000-50,000 events were recorded, and flourescence was measured using a 488 nm laser 
with 530nm +/- 15nm detectors 
 
Annexin V stain 
 293 cells were transfected with pGL3-basic or pΔN-Bax-N1using Lipofectamine 
2000 (Invitrogen) in 6-well dishes. Camptothecin was added to the media of 
untransfected cells as a positive control. Twenty-four hours after transfection, cells were 
trypsinized to generate a single cell suspension, then stained with Annexin V-PE staining 
kit (Invitrogen). Results were analyzed using a BD FACSort flow cytometer. Annexin V 
positive/Propidium Iodide (PI) negative cells were considered apoptotic, and Annexin 
V/PI double positive cells were quantified as dead. Post acquisition analysis was 




 3T3 cells were transfected with pGL3-basic or pΔN-Bax-N1 using nucleofection 
and cultured in 6-well plates. Camptothecin was added to the media of untransfected cells 
as a positive control. Camptothecin hours after transfection, the Vybrant Apoptosis Assay 
Kit 4 (Invitrogen) was used to stain cells. Results were analyzed using a BD FACSort 
 79
flow cytometer. YO-PRO-1 positive/Propidium Iodide (PI) negative cells were 
considered apoptotic, and YO-PRO-1/PI double positive cells were quantified as dead. 
Post acquisition analysis was performed using FlowJo software. 
 
MTT Assay 
 293 cells were transfected with pEGFP-N1 or pΔN-Bax-N1 in a flat-bottomed 96-
well plate using Lipofectamine 2000. Four days after transfection, a Cell-Titer 96 MTT 
assay was performed (Promega). Cells were incubated overnight under standard culture 
conditions with the manufacturer’s dye solution, then absorbance was measured at 570 
nm using a 96-well plate reader.    
 
Results 
Generation of ΔN-Bax Constructs 
We generated two expression constructs containing the C-terminal region of the 
human pro-apoptotic Bax gene (ΔN-Bax) for transfection experiments in cultured cells. 
In order to aid in the visualization of ΔN-Bax over-expression, one construct was 
generated containing ΔN-Bax fused to the C-terminus of enhanced green fluorescent 
protein (EGFP) under transcriptional control of the cytomegalovirus (CMV) promoter. 
The ΔN-Bax sequence was generated from a cDNA library derived from the HL60 cell  
line and cloned into the pEGFP-N1 vector. The resulting construct, identified as 
pEGFP:ΔN-Bax (Figure 4.1), contains the ΔN-Bax fragment immediately following the 
final Lysine codon of EGFP, allowing for in-frame translation of the ΔN-Bax protein.  To 












Figure 4.1: Plasmids Containing ΔN-Bax Sequence. To generate ΔN-Bax expression 
constructs, the sequence pertaining to amino acids 112-192 of the human Bax gene was 
cloned in frame to the EGFP sequence of pEGFP-N1. A) pEGFP-N1. B) pEGFP:ΔN-Bax 
(B), containing a EGFP:ΔN-Bax fusion protein. C) pΔN-Bax-N1, in which the EGFP 
gene in pEGFP-N1 was replaced entirely with ΔN-Bax . D) Direct sequencing of 
pEGFP:ΔN-Bax indicated a deletion in the stop codon of the ΔN-Bax fragment, leading 
to translation of a 7 amino acid C-terminal tail. E) Sequencing of pΔN-Bax-N1 confirmed 
the predicted sequence. 
 
 
Bax, a construct lacking EGFP was also generated. The pΔN -Bax-N1 construct (Figure 
4.1) contains ΔN-Bax driven directly by the CMV promoter. Sequences of both pEGFP-
N1 and pΔN -Bax-N1 were confirmed by restriction digest and direct sequencing (Figure 
4.1). 
 
Expression of ΔN-Bax induces changes in HEK-293 cell morphology 
 Our preliminary transfection experiments were carried out in the HEK-293 cells. 
The HEK-293 line, derived from human embryonic kidney cells, is widely noted for the 
ease in which it is transfected by calcium-phosphate and poly-cation mediated gene 
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delivery methods. In our hands, 293 cells transfected with pEGFP-N1 using 
Lipofectamine-2000 showed robust EGFP expression 24 hrs after addition of the plasmid  
 (Figure 4.2). Visual inspection of the cells at low magnification indicated strong EGFP 
fluorescence and a high transfection efficiency. Closer examination of the EGFP-
expressing cells revealed diffuse fluorescence signal throughout the cells, and 
morphology consistent with that of non-transfected cells.  
  After transfection of HEK-293 cells with pEGFP:ΔN-Bax, the percentage of GFP-
positive cells after 24 hours was dramatically lower than that seen following transfection 
with pEGFP-N1. The intensity of GFP fluorescence was also noticeably weaker in 
pEGFP:ΔN-Bax transfected cells compared to pEGFP-N1 transfected cells. When viewed 
under higher magnification, the cells expressing EGFP:ΔN-Bax had a rounded 
morphology indicative of the “blebbing” often observed in adherent cells undergoing 
apoptosis. Additionally, individual EGFP:ΔN-Bax positive cells exhibited an uneven, 
heterogeneous EGFP signal. This distinctive punctate patterning is similar to that seen in 
previously published reports, in which expression of GFP-Bax fusion proteins was 
detected in apoptotic cells (147; 149).  
 
Frequency and Intensity of EGFP Fluorescence In Cells Expressing EGFP:ΔN-Bax  
 Expression of EGFP was quantitatively assessed in 3T3 cells using flow 
cytometry within 6 hours of transfection with either pEGFP-N1 or pEGFP:ΔN-Bax. The 
total number of EGFP-positive cells was noticeably lower in the pEGFP:ΔN-Bax 
transfected group than in the pEGFP-N1 transfected group (Figure 4.3). Mean percentage 
of EGFP-positive cells was 2.5-fold higher in cells transfected with pEGFP-N1 than in  
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Figure 4.2: Cell Morphology Following EGFP:ΔN-Bax Expression. HEK293 cells 
were transfected with pEGFP-N1 or pEGFP:ΔN-Bax and imaged with an inverted 
fluorescent microscope at 48 hours. Membrane blebbing (arrows) seen in cells expressing 
pEGFP:ΔN-Bax is indicative of apoptotic cell death. 
 
 
 cells transfected with pEGFP:ΔN-Bax. Furthermore, intensity of the EGFP signal was 
considerably lower in cells expressing EGFP:ΔN-Bax.  
 
Transfection Efficiency Is Unaffected by DNA Concentration 
 Transfection protocols can be highly erratic, with optimal transfection conditions 
varying widely between different cell types.  Furthermore, different plasmids transfected 
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into the same cell type may result in markedly different transfection efficiencies. In order 
to ensure that the differences in GFP expression observed between pEGFP-N1 and 
pEGFP:ΔN-Bax were due to the effect of the fusion protein and not sub-optimal  
transfection conditions, we independently optimized transfection conditions for both the 
pEGFP-N1 and pEGFP:ΔN-Bax plasmids in NIH-3T3 cells. Transfections were 
performed using the AMAXA electroporation system and the concentration of plasmid 
DNA for both plasmids was varied from 2-8 μg per transfection. No significant change in 
transfection efficiency was observed for either pEGFP-N1 or pEGFP:ΔN-Bax over the  
range of DNA concentrations tested. (Figure 4.3). Under all conditions, pEGFP-N1 
transfection efficiencies were 3-fold higher than pEGFP:ΔN-Bax. 
 
EGFP:ΔN-Bax Protein Forms Extra-Nuclear Aggregates 
 To further examine the morphological effects of EGFP:ΔN-Bax expression and 
sub-cellular localization of the fusion protein, we imaged transfected 3T3 cells using 
scanning laser confocal microscopy. We observed that, when transfected with the 
pEGFP:ΔN-Bax plasmid, the number of fluorescent 3T3 cells would gradually decrease.  
To visualize the cells when GFP flourescence was highest, confocal images were 
captured 4 hours after transfection with the Amaxa Nucleofection system.  
 Cells transfected with pEGFP-N1 (Figure 4.4) exhibited a homogeneous, diffuse 
EGFP signal throughout the cytoplasm and nucleus.  Morphologically, cells expressing 
EGFP were indistinguishable from non-transfected cells. Cells expressing the EGFP:ΔN-
Bax fusion protein, on the other hand, contained distinct aggregates of the fusion protein. 


































Figure 4.3: Flourescence of Cells Expressing EGFP:ΔN-Bax or EGFP. Flow 
cytometry was performed on 293 cells transfected with pEGFP-N1 or pEGFP:ΔN-Bax. 
A) A dot plot of transduced cells shows both the number of GFP positive cells and the 
fluorescence intensity was lower in cells expressing EGFP:ΔN-Bax compared to EGFP 
alone. B) The quantity of DNA used for transfection of each plasmid was varied from 2-8 
μg. Flow cytometry was performed to quantify the number of GFP-expressing cells. No 
change in GFP positive cells was observed when the quantity of DNA used for 




 and compartmentalization. In a non-apoptotic state, full length Bax forms a heterodimer 
with Bcl-2 in the cytoplasm. However, upon apoptotic activation, Bax is translocated to 
the mitochondria forming pore complexes which lead to depolarization of the  
mitochondrial membranes. Therefore, we attributed the aggregation seen in cells 
expressing the EGFP:ΔN-Bax fusion protein to mitochondrial translocation during a pro-
apoptotic state. 
 
Temporal expression of EGFP:ΔN-Bax  
 Visual observation of 3T3 cells transfected with pEGFP:ΔN-Bax confirmed that 
GFP flourescence decreased within 24 hours of transfection to nearly undetectable levels 
within 48 hours. Using flow cytometry, the percentage of EGFP positive 3T3 cells was 
quantified from 4-48 hours following transfection with pEGFP:ΔN-Bax or pEGFP-N1 
(Figure 4.5). Transfection with pEGFP-N1 resulted in sustained fluorescence in 38-55% 
of the cell population throughout the time course. Cells transfected in parallel with the 
pEGFP:ΔN-Bax fusion construct, however, reached a maximum transfection efficiency 
of 20% after just 4 hours.  By 48 hours, GFP fluorescence was undetectable by flow  
cytometry. The loss of fluorescence could potentially be caused by accelerated 
degradation of the plasmid DNA, RNA or protein. However, this scenario is unlikely 
since cells transfected with the plasmid encoding EGFP alone exhibited constant 
fluorescence over the same time  course. Therefore, we suspected that the loss of 
fluorescence was due to apoptosis of the transfected cells.  
 Our interest in ΔN-Bax protein (as described in Chapter 3) was for the induction 

















Figure 4.4: EGFP:ΔN-Bax Expression Results In Punctate Extra-nuclear 
Aggregation. 3T3 cells were transfected with pEGFP-N1 or pEGFP:ΔN-Bax and imaged 
with confocal microscopy after 6 hours. Confocal slices through cells transfected with 
pEGFP-N1 show homogeneous, diffuse fluorescence. Cells expressing the EGFP:ΔN-
Bax fusion protein exhibit punctate fluorescence that is largely extranuclear. 
 
 
we performed transfection experiments in Human Umbilical Vein Endothelial Cells 
(HUVECs). As we observed in 3T3 cells, HUVECs transfected with pEGFP:ΔN-Bax 
showed a steady decrease in GFP expression from 35% at 4 hours post-transfection to 
nearly undetectable levels after 48 hours. HUVECs transfected with pEGFP-N1,  
however, maintained consistent transfection efficiencies of ~55% during the time course. 
We attributed the reduction, and eventual loss, of EGFP signal to cell death as a result of 
eGFP-Bax induced apoptosis.  
 Since the initial transfection experiments with pEGFP:ΔN-Bax  were performed 
in HEK-293 cells, we also examined the temporal effects of EGFP expression 
quantitatively in this cell line. The percentage of EGFP-positive HEK-293 following 
















































































Figure 4.5: Timecourse of Flourescence Following Transfection. Flow cytometry was 
performed on (A) 3T3 cells, (B) HUVECs, and (C) 293 cells at multiple time points 
following transfection with either pEGFP-N1 or pEGFP:ΔN-Bax. Both 3T3 and 
HUVECs transfected with pEGFP:ΔN-Bax  showed an immediate loss of GFP expression 
within 24 hours which was undetectable after 48 hours. EGFP expression remained 
constant in these cells over the time course following pEGFP-N1 transfection. GFP 
expression in 293 cells transfected with pEGFP:ΔN-Bax  was maintained over the time 
course, but was considerably less than that seen following pEGFP-N1 transfection. 
 
 
after treatment. Comparatively, transfection of HEK293 cells with pEGFP-N1 resulted in 
transfection efficiencies of 95% over the same time course. Peak levels of fluorescence in 
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pEGFP-N1 transfected cells were not reached until 72 hours post-transfection, while peak 
EGFP levels were reached 24 hours following transfection with pEGFP:ΔN-Bax. The 
sustained fluorescence in HEK-293 cells transfected with pEGFP:ΔN-Bax contradicts the 
findings from 3T3 and HUVECs, where fluorescence was extinguished within 48 hours. 
These disparate results could indicate either cell-type specific toxicity of ΔN-Bax, or 
differences in EGFP:ΔN-Bax degradation rates. 
 
EGFP:ΔN-Bax Expression Leads To Changes In Nuclear Morphology 
 Loss of EGFP signal, though a potential consequence of cell death, does not 
necessarily indicate that apoptosis has occurred. In order to directly address whether 
EGFP:ΔN-Bax expression correlates to apoptotic cell death, the nuclear microstructure of 
HCT-15 cells following transfection with pEGFP:ΔN-Bax was examined . Fluorescence 
was considerably less intense and transfection efficiencies were lower in HCT-15 cells 
transfected with pEGFP:ΔN-Bax compared to cells transfected with pEGFP-N1. 
Fluorescence in cells transfected with pEGFP:ΔN-Bax was nearly undetectable after 24 
hours, so cells were stained with DAPI and nuclear morphology was examined at 12 and 
15 hours post-transfection. 
 Despite visual inspection after 12 hours, the frequency of EGFP positive cells was 
dramatically lower in cells transfected with pEGFP:ΔN-Bax than with pEGFP-N1 alone 
(Figure 4.6).  At both time points, fluorescent cells transfected with pEGFP:ΔN-Bax 
exhibited a fractured, condensed, and highly textured nuclear staining pattern (Figure 
4.6). This type of nuclear fragmentation, due to the cleavage of DNA during the apoptotic 
 89
program, is a hallmark of apoptosis and was only seen in cells expressing EGFP:ΔN-Bax, 
but not in those expressing EGFP alone.    
 
Detection of ΔN-Bax in transfected cells 
 Although the EGFP:ΔN-Bax fusion protein allowed visualization of cells 
expressing the truncated Bax fusion protein, the EGFP tag has the potential to interfere 
with the apoptosis inducing-activity of the Bax fragment. The inclusion of a 7 amino acid 
extension at the C-terminal end of EGFP:ΔN-Bax could further inhibit the endogenous 
activity of the truncated protein. Therefore, we sought to determine the apoptotic effect of 
expression of the non-fusion protein, or ΔN-Bax alone.  
 The absence of a fluorescent tag in the pΔN-Bax-N1 construct prevented us from 
assessing transfection efficiencies using the pΔN-Bax-N1 plasmid. Therefore, it was 
extremely difficult to determine the net apoptotic effect of ΔN-Bax expression in 
transfected cells. Quantification of gene product using qRT-PCR showed that relative 
mRNA levels of ΔN-Bax in cells transfected with pΔN-Bax-N1 were comparable to 
relative levels of EGFP mRNA in cells transfected with pEGFP-N1 (Figure 4.7). 
However, using an antibody raised against a peptide fragment containing amino acids 
150-165 of the full length Bax, we were unable to detect a band representative of the ΔN-
Bax protein via western blot of lysates from transfected 293 cells. The native full length 
Bax was observed at 22kDa, but no band could be seen at the size 6 kDa size predicted 
for ΔN-Bax (Figure 4.7). The inability to detect ΔN-Bax in lysate from cells transfected 
with pΔN-Bax-N1 could be indicative of the hypertoxic effect of the ΔN-Bax protein. 




Figure 4.6: Nuclear Fragmentation of Transfected Cells. HCT-15 cells were 
transfected with pEGFP-N1 or pEGFP:ΔN-Bax. Transfected cells were then cytospun 
and mounted with DAPI, then imaged at (A) 12 and (B) 15 hours after transfection. The 
majority of cells expressing EGFP showed intact, non-apoptotic nuclear staining (white 
arrows). Cells expressing EGFP:ΔN-Bax frequently had small, fragmented nuclei (red 
arrows) indicative of apoptosis.  
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techniques, could cause the cells to undergo apoptosis before they are capable of 
producing a detectable quantity of ΔN-Bax. It is also possible, however, that the pΔN-
Bax-N1 plasmid translates an out of frame protein, which could result in a peptide 
sequence different from the predicted ΔN-Bax sequence. Interestingly, when a western 
blot was performed on lysate from 293 cells transfected with pEGFP:ΔN-Bax using an 
anti-GFP antibody, a light band was detected at 33 kDa (Figure 4.7). The intensity of this 
band was extremely faint compared to the GFP band seen in lysate from cells transfected 
with pEGFP-N1, but it corresponds to the predicted size of the EGFP:ΔN-Bax fusion 
protein. This indicates that either the anti-Bax antibody is not sensitive enough to detect 
the trace amount of EGFP:ΔN-Bax fusion protein, ΔN-Bax generates a peptide sequence 
unrecognizable by the Bax antibody, or ΔN-Bax is degraded so quickly it cannot be 
detected by western blot.  
 
ΔN-Bax Does Not Induce Apoptosis 
 Loss of plasma membrane asymmetry is one of the earliest features of apoptosis, 
causing cytoplasmic phosphatidylserine to be exposed to the extracellular environment. 
Cells in the early stages of apoptosis stain positively for Annexin V, which preferentially 
binds the exposed, extracellular phosphatidylserine, but the intact membrane prevents 
staining with Propidium Iodide (PI). Late-stage apoptotic cells, whose membranes have 
been compromised, stain positive for both Annexin V and PI. As a means of quantifying 
the overall apoptotic effect of ΔN-Bax  expression, 3T3 cells were transfected with either 
pEGFP-N1 or pΔN-Bax-N1 and 24 hours later stained with an Annexin V-PE conjugate 




Figure 4.7:  Detection of ΔN-Bax mRNA and Protein In Transfected Cells. A) qRT-
PCR was performed on RNA isolated from 3T3 cells 24 hours following transfection 
with pEGFP-N1 or pc. Copy number was determined for GFP and Bax in cells 
transfected with pEGFP-N1 or pΔN-Bax-N1, respectively. B) Western blot with an anti-
GFP antibody was able to detect a faint 32 kDa band in lysate from 3T3 cells transfected 
with the EGFP:ΔN-Bax fusion construct (lane 1). The WT GFP band was observed at 27 
kDa in lysates from cells expressing transfected with pEGFP-N1 (lane 2). C) Lysate from 
cells transfected with pΔN-Bax was probed with an anti-Bax antibody. Only the native 
form (22kDa) of Bax could be detected in 4 separate trasnfections (lanes 1-4). No band 
was observed at 6kDa; the predicted size of or ΔN-Bax. All lanes contain lysate from 3T3 





N1 and pΔN-Bax-N1 transfected cells (Figure 4.8). Camptothecin treatment, which was 
used as a positive control, induced a robust increase in both early apoptotic and dead 
cells. This result is in contrast to our earlier findings, and suggests that ΔN-Bax may not 
induce apoptosis.  
 Changes in membrane permeability resulting from apoptosis can also be detected 
with nucleic acid dyes, which have variable access to the nucleus depending on the stage 
of apoptosis. The YO-PRO-1 dye is cell permeable during early apoptosis, while PI can 
only access the nuclear components during late stage apoptosis. 3T3 cells were 
transfected with either pBax-N1 or the pGL3-basic vector, stained with YO-PRO-1 and 
PI, then analyzed with flow cytometry. Fourty-eight hours after transfection, ΔN-Bax 
generated no noticeable change in apoptosis compared to the pGL3-basic control (Figure 
4.8). 3T3 cells treated with camptothecin, on the other hand, showed a significant 
increase in YO-PRO-1 staining over the same time course.  Due to the fact that YO-PRO-
1 is an early indicator of apoptotic cell death, it is possible that at 48 hours the apoptotic  
program has progressed past the point of selective cell permeability. However, there was 
also no detectable change in PI staining, which signifies that there was no increase in cell 
death (i.e. late apoptosis) following ΔN-Bax expression .  
 The net effect of ΔN-Bax-induced cell death on metabolic activity was assessed 
using a modified MTT assay. The colorimetric MTT assay quantifies the conversion of a 
soluble tetrazolium dye to a non-soluble formazan byproduct by live cells. Cells which 
have undergone apoptosis (and are therefore metabolically inactive) are unable to 
generate the soluble formazan product. Five days following transfection of 293 cells with 
pEGFP-N1 or pΔN-Bax-N1, there was no observable difference between the transfection  
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Figure 4.8: Apoptosis Following Transfection With pΔN-Bax-N1. A) Flow cytometry 
was performed 24 hours after transfection of 3T3 cells with pGL3-basic or pΔN-Bax-N1, 
and apoptosis was assessed by Annexin V staining. Apoptotic cells stained positively for 
Annexin V, while dead cells stained positively for both Annexin V and Propidium Iodide. 
B) YO-PRO-1 staining was performed 24 hours after transfection of 3T3 cells with 
pGL3-basic or pΔN-Bax-N1, and apoptosis was quantified using flow cytometry. 
Apoptotic cells stained positively for YO-PRO-1, while dead cells stained positively for 
both YO-PRO-1 and Propidium Iodide. C) Metabolic activity was analyzed in 293 cells 




groups. However, both groups of transfected cells showed a modest reduction in 
metabolic activity compared to the untreated control group.  
 We assessed three different indicators of apoptosis to determine the effect of ΔN-
Bax expression on cell death, and in each case we were unable to detect ΔN-Bax-induced 
cell death. Taken together, these data suggest that the temporal loss of florescence 
observed following pEGFP:ΔN-Bax transfection, may be attributable to accelerated 
protein degradation rates rather loss of cell viability.  
 
Discussion 
 Although the role of Bax in the apoptotic pathway has been studied extensively, 
the mechanism by which Bax leads to mitochondrial dysfunction, as well as its 
interaction with other Bcl-2 family members, is not fully understood. Despite the 
enigmatic nature of the protein, over-expression of Bax has been widely exploited as a 
means to induce apoptosis. Our goal in the previous chapter was to develop a potent 
vector for the induction of apoptosis. Therefore, in this chapter, we explored the use of a 
truncated form of the human Bax gene in an expression construct as a means for 
augmenting cell death. The truncated Bax, which consisted of amino acids 112-192 of the 
full-length protein, was selected because it had previously been used for treatment of a 
mouse model of non-small cell lung cancer in an adenoviral vector (151). The enhanced 
potency seen with ΔN-Bax compared to full-length Bax made it a particularly appealing 
candidate for our bone marrow transplantation strategy.  
 Using an adenoviral strategy to overexpress ΔN-Bax, Usui et al. (151) were able 
to initiate cell death in 80% of A549 cells 48 hours after infection. The disparity between 
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results noted by Usui et al. (151) and the results observed here could potentially be 
attributed to differences in the cell type used. It is also important to note the role vector 
type could potentially play in the gene transfer process. Adenoviral vectors, as used by 
Usui et al. (151), permit high infection efficiency and sustained gene expression over 
reasonable time courses. More standard plasmid transfection techniques, such as the 
Lipofectamine 2000 and Amaxa electroporation techniques that we employed, may 
convey considerably lower transfection efficiencies. Furthermore, the transfection 
procedure itself can lead to substantial cellular toxicity.  
Prior to the publication by Usui et al. (151), the same group reported that transient 
transfection of FDC-P1 cells using electroporation with an ΔN-Bax expression vector led 
to apoptosis in just 2% of cells (152). The percentage of apoptotic cells increased to 4% 
when ΔN-Bax was co-transfected with Bcl-2 or Bcl-XL. Transfection of full length Bax 
was only able to induced apoptosis in <1% of cells when co-transfected with Bcl-2 or 
Bcl-XL, compared to ~4% when co-transfected with a neomycin resistance cassette. 
These two reports, which were generated by the same group, show remarkable 
differences in potency of ΔN-Bax expression. The disparate results noted between these 
two reports, as well as the absence of a noticeable effect of ΔN-Bax expression in our 
own study, raise questions about the interpretation of the results reported by Usui et al 
(151).  
In our hands, transfection with a plasmid containing ΔN-Bax showed no pro-
apoptotic effect that could be directly attributed to ΔN-Bax expression. Interpretation of 
our results is somewhat confusing, however, due to our inability to directly observe the 
expression of ΔN-Bax without the GFP tag. The sequencing data from pΔN-Bax -N1 
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aligned correctly with the predicted sequence, and no cryptic start codons were detectable 
that could potentially lead to an out-of-frame polypeptide. Furthermore, robust ΔN-Bax 
message was detected using qRT-PCR. Although the PCR primers were unable to 
distinguish the truncated transcript from the native form, the inability to detect message 
in cells not transfected with pΔN-Bax -N1 suggest that that endogenous levels of full 
length Bax were insignificant compared to that seen in transfected cells. The presence of 
ΔN-Bax  mRNA suggests that the ΔN-Bax gene was expressed. Ideally we would have 
liked to detect the expressed protein directly; however the majority of the antibodies for 
Bax are raised against a peptide fragment derived from the N-terminal region of the full 
length protein. The antibody used in Figure 4.7 should have been capable of detecting 
both the native and recombinant forms of Bax; however we were only able to detect a 
band corresponding to the full length protein. 
  In an effort to circumvent the issue of ΔN-Bax detection, we generated a 
EGFP:ΔN-Bax fusion construct which allowed us to visually observe transfected cells. 
Although we were still unable to quantify the apoptotic effect of EGFP:ΔN-Bax 
expression, distinct phenotypic changes in transfected cells were observed that could be 
attributed to apoptosis. Endogenous Bax is largely cytosolic in the absence of apoptotic 
stimuli. Following activation of the intrinsic pathway, a change in Bax conformation 
leads to translocation of Bax from the cytoplasm to the MOM (147). Imaging of cells 
expressing a Bax-GFP fusion  (containing the full length Bax) results in a diffuse, 
homogeneous fluorescence pattern throughout the cell. Following apoptosis, a punctate 
signal is observed which colocalizes to the mitochondria (147); (153); 154). The resultant 
fluorescent patterning is markedly similar to that which we observed following 
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transfection with pEGFP:ΔN-Bax (Figure 4.4). The same punctate GFP patterning was 
also seen when cells expressed a GFP-Bax fusion protein containing a single serine 
deletion (amino acid 184) in the C-terminal transmembrane domain of full length Bax. 
The deletion led to changes in protein confirmation so that it resided permanently in 
MOM-bound form. Expression of the Bax deletion mutant also lead to a modest increase 
in toxicity relative to the native form (153).  
Given the results described here characterizing expression of the EGFP:ΔN-Bax 
fusion construct, in addition to the absence of any net effect of ΔN-Bax expression alone, 
it is the opinion of this author that expression of ΔN-Bax does NOT result in apoptotic 
cell death. The rationale for this conclusion is largely based on speculation, although 
there is a plethora of literature which supports this hypothesis.  
Despite the extensive research exploring the functional role of Bax in apoptosis, 
the mechanism by which it contributes to MOM instability is not well understood. It is 
widely accepted that the intrinsic apoptotic pathway is highly dependent on Bax and the 
rest of the Bcl-2 family members. The interplay between the three established Bcl-2 
family member groups and their relative concentrations is a requisite event for the 
initiation of the apoptotic pathway, and could offer some insight into why ΔN-Bax is not 
capable of inducing cellular toxicity as expected. 
The first group of the Bcl-2 family contain the survival proteins (Bcl-2, Bcl-XL), 
each of which contain 4 of the Bcl-2 homology domains (BH1-4). The second group of 
the Bcl-2 family, the pro-apoptotic proteins (Bax, Bak and Bok), contain only the 
domains BH1-3. The third family, the BH3-only proteins (Bim, Bid) contain only the 
BH3 domain . 
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Figure 4.9: Structure of Bax. The full length Bax protein consists of 9 amphipathic α 
helices. In the 3-dimensional conformation, a hydrophobic groove is formed between α2-
α5. The BH3 domain is essential for BH3-only activation of apoptosis as well as well as 
the homo-oligimerization required for pore formation in the MOM. The TM domain of 
ΔN-Bax keeps it restricted to the MOM. 
 
 
The structure of full length Bax consists of 8 amphipathic α-helices surrounding a 
single hydrophobic groove. Figure 4.9 shows the distribution of the 8 α-helices along the 
Bax gene, as well as the positioning of each of the BH-domains. Bak, another pro-
apoptotic Bcl-2 family member, may be associated with the mitochondria even in the 
absence of apoptotic stimuli (147), but inactive Bax exists in a cytosolic state.  The three-
dimensional structure of Bax undergoes a multistep transition starting from the inactive 
cytosolic state and end in the formation of a pore complex in the MOM. In a non-
apoptotic setting, the BH1, BH2 and BH3 domains of the survival protein Bcl-2 form a 
hydrophobic groove on the protein surface (155) that accommodates the corresponding 
BH3 domain of Bax.  The result is that Bax is sequestered and unable to homodimerize, 
leading to inhibition of its innate death-inducing abilities (149; 148). Bax is only 
translated to the MOM once the cell death program has been initiated (147). In it’s 
inactive state, the hydrophobic transmembrane (TM) C-terminal tail of Bax is folded into 
the hydrophobic pocket created by the BH1, BH2 and BH3 domains (154), thereby 
preventing insertion of the protein in the MOM. Bax undergoes a conformational change 
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following apoptotic activation that exposes the C-terminal tail and allows for insertion in 
the MOM (153; 156). Targeted mutations and deletions in Bax have been generated that 
leave the TM tail exposed and result in MOM localization even in the absence of 
apoptotic stimuli. Permanent translocation of Bax to the mitochondria using the deletion 
mutants generates a more cytotoxic effect than the WT protein (101; 153; 156; 157).  The 
ΔN-Bax construct utilized in our study lacks the BH3 and BH1 domains necessary for 
maintaining the “inactive” cytosolic conformation (Figure 4.9).  Therefore, ΔN-Bax may 
exist in an uninhibitable MOM-targeted state. The result of the ΔN-Bax conformation, 
observed in cells expressing the EGFP:ΔN-Bax fusion construct, is that ΔN-Bax has a 
continually exposed TM domain which keeps the protein bound within the MOM.  
Usui, et al.(151) hypothesized that because ΔN-Bax lacks the BH3 domain 
required for binding Bcl-2, it was a more potent inducer of apoptosis than the full length 
protein (151). More recently, however, the importance of the BH3 domain in Bax 
activation has been demonstrated, suggesting that perhaps the α2-α5 helices are required 
for pore formation and cytochrome c release from the MOM (96; 158; 159; 160). Direct 
activation of Bax by BH3-only proteins is also mediated by interaction with the BH3 
domain of Bax (93; 95; 96). Given these reports, it seems likely that ΔN-Bax (lacking 
helices α1-α4 and the entire BH3 domain) is unable to be activated by BH3-only proteins 
and unable to oligomerize and form pores in the MOM. As a result, the ΔN-Bax fragment 
is essentially a MOM-targeting sequence without apoptosis-inducing ability.  
From our results, the only evidence that would suggest a pro-apoptotic effect of 
EGFP:ΔN-Bax was the temporal loss of fluorescence noted in 3T3 and HUVECs 
transfected with EGFP:ΔN-Bax. However, the lack of sustained GFP expression could 
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also be explained by an increased rate of protein degradation. In fact, the α5 region of 
Bax is highly susceptible to ubiquitin degradation (161). In the case of full length Bax, 
the α5 helix is shielded within the hydrophobic pocket of the folded protein. However the 
ΔN-Bax peptide leaves the α5 helix fully exposed. This altered conformation could lead 
to accelerated degradation rates which would explain the loss of fluorescence observed in 
our results.  
Expression of ΔN-Bax alone may not be enough to induce apoptosis. However, it 
may cause cells to be more susceptible to Bax-mediated apoptosis. In essence, the 
membrane-bound ΔN-Bax may be “poised to strike”, so that if the endogenous apoptotic 
program is activated the cells undergo death faster and more effectively. There are 
several future experiments that may help to determine what role, if any, ΔN-Bax has in 
apoptosis. We suspect that ΔN-Bax and the EGFP:ΔN-Bax fusion protein are 
automatically targeted to the MOM. This hypothesis could be confirmed with co-
localization of mitochondrial staining and EGFP fluorescence.  
Regardless of the mechanism with which ΔN-Bax interacts with the endogenous 
apoptosis pathway, expression of ΔN-Bax alone is ineffective at inducing apoptosis. 
These results also explain why no apoptosis was seen following tamoxifen administration 
in the transgenic CrIED mice described in Chapter 3; ΔN-Bax expression does not kill 




A RETROVIRAL-MEDIATED STRATEGY FOR FLOURESCENT 
LABELING OF BONE MARROW SUBPOPULATIONS  
Introduction 
 In Chapter 3, two different strategies for the elimination of Endothelial Progenitor 
Cells (EPCs) were described. We were unable to implement either the retroviral or 
transgenic strategies for the elimination of bone marrow-derived EPCs. Realizing that the 
failure of these approaches was ultimately due to the complexity of our experimental 
design, we sought to employ a more straightforward methodology to identify 
subpopulations of bone marrow cells and determine the role of these cells in 
neovascularization 
Increasing evidence suggests that bone marrow-derived cells play a key role in the 
formation of new blood vessels, redefining the prevailing paradigm of post-natal 
neovascularization. A number of reports have identified bone marrow (BM)-derived 
precursor cells that incorporated into the endothelial layer and contributed directly to the 
growth of new blood vessels (12; 13; 126; 14; 127; 128; 162).  Recently, these findings 
have been challenged by reports (3; 44; 45) which refute claims of the direct involvement 
of bone marrow cells in endothelial regeneration. Instead of transdifferentiating into 
endothelial cells, it has been argued that BM-derived cells aggregate around nascent 
vessels in a perivascular location within the vessel wall, potentially augmenting 
angiogenesis through a paracrine role rather than the formation of de novo blood vessels  
A growing body of work in the cancer literature indicates that cells of myeloid 
origin may be relevant to tumor angiogenesis (163; 164). Several important 
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subpopulations have been implicated in the formation of tumors, such as tumor 
associated macrophages (TAMs), Tie-2 expressing monocytes (TEMs) (54), vascular 
leukocytes (55), and myeloid derived suppressor cells (MDSCs) (165). The majority of 
these myeloid-derived cells do not incorporate directly into the endothelium, but they 
have been shown to express some endothelial-type markers and their depletion from the 
angiogenic milieu of tumorigenic tissue has been shown to suppress tumor vessel 
formation (53; 54; 60). Although each of the myeloid-derived cell types were identified 
by independent methods, phenotypic overlap between the cell types is likely, given their 
functional and genetic similarities (62).  The apparent heterogeneity of pro-angiogenic 
cell populations in peripheral blood, and a lack of consensus regarding characterization of 
these different cell populations, obviates the need for systematic assessment of BM-
derived cell types involved in neovascularization. 
 Colony forming assays are frequently used to identify endothelial progenitor cell 
(EPC) populations from peripheral blood. However, several different assays exist that 
generate endothelial colonies from PB-MNCs, with each assay likely identifying a 
different population of cells (28). Endothelial progenitor cells derived from an adherent 
cell population that forms within 7 days in endothelial-rich culture are frequently referred 
to as “early EPCs”.  A second, highly proliferative population referred to as outgrowth 
endothelial cells (OECs) can be identified after 21 days under the same culture conditions 
(24). Colony forming unit endothelial cells (CFU-ECs) are derived from an adherence 
depleted population of PB-MNCs, and give rise to small endothelial-like cell clusters 
after 5 days(2).  
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 In addition to the colony forming assays, another common method often 
employed to identify circulating progenitor cells is through surface marker identification 
via flow cytometry. In this technique, categorization is based on a combination of surface 
markers such as CD34, CD133, and VEGFR-2 (32; 84; 88; 89; 166). Flow cytometry is 
an extremely fast and highly quantitative method of characterizing cells, but it suffers 
from several limitations. Most importantly, the markers used to define a progenitor cell 
population are not unique.  Although the combination of CD34, CD133, and VEGFR-2 
are frequently used to quantify the number of endothelial progenitor cells, it has been 
demonstrated that cells that co-express all of these markers are unable to fully 
differentiate into endothelial cells in culture (43). Low levels of circulating 
CD34+/CD133+/VEGFR-2+ cells may serve as an indicator of impaired vascular 
function (40; 42; 82; 86; 87), however this cell population does not directly incorporate 
into the endothelium. Furthermore, there is a marked absence of data linking circulating 
EPCs (as defined by these surface markers) to the EPC colonies formed in culture assays.  
An additional limitation to the use of surface markers for EPC identification is 
that surface antigens cannot be used to predict a functional role in neovascularization. 
Expression of CD34, for example, can only be used as an indicator of hematopoietic 
pluripotency; and even this characteristic has recently been challenged (167; 168). The 
marker CD34 cannot be used to conjecture the functional fate of cells, as its expression 
does not confer a functional outcome. Characterization of intracellular protein expression 
could potentially offer more insight into progenitor cell function. For example, if a 
population of circulating cells that express VEGF could be identified, then it would 
reason that those cells would augment angiogenesis through VEGF secretion if recruited 
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to ischemic tissue. Similarly, if circulating cells that express eNOS could be 
prospectively identified, it follows that those cells would augment angiogenesis in 
ischemic tissues through generation of nitric oxide. Staining for intracellular proteins 
such as VEGF and eNOS requires membrane permeabilization, resulting in a loss of cell 
viability (169). Consequently, in order to monitor the expression of intracellular proteins 
in live circulating cells in vivo, transgenic reporter mice are necessary. The use of 
transgenic mice for cell labeling is an approach that is both extremely time consuming 
and costly due to generation and maintenance of the animal colonies.  
 To circumvent the problems associated with intracellular labeling techniques, we 
have developed a novel method for the fluorescent labeling of bone marrow cells using 
self-inactivating retroviral vectors with tissue specific promoters. Using the VEGF, VE 
Cadherin and eNOS transcriptional regulatory sequences, we were able to transduce 
mouse bone marrow with a unique set of retroviral constructs. Following transplantation 
into lethally irradiate recipients, we were able to identify novel populations of bone 





Wild type C57BL/6J mice were purchased from the Jackson Laboratory. All 
animals were fed standard chow ad libitum and had free access to water. All protocols 
were approved by the Institutional Animal Care and Use Committee and done in 
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accordance with the federal guidelines on the principles for the care and use of animals in 
research. 
 
Generation of Retroviral Plasmids 
 All plasmids were propagated in Top10 E.Coli (Invitrogen). Transformed E.Coli 
were grown on LB-Agar plates containing 100 μg/mL of Kanamycin. For large scale 
plasmid preparation, inoculated cultures were grown in 2L Erlenmeyer flasks containing 
200 mL of LB-broth supplemented with 100 μg/mL Kanamycin. Cultures were 
propagated overnight in a rotary shaker at 250 rpm and 37 oC. Plasmid DNA was isolated 
using Qiagen HiSpeed Plasmid Maxi-prep.  
 All constructs were derived from the pQCXIX (Clontech) vector. To generate the 
constructs, pQCXIX was first digested with Not I and Mlu I. The fragment containing an 
Internal Ribosome Entry Site (IRES) was separated by electrophoresis in a 1% gel. The 
remaining sequence was extracted and religated with T4 DNA Polymerase (New England 
Biolabs). For pSINrv:CMV-tdT, the tdTomato sequence from ptdTomato (Clontech) was 
cloned into the EcoRI and XhoI sites remaining in the QCXIX backbone.  
A promoterless vector, pSINrv:X-tdT, was generated by digesting pSINrv:CMV-
tdT with Stu I and Not I (New England Biolabs). The fragment containing the CMV 
promoter was separated by electrophoresis in a 1% gel. The remaining sequence was 
extracted and religated with T4 DNA Polymerase.  
To generate pSINrv:eNOS-tdT, the 1.8 kb fragment of the eNOS promoter was 
amplified from genomic mouse DNA by PCR (See appendix for primers) using Hi-
Fidelity Platinum Taq DNA Polymerase (Invitrogen). The PCR product was incorporated 
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into pCR4 using a TOPO-TA cloning kit (Invitrogen), and the sequence was verified with 
direct sequencing. Pac I and BsI WI restriction sites were added to the 5’ and 3’ ends, 
respectively, of the promoter sequence through a second round of PCR using the pCR4-
eNOS plasmid as a template. The resulting PCR product was cloned into the 
corresponding Pac I and BsI WI restriction sites of pSINrv:X-tdT.  
To generate pSINrv:VEGF-tdT, the 1.8 kb fragment of the VEGF promoter was 
generated by PCR from genomic mouse DNA (See appendix for primers) using Hi-
Fidelity Platinum Taq DNA Polymerase (Invitrogen). The PCR product was incorporated 
into pCR4 using a TOPO-TA cloning kit (Invitrogen), and the sequence was verified with 
direct sequencing. Pac I and BsI WI restriction sites were added to the 5’ and 3’ ends, 
respectively, of the promoter sequence through a second round of PCR using the pCR4-
VEGF plasmid as a template. The resulting PCR product was cloned into the 
corresponding Pac I and BsI WI restriction sites of pSINrv:X-tdT.  
 To generate pSINrv:CD68-tdT, PCR was used to add Pac I and BsI WI to the 
CD68 promoter from pDRIVE-mCD68 (Invivogen). The resulting 0.6 kb PCR product 
was cloned into the corresponding Pac I and BsI WI restriction sites of pSINrv:X-tdT.  
 To generate pSINrv:VE Cad-tdT, Pac I and BsI WI restriction sites were added to 
the 5’ and 3’ ends, respectively, of the VE Cadherin promoter sequence through PCR 
using the murine VE Cadherin promoter sequence from pVEcad (generously donated by 
Dr. Roy Sutliff, Emory University) as a template. The resulting PCR product was cloned 





293-derived Phoenix Ecotropic (Phx-Eco) packaging cell lines [3] (ATCC) were 
grown to 80% confluence in 100ml plates with growth media consisting of DMEM 
(Gibco) supplemented with 10% Fetal Bovine Serum, L-glutamine, and Pen/Strep. 
Before transfection, 10 ml of fresh media was added to each plate. Transfections were 
performed following the JetPRIMETM manufacturers recommended protocol (Polyplus). 
Briefly, 10 μg of plasmid DNA was added to 500 μL of JetPRIMETM buffer then briefly 
vortexed and centrifuged. 20 μL of JetPRIMETM was then added to the DNA mixture, 
which was again briefly vortexed and centrifuged. Following a 10 minute incubation at 
room temperature, the DNA/ JetPRIMETM solution was added to the cells in a drop-wise 
manner and transported to a 37 Co/5% CO2 incubator. After 6-8 hours, transfection media 
was aspirated and replaced with 25ml of fresh media. 24 hours after the start of 
transfection, the media was again aspirated, 9 ml of fresh media was added, and the cells 
were transferred to a 32 Co/5% CO2 incubator. 48 hours after transfection, the conditioned 
media was collected in a 10 mL syringe and passed through a 45µm low protein binding 
filter (Nunc) and either frozen and stored at -80 ˚C or used immediately for transduction. 
Conditioned media was collected afterward at 12 hour intervals for up to 7 days 
following transfection. 
 
Bone Marrow Isolation and Transduction 
 A detailed protocol for bone marrow transduction, modified from Ide et al. (133), 
is included in the Appendix. Briefly, mice were euthanized by CO2 inhalation and long 
bones were flushed with cold PBS.  Bone marrow cells were labeled with anti-Sca1-PE 
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antibodies, then separated with anti-PE micro-beads using an AutoMACS sorter 
(Miltenyi).  Sorted cells were cultured in Stempro-34 media supplemented with mSCF 
(100 ng/ml, Sigma), Flt-3 (100 ng/ml, R and D), Il-3 (20 ng/ml, Sigma), and Il-11 (100 
ng/ml, Sigma) for 24 hrs.  RV supernatant was centrifuged overnight at 4˚C and 9000g, 
and resuspended in 1/20 the original volume of complete Stempro-34 with cytokines.  
Retrovirus was bound to retronectin coated plates by centrifugation for 1 hr at 4 ˚C and 
2500rpm.  Bone marrow cells were plated on RV/retronectin plates, and cultured for 24 
hrs at 32 Co. 
 
Bone Marrow Transplants 
One day prior to transplantation, recipient mice were irradiated with 11Gy in 
order to eliminate the regenerative capacity of the endogenous bone marrow.  On the day 
of transplantation, bone marrow cells modified by retroviral transduction were washed in 
sterile phosphate buffered saline (PBS) containing 2% fetal calf serum.  Recipient mice 
were anethsetized with Avertin, 375-mg/kg, and given 5x105 cells by retro-orbital 
injection.  For 3 weeks following transplantation, mice were mainatainied on broad 
spectrum antiobiotics delivered through the drinking water. Mice were allowed an 
additional 3 weeks of recovery prior to experimentation. 
 
Cell Lines and Culture 
NIH/3T3 cells were grown at 37 Co, 5% CO2 in DMEM supplemented with 10% 
calf serum, L-glutamine, and Pen/Strep. 3T3 cells were grown in 10 cm tissue culture-
treated dishes until 80% confluent, then passaged at a ratio of 1:5. MS1 cells (ATCC) 
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were grown at 37 Co, 5% CO2 in DMEM supplemented with 10% fetal bovine serum, L-
glutamine, and Pen/Strep in 10 cm tissue culture-treated dishes coated with gelatin until 
80% confluent, then passaged at a ratio of 1:5.  
 
Flow Cytometry 
 Mice were sacrificed and 0.5-1.0 mL of peripheral blood was collected in a 1.5 
mL micro-centrifuge tube from the right ventricle in 100 μL of heparin sodium solution. 
RBC lysis was performed with Pharym-Lyse (BD Bioscience) to obtain PB-MNCs. For 
CD14 staining, 1e6 cells were suspended in FACS staining buffer (BD Biosciences) and 
incubated with anti-CD14-PerCP cy5.5  antibody (eBioscience). For VEGFR-2, CD34, 
and CD45 staining, 1e6 cells were preincubated with 1 μg mouse seroblock (R and D 
systems), then stained with anti-CD34-eflour450, anti-CD45-eflour APC-750 , and anti-
Flk1-APC antibodies (eBioscience) in FACS staining buffer. For eNOS and VEGF 
staining, cells were treated with fixation and permeabilization solution (BD Bioscience) 
following RBC lysis, and labeled with either anti-eNOS-Alexa647 (BD Bioscience) or 
anti-VEGF-APC (R and D Systems) antibodies.  Flow cytometry was performed with a 
BD LSRII analyzer (BD Biosciences), and a minimum of 50,000 events were recorded. 
Dot plots were generated in BD FACSDiva, and analysis was performed using FlowJo 
software.  
 
In vivo Matrigel Assay 
 Matrigel (BD Biosciences) was mixed with 0.5 μg/mL bFGF (BD Biosciences) 
and 64 U/mL heparin sodium (BD Biosciences), and 1x106 MS1 cells transduced with 
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SINrv:CMV-tdT.  The matrigel mixture (500 μL) was implanted subcutaneously in the 
dorsal region of athymic Nude mice (Charles River). After 7 days, animals were 
euthanized by CO2 inhalation, and matrigel plugs were removed and fixed in 10% 
formalin for 4 hours. Following fixation, matrigel was snap-frozen in OCT medium and 
stored at -80 oC.  
 
Histology 
 Matrigel was sectioned into 7 μm thick sections and mounted with Vectashield 
fluorescence mounting media with DAPI (Vector Labs). Images were recorded using a 
Ziess upright fluorescence microscope.  
 
Results 
Design of SINrv:X-tdT constructs 
A series of retroviral plasmids were generated out of a SIN-MMLV vector so that 
expression of the fluorescent protein tdTomato could be regulated by an internal 
promoter. These constructs are referred to as SIN Retrovirus:X-tdTomato, or SINrv:X-
tdT, where X represents the promoter sequence contained in the construct.  To generate 
the promoterless vector, the tdTomato CDS was inserted into an empty SIN-MMLV 
vector between the retroviral LTRs, downstream of an MMLV packaging sequence and 
the promoter cloning sites (Figure 5.1). Five different promoters were identified based on 
their potential relevance to the process of neovascularization (Table 5.1), which were 
then cloned into the empty promoter cloning site in pSINrv:X-tdT. A 2.5 kb fragment of 





Figure 5.1: SINrv Construct Design. A) The SINrv:X-tdT vector consists of a SIN- 
MMLV-based backbone with cloning space for an internal promoter (X) driving the 
fluorescent protein tdTomato, inserted between the packaging sequence (Ψ) and the 
3’LTR. B)Visual detection of tdTomato expression using fluorescence microscopy in  
3T3 cells transduced with SINrv:CMV-tdT (which contains an internal CMV promoter 
to drive expression of tdTomato). 
 
 
endothelial specific expression of tdTomato in target cells and a 0.8 kb fragment of the 
CD68 promoter/enhancer (171) was used to confer macrophage specific expression 
following transduction. Additionally, a 1.8 kb fragment containing both the genomic 
sequence upstream of the murine VEGFa exon 1 (and including the  5’UTR) (172) and a 
1.8 kb of the 5’flanking region of murine eNOS (173) were used for the VEGF and eNOS 
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promoters, respectively. For a constitutively active control retrovirus, the 0.5 kb fragment 
of the human cytomegalovirus immediate-early promoter (CMV) was used to direct 
tdTomato expression. All promoter sequences were confirmed via restriction digestion 
and direct sequencing. 3T3 cells transduced with SINrv:CMV-tdT (which utilizes the 
CMV promoter to drive expression of the tdTomato gene) exhibited dramatic red 
fluorescence, verifying function of the reporter gene (Figure 5.1). 
 
Retroviral Promoter Activity in MS1 cells 
An immortalized mouse endothelial cell line (MS1) was transduced with 
SINrv:eNOS-tdT, SINrv:VEcad-tdT, SINrv:VEGF-tdT and SINrv:CMV-tdT, and then 
imaged for fluorescence. Activity of the CD68 promoter was not assessed in vitro.  
Transduction with SINrv:CMV-tdT resulted in high levels of tdTomato expression. 
Intensity of the fluorescence was clearly lower when tdTomato was regulated by the 
eNOS, VEGF or VE Cadherin promoters compared to CMV, but was detectable 
nonetheless (Figure 5.2). All of the promoters also generated visible fluorescence in 3T3 
cells. Since eNOS and VE Cadherin promoters are tightly regulated and should confer 
strict endothelial specificity, it was surprising that tdTomato was detected in 3T3 cells 
transduced with either SINrv:eNOS-tdT or SINrv:VEcad-tdT . These findings could 
indicate promiscuity of the promoters, although it is also possible that 3T3 cells 
aberrantly express eNOS and VE Cadherin.  
Transduced MS1 cells were analyzed by flow cytometry for quantitative comparison 
of promoter activity. While nearly 30% of MS1 cells expressed tdTomato following 




Figure 5.2: Validation of retroviral constructs in vitro. MS1 and 3T3 cells were 
transduced with SINrv:CMV-tdT, SINrv:VEGF-tdT, SINrv:VEcad-tdT, and 
SINrv:eNOS-tdT. Fluorescent images were recorded after 72 hours. Red indicates 
tdTomato fluorescence.  
 
 
VE Cadherin, eNOS) generated transduction efficiencies of 11% or less. The lower 
frequency of tdTomato positive cells could be attributed to a 3-fold reduction in titer 
observed when the CMV promoter was replaced with eNOS, VEGF, or VE Cadherin 
(data not shown). Mean Fluorescence Intensity (MFI), calculated for tdtomato-positive  
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Figure 5.3: Promoter Characterization In MS1 Cells. Flow cytometry was performed 
on MS1 cells transduced with the SINrv series of retroviral constructs. A) Dot plots of 
MS1 cells transduced with different SINrv constructs compare the different promoters 
used. B) The percentage of positive cells was quantified for each promoter. C) Mean 
Fluorescence Intensity was determined using the positive gated events in the tdTomato 




cells in each treatment group, was also significantly lower when tdTomato was regulated 
by the vascular promoters compared to CMV (Figure 5.3). VE Cadherin generated the 
weakest signal (Figure 5.3), followed by VEGF and then eNOS.  
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Enrichment of tdTomato-positive cells with FACS 
 An inherent advantage of using a fluorescent protein to genetically label cells, is 
that live cells can then be sorted using Flourescence Assisted Cell Sorting (FACS). To 
determine if a heterogeneous cell population could be enriched for tdTomato positivity, 
FACS was performed on a mixed population of MS1 cells transduced with SINrv:VEGF-
tdT. Prior to sorting, less than 4% of the total cell population expressed tdTomato. 
Analysis of the cells post-sort indicated that greater than 99% of the cells expressed 
tdTomato (Figure 5.4). These data demonstrate that sorting for tdTomato can generate 
highly pure samples from rare populations of cells. Therefore, our tdTomato labeling 
approach could be extremely valuable in isolating specific cell populations for cell 
therapy applications.  
 
Detection of Fluorescently Labeled Cells in vivo 
The eventual goal of this project was to utilize the SINrv:X-tdT vectors for live cell 
tracking in a setting of neovascularization in vivo.  To validate this strategy, MS1 cells 
transduced with SINrv:CMV-tdT were seeded in matrigel which was then implanted 
subcutaneously in athymic Nude mice. At 7 days, the matrigel plugs were removed and 
sectioned for histological analysis. Cells within the matrigel plug expressing tdTomato 
were clearly visualized with fluorescence microscopy (Figure 5.5), supporting the 




Figure 5.4: tdTomato Enrichment With FACS. A mixed population of MS1 cells 
labeled with SINrv:VEGF-tdT and unlabeled MS1 cells was enriched using FACS. A) 
Negative control. B) Starting population of fluorescent and non fluorescent cells. Only 
3% of the starting population expressed tdTomato. C) Post sort analysis demonstrating 





Figure 5.5: In vivo Monitoring of tdTomato Expression.  MS1 cells transduced with 
SINrv:CMV-tdT were mixed with Matrigel and bFGF, then injected subcutaneously in 
Nude mice. Plugs were removed at 7 days then imaged for fluorescence. Arrows 
represent tdTomato positive cells within the Matrigel Plug. Top Left: DAPI. Top Right: 














Figure 5.6: Bone Marrow Labeling Strategy. In the retroviral transduction strategy, 
bone marrow cells are isolated from C57B6/J mice, and cultured with viral supernatant 
containing one of the SINrv:X-tdT viruses. Transduced cells are transplanted into a 
lethally irradiated host, and allowed to engraft for 6 weeks. The resulting BM chimera is 
referred to as a SINrv:X-tdT/BMT mouse. Following engraftment, bone marrow-derived 
cells in which the retroviral promoter is active can be detected by flow cytometry or 
fluorescence microscopy.  
 
 
Retroviral Bone Marrow Transduction Strategy  
For live cell tracking of bone marrow subpopulations, we employed a retroviral 
mediated-bone marrow transduction and transplantation approach. Our general strategy, 
outlined in Figure 5.6, was to isolate bone marrow cells from donor mice, transduce the 
cells with one of the SINrv:X-tdT vectors, then transplant the genetically modified cells 
into a lethally irradiated WT host. Following engraftment, only the bone marrow 
component of the SINrv:X-tdT BMT chimera (SINrv:X-tdT/BMT) contains the retroviral 
transgene. Therefore, only the BM-derived cells in which the retroviral promoter is active 
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express tdTomato. Using this technique we were able to specifically label certain 
subpopulations within the bone marrow based on promoter specificity.  
In order to validate the transduction/transplant approach, we transduced isolated bone 
marrow cells with the SINrv:CD68-tdT vector. Transduced BM cells propagated in 
Methocult media were assayed for colony formation and visualized for fluorescence. The 
majority of colonies did not express tdTomato, but several fluorescent colony forming 
unit-macrophage (CFU-M) colonies were observed (Figure 5.7). Flow cytometry on both 
PB and BM isolated from SINrv:CD68-tdT/BMT mice at 6 weeks post-transplant 
identified a small population of low side scatter (SSCLow) cells that expressed tdTomato 
(Figure 5.7), potentially identifying a bone marrow-derived macrophage or macrophage 
precursor.  
 
tdTomato Expression Following Bone Marrow Transduction 
 Bone marrow cells were isolated from C57B6/J mice, sorted for Sca1+, and then 
transduced with either SINrv:CMV-tdT, SINrv:VEGF-tdT, SINrv:VEcad-tdT, or  
SINrv:eNOS-tdT. A sample of transduced BM was then cultured in Methocult and 
assayed for colony formation, while the remaining cells were transplanted into lethally 
irradiated WT recipients and allowed to engraft for 6 weeks. The transplant recipients 
receiving transduced marrow were referred to as SINrv:X-tdT/BMT mice. 
Transduced BM grown in Methocult formed multiple colony forming unit-
granulocyte (CFU-G) colonies. A large proportion of the CFU-G colonies in cells 
transduced with SINrv:CMV-tdT expressed tdTomato. Fluorescent colonies in the 




Figure 5.7: Validation of Bone Marrow Transplant Strategy. Bone marrow cells were 
transduced with SINrv:CD68-tdT and grown in Methocult media for 7 days to allow 
colony formation. (A) Fluorescent CFU-M colonies were detected, indicating successful 
transduction. Transduced cells transplanted into lethally irradiated hosts were allowed to 
engraft for 6 weeks. (B) BM and (C) PB were harvested and analyzed by flow cytometry 
to detect cells expressing tdTomato.  
 
 
Figure 5.8: Expression of tdTomato In Transduced Bone Marrow Colonies. 
Following transduction with SINrv:CMV-tdT, SINrv:VEGF-tdT, SINrv:VEcad-tdT, 
SINrv:eNOS-tdT, BM cells were grown in methocult and imaged for fluorescence after 7 
days. tdTomato-positive CFU-Gs were detected in all groups, however frequency of 
positive colonies was much higher in SINrv:CMV-tdT cells.  
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weeks of engraftment, PB-MNCs from SINrv:X-tdT/BMT mice were analyzed using 
flow cytometry. Only 7.23 % (+/-2.79 SD) of PB-MNCs obtained from SINrv:CMV-
tdT/BMT mice expressed tdTomato. Such a low percentage of transduced cells was 
surprising given the ubiquitous nature of the CMV promoter and the robust expression 
seen from the SINrv:CMV-tdT construct in vitro. This result indicated either low 
transduction efficiency or silencing of the CMV promoter. Given the number of 
fluorescent colonies seen in the Methocult assay following SINrv:CMV-tdT transduction, 
we suspected the latter to be the case. The percentage of tdTomato positive PB-MNCs 
were less than 1.5% in all other transplant groups (Table 5.1). Although these percentages 
were relatively low, this result was expected given the rarity of the target cell 
populations. The tdTomato positive population was clearly discernable in all groups, 
despite the low percentages of fluorescent cells. The low numbers of circulating 
tdTomato cells in the SINrv:VEGF-tdT, SINrv:VEcad-tdT, or SINrv:eNOS-tdT/BMT 
groups were likely due to the rarity of the cell populations in which the vector promoters 
were active, and not because of low transduction rates.  
 
Specificity of Retroviral Promoters in vivo 
 The successful labeling of bone marrow cells using a retroviral BMT strategy is 
dependent upon two factors: 1) the ability to transduce all of the bone marrow cells and 
2) the specificity of the retroviral promoter in vivo. The use of a tissue-specific  promoter 
makes it difficult to address the former, because transduction efficiency does not 
correlate to the percentage of fluorescent cells. Cells in which the retroviral construct is 
present but the promoter is inactive cannot be detected by flow cytometry. Therefore, we  
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Table 5.1: Total tdTomato Expression in PB of SINrv:X-tdT/BMT mice. The 
predicted specificity for each promoter in the SINrv:X-tdT/BMT mice, as well the 
percentage of tdTomato positive cells in total PB-MNCs for each group. Average 



























sought to determine the efficiency with which each subpopulation was labeled. 
In order to determine the labeling efficiency, transduced PB cells from each group 
were stained with antibodies for the proteins corresponding to each retroviral promoter.  
When PB-MNCs were stained with an antibody for VE Cadherin, a large amount of non-
specific background stain was observed (data not shown). As a result, we were unable to 
determine whether the tdTomato-positive cells derived from SINrv:VEcad-tdT/BMT 
marrow were also positive for VE Cadherin via antibody labeling. Permeabilization of  
PB-MNCs permitted staining for VEGF and eNOS, which was then quantified using flow 
cytometry. (Figure 5.9 and 5.10, respectively). Unfortunately, the permeabilization and 
fixation steps required for intracellular staining completely abolished tdTomato 
fluorescence. The loss of flourescence prevented us from co-labeling tdTomato-positive 
cells from SINrv:VEGF-tdT/BMT and SINrv:eNOS-tdT/BMT with VEGF and eNOS 
antibodies, respectively. Although colocalization of signal could not be assessed, a 
striking similarity between the number of tdTomato positive cells in unstained PB from 
SINrv:VEGF-tdT/BMT mice, and the number of VEGF+ cells as determined by antibody  
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Figure 5.9: Intracellular VEGF staining of PB from SINrv:VEGF-tdT/BMT mice. 
PB-cells from untreated and SINrv:VEGF-tdT/BMT mice were permeabilized and 
stained for VEGF. (A) Events for analysis were gated based on SSC and FSC properties. 
Included events are from gate P1. (B) Untreated isotype controls were used to determine 
positive events in VEGF (P2) and tdTomato (P3) channels. VEGF expression was 
assessed in (C) untreated and (D) SINrv:VEGF-tdT/BMT samples. Note that 





Table 5.2: Comparison of Antibody Staining and tdTomato Expression. 
Quantification of the average number of positive events as determined by anti-VEGF or 
anti-eNOS antibody staining compared to tdTomato expression. Values are percentage of 














Figure 5.10: Intracellular eNOS Staining of PB From SINrv:VEGF-tdT/BMT Mice. 
PB-cells from untreated and SINrv:eNOS-tdT/BMT mice were permeabilized and stained 
for eNOS. (A) Events for analysis were gated based on SSC and FSC properties. Included 
events are from gate P1. (B) Untreated isotype controls were used to determine positive 
events in eNOS (P2) and tdTomato (P3) channels. eNOS expression was assessed in (C) 
untreated and (D) SINrv:eNOS-tdT/BMT samples. Note that permeabilization/fixation 
completely abolished tdTomato fluorescence.  
 
 
staining was observed (Table 5.2). This similarity was also observed between the number 
of tdTomato-positive cells in unstained PB from SINrv:eNOS-tdT/BMT mice, and the 
number of eNOS+ cells as determined by antibody staining (Table 5.2). These results 
suggest that expression of tdTomato from the retroviral promoters mimicked expression 





Figure 5.11: Flow Cytometric Analysis of CD14 Expression In Peripheral Blood 
From SINrv:X-tdT/BMT Mice.  PB-MNCs were isolated from SINrv:X-
tdT/BMT mice and stained for CD14 expression. A) Gating strategy was based on 
SSC and FSC properties to eliminate background autofluorescence and exclude 
debris. B) Untreated isotype controls were used to set gates for tdTomato 
fluorescence and CD14 expression. C, D, E, F and G are representative plots from 
Untreated, SINrv:CMV-tdT/BMT, SINrv:VEGF-tdT/BMT, SINrv:VEcad-
tdT/BMT, and SINrv:eNOS-tdT/BMT mice, respectively. Bi-exponential plots 
were used to visualize all events.  
 
 
 CD14 Expression In Peripheral Blood Following Bone Marrow Transplantation 
 Assessment of CD14 expression in PB was used to evaluate the number of 
monocytes in the tdTomato+ population for each BMT group. Peripheral blood MNCs 
were stained with a CD-14 antibody and analyzed by flow cytometry (Figure 5.11). The 
percentage of CD14+ cells out of the total PB-MNC population remained constant across 
all treatment groups, demonstrating that the retroviral BMT procedure did not lead to 
changes in the monocyte population (Figure 5.12). Furthermore, no differences across 
























































Figure 5.12: Quantification of CD14 expression in BMT-PB. Quantification of flow 
cytometric data was used to determine CD14 expression in PB of different treatment 
groups. A) Comparison of the total percentage of CD14 positive cells in PB of all 
treatment groups. B) Percentage of CD14 positive events within the tdTomato fluorescent 





Figure 5.13: PB-MNCs Are Fully Reconstituted Following Retroviral Transduction. 
Peripheral blood from BMTT mice was stained for CD45, CD34 and VEGFR2. Flow 
cytometry on (A) untreated vs. (B) SINrv:CMV-tdT/BMT PB showed similar FSC vs. 
SSC, CD45, CD34, and VEGFR2 expression. Events utilized for analysis were gated 
based on SSC and FSC properties to eliminate background autofluorescence and exclude 
debris (P1). Positive events were determined based on isotype controls (not shown).  
 
 
 CD14 was determined (Figure 5.12). The low percentage of tdTomato positive cells 
expressing CD14 suggests that the majority of circulating VEGF+, VE Cadherin+, and 
eNOS+ cells are not monocytes. 
 
Characterization of Progenitor Cell Markers on Genetically Labeled Cells 
 Our interest in labeling subpopulations of bone marrow cells was to determine the 
role of the different BM cell types in blood vessel growth and maintenance. To compare 
tdTomato BM populations with previously described progenitor cell populations,  
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Table 5.3: Summary of Flow Cytometry On PB From SINrv:X-tdT/BMT Mice. 
Flow cytometry was used to quantify different subpopulations as either a percentage of 
the total number of cells, or a percentage of the total number of tdTomato positive cells 


















































 expression of CD45, CD34 and VEGFR-2 in PB from SINrv:X-tdT/BMT mice was 
analyzed with multicolor flow cytometry. Expression of CD45, CD34 and VEGFR-2 was 
maintained across groups following bone marrow transduction (Figure 5.13), indicating  
that the retroviral transduction/BMT procedure did not alter leukocyte or progenitor cell 
populations in PB-MNCs. 
 The majority of PB-MNCs in all groups were CD45-positive (>85%). A small 
percentage of cells (<0.2%) were double positive for the progenitor cell markers CD34 
and VEGFR-2 (Figure 5.13 and Table 5.3). The percentage of tdTomato+-positive cells 
that expressed both CD34 and VEGFR2 was somewhat higher in the SINrv:VEcad-
tdT/BMT and SINrv:eNOS-tdT/BMT groups, however the low frequency of total 
tdTomato-positive cells led to considerable variability in this result. The majority of the 
tdTomato positive cells in each group were CD45+/CD34-/VEGFR2- (Figure 5.14 and 
Table 5.3), which was comparable to that seen in the ungated population of cells. The 
expression of CD45 suggests that these cells are of hematopoietic origin, but the absence 
of CD34 indicates that they were not an HSC. Although less than 1% of the tdTomato-
positive populations for all groups were CD45-negative, the majority of the 











Figure 5.14:  Characterization of tdTomato Positive Cells In PB From SINrv:X-
tdT/BMT Mice. PB from different treatment groups were stained for VEGFR-2, CD45, 
and CD34 and analyzed with multicolor flow cytometry. Cells were first gated based on 
SSC and FSC properties (P1), and then gates for positive events were determined using 
isotype controls. Total cells were analyzed for antigen expression, and then tdTomato 
positive cells only were gated and assessed for expression of each surface marker. A, B, C 
and D are representative PB samples from SINrv:CMV-tdT/BMT mice, SINrv:VEGF-





 groups were CD34-positive. This suggests that the VE Cad+ and eNOS+ populations 
may be enriched for hematopoietic progenitor cells. However, due to the small sample 
size in these experiments, these results should be interpreted with caution. 
 
Discussion 
Here we have demonstrated a novel method for the fluorescent labeling and live 
cell tracking of bone marrow cells in vivo. The use of self-inactivating retroviral vectors 
containing the VEGF, and eNOS promoters allowed us to identify rare populations of 
circulating BM-derived cells in the peripheral blood, which may play a role in 
neovascularization. Due to the intracellular localization of VEGF and eNOS, antibody 
labeling techniques for these proteins are not permitted in live cells. Our approach, 
however, allows for the identification of VEGF and ENOS expression in viable cells. 
Circulating cells that express VEGF, if recruited to areas of ischemic tissue, would 
promote vascularization do to secretion of VEGF. Therefore, the tdTomato+ cells from 
SINrv:VEGF-tdT/BMT mice could be potent regulators of angiogenesis. The eNOS 
protein localizes at caveoli on the cytoplasmic side of the plasma membrane (174) and 
leads to the generation of nitric oxide. Therefore, eNOS expressing cells could be 
recruited to the blood vessel wall during angiogenesis and secrete nitric oxide, thereby 
representing a population of cells with pro-angiogenic potential.  
Unlike VEGF and eNOS, it is possible to identify VE Cadherin by staining of 
surface markers with antibodies. However, the paucity of VE Cadherin-positive cells in 
PB of mice makes it extremely difficult to distinguish true VE Cadherin-positive cells 
from background using flow cytometry. The SINrv:VEcad-tdT/BMT mice contain a 
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small but distinct population of circulating tdTomato+ cells. Since VE Cadherin is a 
marker of mature endothelial cells, this population may represent a true endothelial 
precursor. 
To summarize these data, the use of self-inactivating retroviral vectors for 
labeling of BM-cells represents a convenient method for live-cell tracking of VEGF, 
eNOS and VE Cadherin expressing cells in vivo. Furthermore, we have demonstrated that 
it is possible to isolate tdTomato+ cells using this retroviral-mediated approach, so that in 
the future purified cell populations can be isolate for use in therapeutic 
neovascularization.  
An alternative approach for tracking specific subsets of BM-derived cells involves 
the use of transgenic mice. In this strategy, bone marrow from fluorescently labeled 
transgenic mice is transplanted into wild type recipients, permitting the tracking of BM-
derived cell types. In fact, several GFP reporter mice have been generated using VEGF 
(175; 176) and eNOS (177; 178) promoter elements. Transgenic mice have also been 
developed which employ the VE Cadherin promoter to drive expression of Cre 
recombinase (179) or a tamoxifen-inducible Cre-fusion protein (180). Our approach 
offers several advantages over a transgenic strategy. With the retroviral-mediated 
methodology described here, it is not necessary to establish and maintain a colony of 
transgenic animals, saving a considerable amount of time and money. Our vectors also 
provide considerable plasticity in experimental approach, since they can be used with any 
available knockout or transgenic mouse without the need for additional breeding with 
GFP or LacZ reporter mice. Our retroviral based system is also extremely versatile. A 
new promoter can quickly be cloned into the empty SINrv:X-tdT vector, virus can be 
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generated, and transplants can be performed within several weeks. Generation of a new 
tissue specific transgenic-reporter mouse, on the other hand, requires considerably more 
time at a substantially higher cost.   
The circulating VEGF+ cells identified in PB-MNCs could potentially be a pro-
angiogenic cell source involved in neovascularization. Culturing of adherent cells from 
human  PB-MNCs in endothelial-favorable growth conditions leads to the formation of 
early-EPC colonies in 7 days, followed by highly proliferative outgrowth endothelial 
cells (OECs) at 21 days(24). The early EPC population has been shown to express high 
levels of VEGF compared to OECs (22; 23), and transplantation of a mixed population of 
early EPCs and OECs into nude mice showed greater angiogenic response than either cell 
type alone(23). Therefore, it may be possible to prospectively identify early EPCs based 
on VEGF expression. In future work, we will explore the link between circulating 
VEGF+ cells and early EPC formation, as well as their potential role in a setting of 
neovascularization. 
In contrast to VEGF, eNOS expression is higher in OECs derived from cultured 
PB-MNCs than in early EPCs(21). Furthermore, only GFP+ positive BM cells isolated 
from eNOS-GFP transgenic mice were capable of forming CFU-ECs; depletion of the 
GFP+ cells from PB-MNCs prevented CFU-EC formation (181). The angiogenic 
potential of bone marrow cells in eNOS -/- mice is also severely impaired (182; 183), 
suggesting a functional role for eNOS in neovascularization. The SINrv:eNOS-tdT/BMT 
mice may be a useful tool in determining which cell populations are capable of forming 
OECs and CFU-ECs. Furthermore, the tdTomato+ cells from these mice may represent a 
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population of cells that are functionally relevant toward blood vessel growth and repair. 
This hypothesis will be explored in future work.  
Expression of VE Cadherin is frequently used to identify cells from EPC culture 
assays as “endothelial cells”. VE Cadherin expression has been documented in Early 
EPCs, OECs and CFU-ECs (29). However, it is unclear whether VE Cadherin expression 
is a result of the culture conditions, or if the cells that give rise to the colonies already 
expressing VE Cadherin. Existing data seems to support the former, since VE Cadherin 
expression can be induced in a purified monocyte population (49). The use of our 
SINrv:VEcad-tdT/BMT mice clearly identified a subset of VE Cadherin+ cells.  Future 
studies will determine if the VE Cadherin+ circulating cells are capable of forming EPCs 
in culture, and potentially prospectively identifying cultured EPCs. 
 A recent study, in which a lineage tracking system was used to examine the role 
of VE Cadherin in embryonic vasculogenesis and hematopoiesis, found that at least a 
fraction of hematopoietic cells in the adult are derived from VE Cadherin expressing cells 
in the aortic-gonado-mesenephros (AGM) region during embryonic development. Using 
lineage tracing techniques, it was concluded that the hematopoietic cells arise from VE 
Cadherin-positive endothelium within the AGM.  These results suggest that during a brief 
period of embryonic development, the hemangioblast is identifiable by VE Cadherin 
expression. An intriguing possibility is that this observation may be recapitulated in the 
adult mouse in a setting of hematopoietic reconstitution. The tdTomato+ population 
identified in SINrv:VEcad-tdT/BMT mice may identify the elusive adult hemangioblast. 
We have developed a second set of retroviral vectors in which tdTomato is replaced with 
Cre recombinase gene to explore this hypothesis. Transduction of donor cells from a 
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floxed reporter mouse with a VE Cadherin-Cre retrovirus will allow us to determine if 
any of the hematopoietic cells reconstituted in a lethally irradiated transplant currently 
express or have expressed VE Cadherin at some point during their differentiation.  
 In summary, we have developed a novel method of fluorescently labeling bone 
marrow subpopulations using retroviral-mediated bone marrow transplantation approach. 
This highly versatile methodology has broad applications in elucidating the role of bone 
marrow-derived progenitor cells in post-natal neovascularization. 
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CHAPTER 6 
SUMMARY AND FUTURE CONSIDERATIONS 
Specific Aims I and II 
 The retroviral strategy outlined in Chapter 3, which utilized the RED vector to 
overexpress ΔN-Bax, was unsuccessful at inducing cell death in targeted endothelial 
cells. As we established in Chapter 4, expression of the ΔN-Bax fragment does not lead 
to apoptosis. However, successful implementation of this approach was hindered by our 
failure to systematically build the complexity of our construct design.  
Before we had tested any individual features included in the RED vector, we 
generated the full RED and REF plasmids. Therefore, when evaluation of the construct 
yielded negative results, we had to back-track significantly to isolate potential problems. 
A continued source of trouble in this approach was the use of the VE Cadherin promoter. 
While it is generally accepted that the VE Cadherin promoter confers the greatest 
specificity for endothelial-specific gene expression (179; 180; 170), we found that the 
promoter fragment we used led to weak gene expression in vitro. Multiple endothelial 
cell lines were transduced with the REF3 construct (containing the VE Cadherin 
promoter driving expression of GFP directly), however in each case the promoter was too 
weak to allow for effective characterization of the RED construct. We suspected that the 
weak transcriptional activity of the promoter was due to culture conditions in vitro. When 
used in vivo, we reasoned that the VE Cadherin promoter would robustly express our 
transgene. In fact, this hypothesis was confirmed following generation of the transgenic 
CrIED mouse. The CrIED mouse contained the same transgene as that contained in the 
RED vector. However, in contrast to the VE Cadherin promoter activity detected in 
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cultured endothelial cells, VE Cadherin activity in the CrIED mouse was robust in highly 
vascularized issues such as lung and aorta.  
We initially hypothesized that our inability to utilize the RED and REF constructs 
was due to low titer. Surprisingly, retroviral titer (as determined by qPCR on retroviral 
supernatant) from these constructs was comparable to that of the control virus, TJ124. 
However, qRT-PCR on genomic DNA from transduced target cells indicated that 
integration of TJ124 in target cells was significantly higher than that seen with RED and 
REF. The inability of RED and REF to integrate into the genomic DNA of target cells 
may have been due to a cryptic poly-A signal contained in the vector insert. The poly-A 
sequence could have prematurely terminated transcription of the viral mRNA so that the 
3’LTR was not included in the virion. The absence of the 3’LTR would not effect virion 
production, but would severely impair integration following transduction. Cloning cDNA 
generated from the viral mRNA could confirm this hypothesis, however we felt it 
unnecessary to pursue this approach, and eventually abandoned the retroviral strategy 
altogether to focus on the transgenic CrIED mouse. 
The generation of the transgenic CrIED mouse confirmed the functionality of the 
VE Cadherin-luciferase reporter portion of our construct. Unfortunately, following 
tamoxifen induced Cre activation and recombination, we did not observe endothelial cell 
death as anticipated. Although some design flaws in our construct may have contributed 
to our inability to induce endothelial cell apoptosis, it is more likely that expression of 
ΔN-Bax fragment did not induce apoptosis. The results from Chapter 4 supported this 
hypothesis, so we abandoned the CrIED approach as well.  
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ΔN-Bax in Apoptosis 
 The ΔN-Bax  constructs generated in Chapter 3 (containing the sequence 
corresponding to the C-terminal region of Bax) were unable to reliably induce apoptosis 
in endothelial cells (or, for that matter, any other cells). Although changes in cell 
morphology were observed following ΔN-Bax-EGFP fusion protein expression, 
expression of ΔN-Bax did not cause cellular toxicity as we anticipated. Our data strongly 
suggest that the ΔN-Bax fragment is permanently bound to the mitochondrial outer 
membrane (MOM), however we lack direct evidence to support this conclusion. 
 Determining the cellular localization of ΔN-Bax is an imperative step in 
elucidating the functional contribution of the C-terminal fragment of Bax in apoptosis. 
We hypothesize that α-helices 6-9 are responsible for MOM-translocation and 
aggregation prior to pore formation, but it is α-helices 2-5 that are responsible for the 
physical formation of the pore itself. We anticipate studies utilizing the EGFP-ΔN-Bax 
construct used in concert with Mitotracker red (184) will allow us to visually confirm the 
direct involvement of EGFP-ΔN-Bax with the mitochondria. If indeed the truncated ΔN-
Bax is localized to the MOM, the functional role of the α-helices 6-9 can be more closely 
studied.  
Although it was surprising that ΔN-Bax expression did not lead to robust cell 
death, we neglected to determine whether expression of EGFP-ΔN-Bax sensitizes cells to 
apoptotic signals. Ongoing studies will explore whether the localization of ΔN-Bax in the 
MOM results in sensitization of cells to specific apoptotic stimuli. The aggregation of 
ΔN-Bax at the MOM may leave the cell “locked and loaded” for apoptosis. Various 
stimuli that activate the intrinsic apoptotic pathway (UV exposure, hypoxia, serum 
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starvation) may be necessary for the toxicity of ΔN-Bax overexpression to be apparent. 
Cells that might be otherwise resistant to certain apoptotic stimuli may gain sensitivity to 
these stimuli following ΔN-Bax overexpression. Hypersensitivity to apoptosis would be 
extremely relevant in a setting of cancer and, were this result true, ΔN-Bax might provide 
a novel therapeutic target for sensitizing cancer cells to apoptotic stimuli.  
The specific function of α-helices 6-9 can also be examined in an artificial lipid 
membrane. For these studies, lipid vesicles containing recombinant ΔN-Bax would be 
generated and used to encapsulate FITC-labeled dextran molecules of varying size (146; 
148). Florescence of the artificial membrane bound vesicles could be used to determine if 
α-helices 6-9 can indeed form pore structures in lipid membranes. Addition of t-Bid, Bim 
or Puma to the artificial membrane system would allow us to determine whether binding 
of BH3-only proteins is a prerequisite to pore formation by ΔN-Bax. Involvement of the 
BH3-only proteins might aid in resolving the direct versus indirect activation debate 
surrounding BH3-only induced apoptosis. 
 
Specific Aim III 
The results from Chapter 5, although still somewhat preliminary, clearly 
demonstrate the feasibility of a retroviral bone marrow transduction and transplantation 
approach to labeling subpopulations of cells within the bone marrow.  Using the VEGF, 
eNOS and VE Cadherin promoters, we were able to clearly identify fluorescently labeled 
cells circulating in the peripheral blood. This SINrv:X-tdT/BMT strategy is particularly 
valuable because it does not require cell permeabilization to detect protein expression, 
hence preserving cell viability. Furthermore, the strength of tdTomato fluorescence 
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allows for accurate detection of rare events, as was observed when using the VE 
Cadherin promoter. We also demonstrated that genetically labeling cells with a 
fluorescent protein permits enrichment for rare events through FACS, allowing isolation 
of cells that are identifiable based on the expression of intracellular proteins 
Current bone marrow labeling strategies include antibody staining and the use of 
transgenic reporter mice. Antibody labeling is fast, convenient, cost effective, and allows 
for the identification of multiple antigens simultaneously. A major weakness of the 
antibody-based approach is that recognition of intracellular proteins, which could 
potentially reveal functional characteristics of the cells, requires permeabilization of the 
cell membrane resulting in a loss of cell viability. Therefore bone marrow cells sorted 
based on staining of intracellular antigens cannot be used for cell therapy strategies and 
the augmentation of neovascularization in animal models.  
Transgenic reporter mice can be used to circumvent the viability problems 
associated with antibody staining. Indeed, several VEGF-GFP reporter mice (176; 185), 
eNOS-GFP (177), and eNOS-LacZ (186) reporter mice have been produced. Generation 
of bone marrow chimeras by transplantation of marrow from these transgenic animals 
into wild type recipients permits tracking of eGFP-positive or LacZ-positive bone 
marrow cells. However, experiments on these mice are restricted to the strains on which 
the transgenic animals are bred. Cell tracing is not possible in knockout animals or other 
transgenic mice without crossing them with the reporter strains. The inconvenience of a 
transgenic mice strategy for BM cell labeling purposes is particularly evident in the case 
of the VE Cadherin promoter. Both VE Cadherin-Cre (179) and VE Cadherin-tamoxifen 
inducible-Cre transgenic mice (180) have been generated. To track VE Cadherin 
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expressing BM cells, the VE Cadherin Cre mouse must first be crossed with a Flox-
reporter mouse, and only the bone marrow from the offspring can be used for cell 
tracking experiments. This scenario clearly demonstrates that the use of transgenic 
animals is extremely restrictive in terms of time and associated costs. The SINrv:X-
tdT/BMT strategy, on the other hand, can easily be utilized with any knockout, 
transgenic, or background strain.  
The potential versatility that the SINrv:X-tdT/BMT methodology affords 
significant advantage. Any transcriptional regulatory sequence can be cloned into the 
empty SINrv:X-tdT vector, and therefore a plethora of subpopulations within the bone 
marrow can easily be targeted. This approach is ideally suited  for the isolation of 
regulatory T-cells, (Treg). Currently, identification of Treg cells in mice requires 
intracellular staining of the FoxP3 transcription factor(187). Isolation of Treg cells 
requires use of transgenic mice containing a FoxP3-GFP fusion protein. However, fusion 
of the GFP gene inactivates the FoxP3 protein, so that only heterozygous mice carry both 
the GFP reporter and a functional FoxP3 protein (188). Generation of a SINrv:FoxP3-tdT 
construct would not only provide a simple method for quantification of Treg cells, but 
would also allow for the identification and isolation of  Treg cells from any knockout or 
transgenic mouse line without the need for additional breeding. 
 
Limitations 
Despite the many advantages described above, the SINrv:X-tdT/BMT strategy is 
not without its limitations. One issue that has not been resolved is the overall transduction 
efficiency following reconstitution in vivo. Since our constructs are self-inactivating 
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vectors with tissue-specific promoters, we are unable to determine the transduction 
efficiency by examination of tdTomato expression alone. Even if the majority of the bone 
marrow cells carry our transgene, only those in which the promoter is active will be 
fluorescent. We attempted to address the issue by co labeling cells transduced with 
SINrv:VEGF-tdT and SINrv:ENOS-tdT with antibodies for VEGF and eNOS, 
respectively. Our rationale was that determining the percentage of tdTomato-positive 
cells that co stained with antibodies for VEGF and eNOS would allow us to estimate our 
labeling efficiency. While we observed that the percentage of labeled cells was 
comparable to the percentage of tdTomato positive cells in both groups, the 
permeabilization of the cells required for intracellular staining completely abolished 
tdTomato fluorescence. As a result, we were unable to observe co localization of signal.  
A quantitative PCR-based technique could also be used to estimate transduction 
efficiency with the SINrv:X-tdT vectors. Individual colonies could be picked from BM 
cells derived from the SINrv:X-tdT/BMT mice and grown in Methocult media. PCR 
performed on isolated genomic DNA from each of these colonies could identify the 
number of colonies which contain the retroviral transgene, and therefore estimate 
transduction efficiency. Although extremely laborious and time consuming, this approach 
would provide an estimate of our overall transduction efficiency. 
The problem of transduction efficiency was evident in the SINrv:CMV-tdT/BMT 
mice. The CMV promoter should be efficiently expressed constitutively across all cell 
types. However, we found only ~7% of PB-MNCs were fluorescent following bone 
marrow engraftment. Although this result could be indicative of low transduction 
efficiency, we suspect that instead this is due to silencing of the CMV promoter.  The 
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phenomenon of retroviral promoter silencing is frequently observed a number of 
situations, notably in the generation of induced pluripotent stem cells (iPSCs) (189). 
Silencing of the CMV promoter has been specifically observed after transduction of bone 
marrow cells (190), and viral transgene expression following long-term engraftment of 
transduced cells is considerably lower in constructs containing the CMV promoter 
compared to other constitutively active promoters, such as PGK (53).To ascertain 
whether the CMV promoter was silenced, we replaced the tdTomato CDS in 
SINrv:CMV-tdT with the CDS for Cre recombinase. The resulting construct, renamed 
SINrv:CMV-Cre (Figure 6.1), was used to transduce bone marrow from a floxed GFP 
reporter mouse (191). In this mouse, cells express GFP at the ROSA26 locus following 
Cre-mediated recombination of a floxed stop sequence upstream of the GFP reporter. 
Therefore, cells that express Cre will also express GFP. Even if Cre expression is lost, the 
cells and all of their progeny will continue to express GFP, since expression of the 
reporter gene is regulated by the ROSA26 locus. In the event of promoter silencing, we 
expect a low percentage of tdTomato positive cells in SINrv:CMV-tdT/BMT mice, and a 
high percentage of GFP+ cells in SINrv:CMV-Cre/floxed GFP/BMT mice. In fact, this is 
precisely what we observed (Figure 6.2). Roughly 7% of PB-MNCs from SINrv:CMV-
tdT/BMT expressed tdTomato, but ~30% of PB-MNCs and bone marrow cells from the 
SINrv:CMV-Cre/floxed GFP/BMT mice expressed GFP.  
Although we have expounded on the versatility of our SINrv:X-tdT vectors and 
the ability to use any promoter to drive tdTomato expression, careful consideration is 




Figure 6.1: Design and Validation of SINrv:X-Cre Vectors. The SINrv:X-Cre vectors 
(A) were created by replacing the tdTomato sequence in SINrv:X-tdT with the 
bacteriophage P1 Cre recombinase (192). B) Western blot for Cre on lysates from cells 
transduced with SINrv:CMV-Cre. The band at 37 kDa represents Cre. 
 
 
mRNA to be efficiently packaged, the transcript length (from 5’LTR to 3’LTR) should be 
kept under 8 kb (193). Therefore, promoter size in the SINrv:X-tdT must be less than  
5 kb to prevent a reduction in titer. The use of MMLV-based retroviral vectors may also 
result in insertional mutagenesis(194; 195), so this approach may have limitations in 
certain tumor models.  
Future Directions 
There are a number of animal models in which the SINrv:X-tdT/BMT approach 
will be implemented immediately. Bone marrow-derived cells are recruited to sites of 
nascent vessel formation in both the hind limb ischemia and matrigel plug assays (12; 
(14); 3). Given this data, we first plan to address whether the number of circulating  
 145
 
Figure 6.2: GFP Expression Following Retrovirus-Induced Cre Expression In 
ROSA26-GFPFlox BM and PB. Bone marrow was isolated from ROSA26-GFPFlox mice, 
transduced with the SINrv:CMV-Cre vector, and transplanted into lethally irradiated WT 
recipients. A) The ROSA26-GFPFlox  construct contains a PGK driven cytosine 
deaminase gene (PGK-CD) and PGK driven puromycin resistance gene (PGK-Puro) 
flanked by loxP sites. Downstream of PGK-Puro is a floxed triple poly-adenylation 
sequence (STOP). An enhanced green fluorescent protein-βgeo fusion protein (EGFP- 
βgeo) completes the construct. The entire construct was targeted to the Rosa26 locus and 
is inserted between 2 long terminal repeats (LTRs). B) Bone marrow and peripheral 
blood isolated from mice receiving ROSA26-GFPFlox  marrow transduced with 
SINrv:CMV-Cre expressed EGFP, while no fluorescence was detected in untreated 
controls.  
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tdTomato-positive cells in SINrv:X-tdT/BMT mice increases in response to HLI or 
matrigel injections. Second, we will perform histological analysis of sections of the  
surgical leg or matrigel to determine if tdTomato-positive cells are recruited to sights of 
neovascularization. This data could potentially identify VEGF, eNOS, or VE Cadherin-
positive cells in the PB as significant contributors to post-natal blood vessel growth, and 
permit the characterization of new progenitor cell populations.  
As demonstrated in Chapter 5, it is possible to isolate tdTomato-positive cells 
using FACS. Enriched cell populations isolated from the bone marrow or peripheral 
blood of SINrv:X-tdT/BMT mice for re-implantation in the ischemic hind limb of wild 
type mice could be used for therapeutic augmentation of blood vessel growth. A 
comparison between mice receiving sorted or unsorted BM cell populations will allow us 
to determine if the progenitor populations isolated from SINrv:X-tdT/BMT mice have 
enhanced pro-angiogenic capacity. These experiments could potentially identify a novel 
target for therapeutic neovascularization. 
We have also begun to pursue a strategy for the lineage tracing of bone marrow 
cells. By replacing the tdTomato CDS in the SINrv:X-tdT constructs with the CDS for 
bacterial Cre recombinase, we were able to generate the SINrv:X-Cre series of vectors 
(Figure 6.1). The constructs were verified by restriction digest, and western blot on 
lysates from 3T3 cells transduced with SINrv:CMV-Cre showed a distinct band 
corresponding to the correct size of the Cre protein (Figure 6.1). For lineage tracing 
experiments, donor BM will be obtained from ROSA26-EGFPFlox transgenic mice (191). 
These mice contain a floxed puromycin resistance gene and stop signal upstream of the 
GFP coding region targeted to the ROSA26 locus (Figure 6.2). The stop sequence blocks 
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transcription of the GFP gene, so that the reporter construct is silent in all cells. In the 
presence of Cre, however, the stop sequence and puromycin resistance cassette are 
excised, leading to robust GFP expression. The expression of GFP is then driven directly 
by the ROSA26 locus. The site specific recombination is irreversible, so even if Cre 
expression is stopped, the cell will continue to express GFP. Furthermore, the Cre-
mediated recombination results in permanent genomic modification, so that all progeny 
will also express GFP (Figure 6.3).  
The SINrv:X-Cre vectors will be used in BM transduction/transplantation 
experiments in which donor marrow is obtained from ROSA26-EGFPFlox mice, 
transduced with  SINrv:X-Cre vectors, and transplanted into lethally irradiated hosts. 
Preliminary experiments using ROSA26-EGFPFlox bone marrow transduced with 
SINrv:CMV-Cre and transplanted into lethally irradiated wild type mice have confirmed 
the feasibility of this approach (Figure 6.2). Recombination mediated by retroviral 
expressed Cre led to GFP expression in nearly 30% of the bone marrow and peripheral 
blood cells. Further implementation of this strategy will allow us to determine if the 
progenitor cells identified in chapter 5 are terminally differentiated, or if the expression 
of VEGF, eNOS, and VE Cadherin in PB-MNCs identify a more primitive cell 
population that give rise to a larger progenitor pool.  
In Chapter 5, we speculated that VE Cadherin positive PB-MNCs could be the 
elusive adult hemangioblast that is often alluded to in the literature, but has never been 
found. It was shown in the mouse embryo that VE Cadherin positive endothelial cells in 
the aortic-gonado-mesenephros (AGM) region ultimately gave rise to a significant 
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Figure 6.3: SINrv:X-Cre Lineage Tracing Strategy. A) Our overall approach will be to 
transduce cells from a donor mouse with a retrovirus, then transplant the cells into a 
lethally irradiated WT animal. B) In the SINrv:X-tdT/BMT strategy, WT BM cells are 
isolated and transduced with a SINrv:X-tdT vector. Following differentiation, cells in 
which the retroviral promoter is active will express tdTomato. All remaining cells will 
not. C) In the ROSA26-GFPFlox with SINrv:X-Cre/BMT strategy, bone marrow will be 
isolated from ROSA26-GFPFlox mice and transplanted into lethally irradiated WT 
recipients. Cre expression will result in excision of the STOP sequence, leading to GFP 
fluorescence. Once Cre-mediated recombination has occurred, both the parent cell and all 
progeny will continue to express GFP. 
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Zovein, et al. (196) found that endothelial cells in the embryonic AGM, as defined 
by VE Cadherin expression, were capable of long term hematopoietic reconstitution. The 
endothelium of the AGM exclusively gave rise to HSCs; in fact, lineage tracing revealed 
that the mesenchymal cells of the AGM (defined by the expression of myocardin) were 
incapable of hematopoiesis (196). Given these data, it is possible that a portion of VE 
Cadherin positive cells in the bone marrow are capable of generating hematopoietic 
progeny. During reconstitution of the HSC population following myeloablative therapy, 
the primitive HSCs may express VE Cadherin. Using the lineage tracking system with a 
Cre retrovirus and floxed-GFP reporter mouse described above, any hematopoietic 
populations that arise from a VE Cadherin positive precursor can be identified. 
The SINrv:X-Cre vectors could be used generate a model in which bone marrow 
subpopulations are eliminated; similar to the approach that was unsuccessfully attempted 
in Chapter 4. We have obtained a transgenic ROSA26-GFP-DTA mouse which contains 
a floxed GFP reporter gene upstream of the sequence encoding diphtheria toxin subunit A 
(DTA) targeted to the ROSA26 locus. ROSA26-GFP-DTA mice  (114) ubiquitously 
express GFP, but transcription of the DTA gene is prevented by a triple poly-adenylation 
sequence downstream of the GFP coding region (Figure 6.4). In the presence of Cre 
recombinase, the GFP and poly-A signal are excised, resulting in DTA  
expression and eventual cell death. When crossed with Nav1.7-cre mice, the ROSA26-
GFP-DTA mice generated progeny that lacked a subset of Nav1.7 neurons. The double 
transgenic mice showed normal neurologic function, but elicited a severely blunted pain 











































Figure 6.4: Future Strategy For Depletion of Bone Marrow Subpopulations. 
Transduction of bone marrow from ROSA26-GFP-DTA mice with the SINrv:X-Cre 
vectors will allow us to eliminate subpopulations of cells from the bone marrow. A) The 
construct contains a floxed GFP reporter/PGK-neomycin resistance cassette with triple 
poly-adenylation sequence targeted to the ROSA26 locus. In the presence of Cre 
recombinase, the floxed sequence is excised, resulting in diphtheria toxin A (DTA) 
expression (Modified from (114)). B) Bone marrow isolated from ROSA26-GFP-DTA 
mice will be isolated and transduced with one of the SINrv:X-Cre vectors. When Cre is 
expressed, the GFP reporter will be excised, and the cells will undergo apoptosis. 
However, if Cre is not expressed, cells will remain viable and GFP-positive. 
 
 
We plan to use the SINrv:X-Cre vectors to transduce bone marrow obtained from 
ROSA26-GFP-DTA mice, and transplant it into lethally irradiated WT recipients. The 
resulting SINrv:X-Cre/BMT should undergo complete hematopoietic reconstitution, but  
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all cells in which the retroviral promoter is active will undergo apoptosis. Therefore, it is 
possible to generate mice in which BM and PB populations are depleted of all VEGF+, 
eNOS+, or VE Cadherin+ cells and their progeny. Using techniques such as microCT 
(198) and LDPI (199), the extent of blood vessel growth in the ischemic hind limb or 
subcutaneous matrigel plug can be quantified. Combining the use of these assays with 
ROSA26-GFP-DTA SINrv:X-Cre/BMT mice, we can elucidate the functional 
contributions of each individual cell type in a setting of post-natal neovascularization.  
In this thesis we have demonstrated a novel strategy for fluorescently labeling 
subpopulations within the bone marrow. Using this technique, we have identified three 
populations of circulating cells which may be comprised of pro-angiogenic progenitors. 
Future work will reveal the therapeutic potential of these cells, and establish the lineage 
of these cells and their progeny. Finally, we will explore the functional role of these cells 
in models of post-natal neovascularization, allowing us to uniquely define EPCs. 
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APPENDIX A 
BONE MARROW TRANSDUCTION PROTOCOL 
(Courtesy of  Dr. Natalia Landazuri) 
Separation of Sca+ cells 
1. Get bone marrow from femur and tibia (flush with DMEM/FBS/PS) 
2. Count nucleated cells (mix cells with 2% acetic acid to exclude RBC). Set aside at 
least 500 000 cells for FACS. 
3. Spin down (300g, 10min).  
4. Resuspend in 90ul buffer per 10^7 cells (buffer: MACS rinsing buffer with MACS 
BSA diluted 1:20) + 10ul of blocking reagent (Miltenyi 130-092-575). 
5. Add 10ul PE-anti-Sca antibody per 10^7 cells (Miltenyi 130-093-224) 
6. Incubate in the fridge for 10 min (dark) 
7. Wash cells by adding 2ml of buffer per 10^7 cells. Centrifuge 10 min, 300g. 
8. Resuspend in 80ul of buffer per 10^7 cells. Add 20ul of Anti-PE micro beads 
(Miltenyi 130-048-801) per 10^7 cells.  
9. Incubate for 15min in the fridge. 
10. Wash cells by adding 2ml of buffer per 10^7 cells. Centrifuge 10 min, 300g. 
11. Resuspend up to 10^8 cells in 500ul of buffer. 
12. Magnetic separations using autoMACS. Possel-S.  
13. Collect positive and negative fractions. Count cells. Set aside at least 200000 cells per 




Culture of Sca1+ cells 
Resuspend Sca1+ cells from 1-2 mice in 1ml of StemPro media containing Pen/Strep 
(1%), L-Glutamine (1%), nutrient supplement (40X), mSCF (100 ng/ml), mIL-3 (20 
ng/ml), hIL-11 (100ng/ml), mFlt-3 (100 ng/ml). Plate in 1 well of a 6-well plate. 
 
Coat wells with retronectin 
1. Make a 1 mg/ml stock of retronectin (in water). Filter 0.22 um. Store at -20C. 
2. Dilute the stock to 40 ug/ml (25X) in PBS. Add 2 ml/well of a 6-well dish (non-tissue 
culture treated). Incubate for 2hrs at RT or O/N at 4C. 
3. To block, add PBS/2%BSA fraction V. Incubate for 30 min at RT.  
4. Wash with PBS. 
 
Transduction of Sca1+ cells 
1. Add 1-2 ml of concentrated virus per well. Spin down 2500 rpm for 1hr at 4C. 
2. Centrifuge cells. Resuspend in virus SN from step 1. Add supplements (see table 
above). Incubate at 32C for 4 hrs, then at 37C. 
 
Measure transduction efficiency 
1. Methylcellulose 
a. Plate ~1000 cells in 1.2ml/well of methylcellulose (in a 6-well plate, non-
tissue culture treated). Thaw methylcellulose at room temperature. Add 
cells to methylcellulose and vortex. Allow for bubbles to rise. Transfer 
cells to a well using a syringe with thick needle.  
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b. Incubate at 37C for 1 week. 
c. Count %transduced colonies (GFP+) 
2. RT-PCR 
a. Spin down ~100000 cells 
b. Isolate genomic DNA using DNeasy kit (Qiagen) 
c. RT-PCR for GFP or transgene. 
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 APPENDIX B 
PCR AND CLONING OLIGONUCLEOTIDES 
Primer Name Sequence 
 
m18s for gaacgtctgccctatcaact 
 
m18s rev ccaagatccaactacgagct 
 
VE cad/BsiWI for ggttttcgtacgctagtagcagaaacaag 
 
VE cad/Pac1rev ggttttttaattaagtcgagagtctgtcca 
 
VEGFa for tttagaagatgaaccgtaagcctag 
 
VEGFa rev gatacctctttcgtctgctga 
 
VEGFa for/Age1 ggaccggttttagaagatgaaccgtaa 
 
VEGFa for/BsiWI ggcgtacgtttagaagatgaaccgtaa 
 
meNOS for aaaagcaaggatgagggataatataa 
 
meNOS rev gccagctgacctcaactctgccgcac 
 
meNOS (BsiWI) for gcccgtacgaaaagcaaggatgagggataa 
 
meNOS (PacI) rev gccttaattaagccagctgacctcaactctg 
 
CD68 prom (BsiWI) for gcccgtacgactagttgattactgaat 
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